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CHAPTER I 
 
INTRODUCTION 
 
 The treatment of bone defects remains a challenging clinical problem. Trauma, 
disease, primary tumor resection, and/or congenital deformation often result in large bone 
losses requiring bone grafting procedures.
1-4
 Bone is the second most commonly 
transplanted tissue after blood.
5
 As shown in Figure 1.1, in the US alone, the number of 
bone grafting procedures has continuously increased since 1990, and in 2005 it surpassed 
1.6 million procedures per year.
6
 As a result, tissue engineering can impact millions of 
patients’ lives by developing bone substitute materials which promote bone-defect 
healing.  
 
Figure 1.1. Number of bone grafting procedures in the US in the last 20 years.
6
 
 
 Established clinical approaches to treat critical-sized bone defects include the 
implantation of autograft or allograft bone, ceramic scaffolds, or metallic devices.
7
 These 
materials offer a temporal solution to large bone loss, however, none of them fulfills all 
the requirements for successful bone scaffolds, namely being osteoconductive, 
biocompatible, resorbable, porous, and having mechanical properties comparable to the 
2 
 
surrounding host bone.
8-10
 Biomaterials research continues to focus on developing 
alternative bone graft formulations that satisfy these characteristics with the dual 
objectives of reducing revision surgeries’ frequency and the rate of secondary 
complications in the clinic.
11
  
Biodegradable, lysine-derived polyurethane (PUR) networks have been developed 
for regenerative medicine applications.
12
 When implanted in vivo, these materials 
generate a minimal and transient inflammatory response, support cellular infiltration, and 
degrade to non-cytotoxic compounds.
13, 14
 Porous, injectable formulations have been used 
as delivery vehicles for biologically active small molecules such as growth factors,
15, 16
 
antibiotics,
17
 and small molecule drugs.
18
 For bone applications, porous and non-porous 
composites incorporating mineralized fillers into a polyurethane (PUR) network have 
been developed and tested in femoral plug bone defects in rats,
19, 20
 rabbits,
21-23
 and 
sheep.
24
 The mineralized matrix provides osteoconductivity to the polymer by acting as a 
porogen that guides cellular infiltration
21
, and the polymer reduces the brittle behavior of 
the ceramics. While pre-clinical testing positioned PUR composites as suitable 
biomaterials for bone regeneration, further formulation development was needed for 
moldable scaffolds to approach weight-bearing capabilities.  
The goal of this dissertation was to formulate and characterize PUR 
biocomposites that participate actively and predictably in the bone healing process. 
Building on previous work in the Guelcher lab, high and low porosity formulations were 
developed to improve the healing outcomes of contaminated and femoral plug bone 
defects. In vitro characterization of the formulations included physical, rheological, 
mechanical and cell culture analyses. In vivo implantation and analysis of healing 
3 
 
progression provided information about the remodeling mechanisms of the different PUR 
formulations. In order to fully characterize the resorptive component of graft remodeling, 
an in vitro osteoclastic culture protocol was developed to enable quantitation and direct 
comparison between volumetric resorptive rates of synthetic matrices. Each chapter in 
this dissertation focuses on a different PUR formulation and its detailed characterization. 
Combined, they offer design guidelines for the development of PUR scaffolds that a) 
protect scaffolds from contamination, and b) maintain bone-like strength while actively 
remodeling.  
Chapter III describes the formulation, characterization, and in vivo evaluation of a 
PUR biofilm-dispersive graft.
25
 Infectious complications in open fractures are a major 
factor contributing to osseous non-union and extremity amputation.
26
 The persistence of 
bacteria within biofilms, despite meticulous debridement and antibiotic therapy, is 
believed to be a major cause of chronic infection.
27
 As a therapeutic strategy for the 
reduction and prevention of biofilm-associated infections, D-Amino Acids (D-AA) with 
biofilm dispersal capabilities were incorporated into porous PUR scaffolds. Detailed in 
vitro characterization of the D-AA effect over the formation and dispersal of clinical 
bacterial strain biofilms is presented. The scaffold’s porosity, mechanical properties and 
D-AA release profile are reported. The in vivo biofilm dispersal potential of the 
augmented PUR scaffolds was evaluated in contaminated rat segmental bone defects.  
Chapter IV continues to present a settable PUR biocomposite formulation 
containing surface modified -tricalcium phosphate (TCP) particles. Previous studies in 
our lab have developed compression molded TCP-PUR composites that supported 
cellular infiltration and remodeling when implanted in femoral condyle defects in rats.
20
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Due to the brittle nature of TCP, high pressure was required to obtain final mechanical 
properties matching those of bone. However, since the compressed composites are 
molded outside the body, their application is limited by the defect geometry. As a result, 
Chapter IV describes the development of a settable TCP-PUR formulation in which the 
surface of the ceramic filler was modified to improve the interactions with the PUR 
binder. The effect of surface modification was evaluated on the mechanical and in vitro 
biological performance of the biocomposites.  
 In contrast to slow resorbing TCP, allograft bone particles (ABP) remodel by 
osteoclastic resorption followed by osteoblastic new bone deposition.
28
 Thus, ABPs were 
included in PUR composites to study the effect of design parameters on the healing of 
settable bone grafts in vivo. The design parameters, studied in Chapter V, are the rates of 
new bone formation, matrix resorption, and polymer degradation. Biocomposites were 
augmented with recombinant human bone morphogenetic protein-2 (rhBMP-2) to 
modulate the rates of new bone formation and polymer degradation. Instead, in Chapter 
VI, the influence of filler particle size, loading, and mineral content on the ABP-PUR 
biocomposites’ remodeling mechanisms are considered. Each chapter reports the 
handling and mechanical properties of the appropriate formulations. The composites were 
delivered to cylindrical defects in the femoral condyle of New Zealand White rabbits, and 
the remodeling progression was evaluated by X-
and histomorphometry at 0, 6, and 12 weeks.  
 In order for biocomposites to be effectively integrated into the bone remodeling 
cycle they must undergo active resorption at a similar rate to that of new bone 
formation.
29
 Consequently, detailed understanding of the osteoclastic effect on different 
5 
 
materials is valuable information for the designing functional biocomposites which 
promote bone regeneration. Chapter VII introduces an in vitro cell culture protocol to 
study the differentiation and resorptive activity of murine bone marrow cells in the 
presence of biomaterials. Implementation of the protocol is described to quantify the 
volumetric resorption rate of dentin in the presence and absence of rhBMP-2.  
 To conclude, Chapter VIII summarizes the main findings of this dissertation and 
Chapter IX presents suggestions for future work. As a whole, this dissertation presents a 
compelling argument for wider use and further development of PUR biocomposites. 
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 CHAPTER II 
 
BACKGROUND 
 
General principles of bone tissue engineering 
 Tissue engineering is “an interdisciplinary field of research that applies the 
principles of engineering and the life sciences towards the development of biological 
substitutes that restore, maintain, or improve tissue function’’.1 As such, bone tissue 
engineering aims to develop scaffolds that promote the healing of bone defects generated 
by trauma, disease, primary tumor resection, and/or congenital deformation.
2-5
  
 Bone is a dynamic tissue under constant remodeling in the body. This is achieved 
by the combined action of 3 cell types: osteoblasts (bone forming cells), osteoclasts (bone 
resorbing cells), and osteocytes (mechanosensor cells entrapped in bone). As a material, 
bone is a natural composite of an organic phase (mainly collagen) and hydroxycarbonate 
apatite.
6
 It is organized in two architectural forms: trabecular or porous bone, and cortical 
or compact bone.
7
 Depending on the location in the body, the architectural organization 
determines target bone mechanical properties. 
 Several requirements have been identified for bone tissue engineering scaffolds. 
These focus on achieving mechanical as well as biological properties that will favor 
scaffold replacement by new and functional bone in time. As a result, successful bone 
scaffolds must: 
(a) be biocompatible, or support normal cellular activity without any local and 
systematic toxic effects to the host tissue,
6
 
9 
 
(b) be osteoconductive, or provide a surface for bone cells to adhere, proliferate, 
migrate, and deposit new bone, 
(c) be osteoinductive, or capable of inducing new bone formation through the 
recruitment of osteoprogenitor cells, 
(d) have mechanical properties similar to those of the surrounding host bone, 
(e) have interconnected pores to facilitate diffusion of nutrients and oxygen required 
for the survival of cells, and 
(f) be bioresorbable or degradable in a controlled manner such that they are replaced 
by new bone. 
 
Characterization of bone scaffolds  
 Proper characterization of bone scaffolds encompasses multiple strategies from 
several design perspectives. Table 2.1 lists various design perspectives, corresponding 
parameters, and utilized methods to characterize bone scaffolds. The list is organized 
generally as proceeding from fabrication (top) to implementation (bottom). This section 
provides a summary of some techniques and protocols listed. A detailed discussion about 
how the techniques work is not provided since this falls outside the scope of the chapter, 
but citations to previous work applying these techniques have been included as reference. 
Characterization of polymer scaffolds often requires analysis of polymer 
composition and structure since these parameters influence scaffold processability and 
final performance. Molecular weight distribution is usually quantified using gas 
permeation chromatography.
34, 35
 Differential Scanning Calorimetry (DSC) is used to 
identify thermal transitions such as the glass transition and melting temperatures.  
 
10 
 
Table 2.1. Characterization methods for bone scaffolds 
Type Category Parameter(s) Method(s) 
Handling  
Viscosity 
Shear rate profile, 
Injectability 
Rheometer, Viscometer 
8
, MTS 
9, 10
 
Cure profile 
Working time 
(storage and loss 
modulus) 
Rheometer, Gillmore 
needle 
9, 11, 12
 
Reaction 
conditions 
Thermodynamics Exotherm  
DSC, Thermal couple
13, 
14
 
Conversion Composition 
NMR 
15
, FTIR 
16, 17
, 
XRD 
18
 
Static  
Volumetric 
properties 
Architecture: 
porosity, size, shape  
SEM 
8, 19, 20, 16, 21, 13, 22, 18, 
9, 11, 15, 23
, mCT 
15
, 
Stereological approach 
13
, Gravimetric 
19, 20, 24, 
16, 9, 11, 12, 25
, Mercury 
intrusion 
16
 
Aqueous 
interaction 
Swelling (volume), 
absorption (mass) 
Gravimetric 
21, 13, 15, 14
 
Biocompatibility  
Cellular 
interaction 
In vitro: cell 
proliferation, 
viability, 
morphology  
MTT 
26, 22, 27
, live/dead 
19, 28, 21, 29, 22, 30, 15, 10, 27
, 
SEM 
30
, Microscopy 
15, 
27
 
In vivo: cell 
identification 
Histology 
28, 26, 17, 31
 
Biomechanics 
Rheology 
Shear rate (Yield 
stress), Elastic 
modulus 
Rheometer 
21
 
Compression 
24
, 
torsion, fatigue, 
tensile, three-
point bending 
Stress vs. strain, 
strength, modulus, 
energy to failure 
DMA 
25
, Instron 
19, 20, 32, 
18, 15
  MTS 
16, 9, 12, 33, 23, 
14
, Universal Testing 
Machine 
10
 
Degradation  
In vitro Composition 
Gravimetric 
26, 9, 11
, 
HPLC 
In vivo Presence  Histology 
26
 
 
Standard thermal analysis protocols include a combination of heat-cool-heat 
cycles with heating and cooling rates of 5-10 C min-1, and identification of the thermal 
transitions from the second heating cycle.
36, 37
 DSC can also be used to quantify the 
crystalline content of the polymeric phases,
38, 34
 although more detailed information about 
crystallinity can be obtained using X-ray diffraction techniques.
39
 Rotational rheometers 
have been used to measure viscosity as well as the storage (G’) and loss (G”) moduli of 
11 
 
flowable formulations.
40
 Additional protocols to measure viscosity include the use of 
more traditional Ubbelohde viscometers.
41, 42
 
The porous architecture of bone scaffolds has a direct impact on the mechanical 
properties, degradation rates, and cellular infiltration of the materials. Although high 
porosity and interconnectivity are desired to support cellular infiltration, mechanical 
properties decrease with porosity
 
squared, while the effect on degradation rates varies 
depending on the material. Pore size distribution and morphology can be evaluated using 
Scanning Electron Microscopy (SEM). To do so, a thin section of the material is gold 
sputter-coated and imaged at different locations. Images are used to measure pore 
diameter which is reported either as an average (n>100) or after applying a statistical 
correction to account for non-ideal spherical pores.
40,42,43
 Porosity is commonly 
determined gravimetrically by comparing dry scaffold density (F) with the density of 
bulk material () according to: .44, 45 X-Ray microtomography (CT) 
has also been used to accurately quantify porosity. In this case, dry scaffolds are scanned 
in a CT system at high resolution modes, and porosity values are obtained after 
thresholding the reconstructed image.
46-48
 Pore size distribution, total pore volume, 
surface area, and density can also be obtained using mercury intrusion porosimetry 
(MIP),
49, 34
 although interconnected pores are required in order to obtain representative 
results using this technique.  
In vitro degradation profiles of scaffolds are determined by incubating samples at 
37C in phosphate-buffered saline (PBS) at various pH levels, enzyme-containing media, 
or oxidative media.
34,50,47,39
 At each time point, the media with degradation products is 
collected and the dry sample mass is measured and compared to the initial sample mass. 
12 
 
In addition to reporting the mass loss in time, the media collected can be analyzed with 
techniques such as high-performance liquid chromatography (HPLC) to determine the 
nature and concentration of the degradation products.  
Depending on the specific application of the bone scaffold, specific mechanical 
requirements must be achieved under tension, compression, and/or torsion. Mechanical 
testing of the samples resulting in stress-strain data is conducted with protocols modeled 
by standard methods.
51-53
 Reported properties usually include compressive and tensile 
modulus and strength.
50,37,44,38,34
 
 
Scaffolding materials for bone tissue engineering 
Autologous bone remains the standard of care for the treatment of bone defects 
due to its ideal osteogenic, osteoinductive and osteoconductive properties for bone defect 
healing. However, limited availability, postsurgical morbidity at the donor site, increased 
lengths of surgery and higher costs associated with autograft use
54
 have increased the 
demand for alternative materials, such as allograft bone. In 2002, more than 980,000 
bone allografts were distributed in the US and their usage was reported to be increasing.
55
 
Even though sterilization and viral inactivation of allograft bone render the material 
suitable for clinical use, the available shapes are limited by the donor source.
56
 As a result, 
bone tissue engineering efforts have focused on the development of synthetic grafts that 
promote healing of bone defects. The following sections discuss the characteristics and 
performance of several of these formulations. 
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Low porosity calcium phosphate cements 
Since their initial discovery in 1982,
57
 injectable calcium phosphate cements 
(CPCs) have been successfully introduced into the clinic for a number or orthopaedic and 
craniomaxillofacial applications, including repair of tibial plateau fractures and calvarial 
defects. CPCs have been investigated extensively as injectable bone replacement 
biomaterials due to their similar chemical composition to the mineral component of bone, 
biocompatibility,
58
 osteoconductivity, and fast setting times (< 5 min).
59
 These 
biomaterials set at a physiological pH with minimal reaction exotherm and do not release 
toxic monomers or solvents.
60, 18
  Apatite, which has low solubility and resorbs slowly, 
and brushite, which has higher solubility than apatite and resorbs more rapidly, comprise 
the two primary classes of CPCs.
61
 While CPCs set by an acid/base reaction that can 
reduce the pH of the paste to values as low as 3,
32
 a number of in vivo studies have 
reported favorable host responses after setting.
24, 17
 In a recent study, the mechanism of 
cell-mediated degradation of brushite CPCs was investigated by culturing RAW264.7 
cells on the cements in vitro.
30
 The RAW264.7 cells differentiated to macrophages, 
multinucleated giant cells, as well as osteoclast-like cells, on the brushite CPCs. SEM 
analysis of the ultra-structure of osteoclast-like cells revealed characteristics associated 
with the osteoclast phenotype, such as formation of a sealing zone and ruffled border. 
Furthermore, osteoclast-like cells were observed to penetrate deep into the interior of the 
cements, which suggests that brushite CPCs are demineralized by osteoclast-mediated 
resorption in vivo.   
In a promising area of new research, the effects of nanometer-scale calcium 
phosphate (CaP) crystals on cellular interactions are under investigation.
62
 Coating of 
14 
 
mesenchymal stem cells with CaP nanorods has been reported to exhibit enhanced 
osteoblastic differentiation and production of extracellular matrix production relative to 
uncoated cells,
63
 which suggests that nanoscale injectable CPCs may be desirable carriers 
for stem cells. However, while nanostructured CaPs enhance osteoblast differentiation, 
the rate of cellular infiltration into monolithic cements is limited by osteoclast-mediated 
resorption. This rate of infiltration is relatively slow (i.e., 0.02 μm3 μm-2 day-1), in 
contrast to migration and proliferation of cells through interconnected pores.
64
 Thus, a 
number of recent studies have investigated new methods for introducing macropores into 
injectable CPCs to enhance cellular infiltration and remodeling. 
 
 Porous calcium phosphate cements 
Primary limitations of first-generation low porosity CPCs restricting their use in 
the clinic include brittle mechanical properties, which lead to low shear strength and 
fracture toughness; slow degradation in vivo;
65
 and the small pore size (0.1 – 10 m), 
which results in slow cellular infiltration and ingrowth of new bone.
58,66
 Both low 
porosity as well as small pore size in CPCs contribute to slow remodeling and ingrowth 
of new bone, and have thus been suggested as a root cause for the failure of CPCs in 
periodontal bone repair.
67
 Slow remodeling of CPCs has also been suggested to 
contribute to their failure in cranioplasty applications.
68
 Therefore, recent studies have 
focused on introducing macropores into CPCs and improving their mechanical properties 
while preserving their favorable biocompatibility in order to improve their clinical 
performance. 
15 
 
 Interconnected macropores >10 μm are essential for promoting infiltration of cells 
and ingrowth of blood vessels and new bone into CPCs,
69, 70
 as well as for polymeric 
scaffolds such as hydrogels.
15
 In order to preserve the excellent biocompatibility and 
osteoconductivity of CPCs, adjuvants added to create macropores must be non-cytotoxic.  
In one approach, multi-phasic cements have been prepared by combining soluble ceramic 
particles, such as calcium sulphate, with less soluble particles, such as triccalcium 
phosphate or hydroxyapatite.
71,23
 A bi-phasic CPC was fabricated by mixing α-tricalcium 
phosphate (α-TCP), calcium sulphate hemihydrate (CSH), and an aqueous solution 
containing 2.5 wt% Na2HPO4.
33
 The resulting cement comprised an apatitic phase 
(calcium-deficient hydroxyapatite, CDHA) and a soluble phase (calcium sulphate 
dihydrate, CSD). After setting, the soluble CSD and CSH phases dissolved, resulting in 
pores that facilitated the ingrowth of new bone in a rat on-lay graft model.
31
 The 
technology has been licensed to BoneSupport and is marketed as CERAMENT™ bone 
void filler for spinal and orthopaedic indications. Recent clinical studies have highlighted 
the potential of the partially resorbable biphasic (60% calcium sulphate/40% 
hydroxyapatite) CERAMENT™ CPC as an effective substitute for non-resorbable 
poly(methyl methacrylate) (PMMA) for treatment of osteoporotic and traumatic vertebral 
fractures.
72, 73
 
 
Composites with calcium phosphates 
A number of other strategies have been investigated for fabricating injectable 
macroporous CPCs. Foaming agents such as surfactants,
12
 hydrogen peroxide solution,
16
 
carbon dioxide,
74
 or hydrophobic liquids,
75
 have been utilized to fabricate injectable 
16 
 
calcium phosphate foams. In one study, the surfactant sodium dodecyl sulphate (SDS) 
was used as an air-entraining agent to create macroporous CPCs.
12
 Micro- and 
macroporosity were controlled by the liquid-to-powder ratio and the concentration of 
SDS, which stabilized the bubbles formed by the setting reaction of the cement. 
Alternatively, biocompatible and degradable polymeric microspheres such as poly(lactic-
co-glycolic acid) (PLGA),
76
 poly(trimethyl carbonate), or gelatin
9, 11
 have been 
investigated to synthesize macroporous CPCs. CPCs incorporating degradable porogens 
offer the additional advantage of local delivery of drugs or growth factors, since biologics 
can be encapsulated in the porogens prior to embedding in the calcium phosphate 
matrix.
77
 While incorporation of PLGA microspheres in CPCs has been suggested to 
improve the initial strength of the composites, the strength decreases upon dissolution of 
the microspheres and does not increase until new bone starts to grow into the 
macropores.
78
 To improve the injectability of CPC incorporating 30 wt% PLGA 
microspheres, sodium citrate was added to the aqueous solution, which reduced the 
viscosity of the paste. Due to their macroporosity, injectable CPCs incorporating a 
porogen have significant advantages compared to monolithic CPCs.  Thus, macroporous 
CPCs are anticipated to be considered a preferred choice for healing of bony defects after 
regulatory approval.
65
 In an alternative approach, CaP granules suspended in aqueous 
solutions of hydroxy-propylmethyl-cellulose promoted faster initial ingrowth of new 
bone at the surface of the material, relative to macroporous CPCs.
28, 79
 It has been 
suggested that the observed early apposition of new bone could potentially enhance the 
interfacial bonding between host bone and the CPC, thus reinforcing the material for 
weight-bearing applications.
65
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 Polymeric bone scaffolds 
Polyesters are among the most studied biodegradable materials for biomedical 
applications.
80-83
 The degradation profiles and mechanical properties of polyesters can be 
tailored according to the final application by modifying the backbone composition. Due 
to this versatility, polyester scaffolds have been developed for bone, cartilage, and 
meniscus among other applications.
84, 82
 The main degradation mechanism of polyesters 
is hydrolytic chain scission of the ester bonds in the backbone.
85, 82, 86, 80
 Degradation 
products in vivo are incorporated into the tricarboxylic acid cycle (TCA) and secreted 
from the body.
82, 85
 
Poly(propylene fumarate) (PPF) is a linear, unsaturated, cross-linkable, and 
biodegradable polyester.
87, 88, 35, 42
 used in bone scaffolds. Physical, mechanical, and 
degradation properties of PPF networks can be tuned by modifying one or several 
formulation parameters such as macromer molecular weight, cross-linking density, nature 
of the cross-linking agents, and porosity. Increased molecular weight of the linear PPF 
has been suggested to increase glass transition temperatures and viscosity.
88
 Increased 
viscosity allows PPF to be injected into irregular shaped defects to later be cross-linked in 
situ. PPF networks exhibit a wide range of mechanical properties, which increase with 
higher cross-linking densities.
89
 PPF degrades by hydrolysis of the ester bonds into 
propylene glycol and fumaric acid.
87
 Fumaric acid is incorporated into the TCA cycle, 
while propylene glycol, which is a commonly used food additive, can be secreted by the 
body without generating any toxic reaction. Techniques to produce porous PPF-based 
scaffolds include crosslinking in combination with salt-leaching,
90
 emulsion templating,
44, 
42
 gas foaming,
91
 and a combination of 3D printing and injection molding.
92
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Tyrosine-derived polymers have been developed as materials with significant 
biological compatibility due to the presence of naturally occurring building blocks and 
degradable bonds, as well as high mechanical properties provided by the aromatic rings 
in their backbone. The main building block of these polymers is the diphenolic monomer 
Desaminotyrosyl-L-Tyrosine alkyl ester (DTR, where R represents the alkyl pendant 
group) which is obtained from the carbodiimide-mediated reaction between L-tyrosine 
alkyl ester and desaminotyrosine (DAT).
93
 DTR can be polymerized with different 
reagents to create tyrosine derived polymers with a range of mechanical properties and 
degradation profiles. Reaction with phosgene, dicarboxylic acids, or alkyl or aryl 
dichlorophosphates generates poly(DTR carbonates),
36
 poly(DTR arylates), or poly(DTR 
phosphate esters) respectively.
93
 Tyrosine-derived polycarbonate foams have been 
prepared using a combination of solvent casting/porogen leaching techniques.
36
 
Polymeric scaffolds for bone tissue engineering have been developed 
incorporating the materials described above. PPF foams prepared by solvent casting 
followed by salt leaching have been tested in calvarial defects in vivo and shown to be 
biocompatible and support new bone formation after 8 weeks.
90
 Tyrosine-derived 
polycarbonates containing DTR, DT, and PEG, prepared using a combination of solvent 
casting, porogen leaching, and phase separation techniques have also been tested both in 
vitro and in vivo. The scaffolds had 85% porosity, a bimodal pore size distribution with 
macropores >200 m and micropores <20 m,36 and a compressive modulus >0.5 MPa 
(minimal requirement for bone graft substitutes) after 6 weeks of incubation in PBS at 
37C.94 When tested in vivo using a critical size calvarial defect in New Zealand White 
rabbits, the materials generated minimal inflammatory response and degraded faster than 
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under in vitro conditions. New bone formation was promoted when the scaffolds were 
loaded with 50 g of recombinant human bone morphogenetic protein-2 (rhBMP-2) or 
coated with calcium phosphate.
94
 Recently, PLGA porous scaffolds with pore sizes in the 
range of 200-600 m were prepared via thermal sintering of PLGA spheres and porogen 
leaching.
48
 The scaffolds had initial mechanical properties in the range of human 
trabecular bone, and improved oxygen diffusion across the scaffold. This last property is 
of interest for the treatment of large-area bone defects to support cellular infiltration deep 
into the scaffolds. In general, the in vivo performance of polymeric scaffolds in bone 
defects has shown to be improved with the incorporation of ceramic fillers or biologics 
which provide osteoinductive properties to the already biocompatible and 
osteoconductive materials. Examples of ceramic fillers include calcium phosphates,
95-97
 
allograft bone,
98
 and bioactive glass,
99, 100
 while biologics include rhBMP-2,
94, 101
 
lovastatin,
102
 and TGF-β.103 
 
 Biodegradable polyurethanes 
 Polyurethanes (PUR
104
) comprise a diverse family of materials including cast 
elastomers, thermoplastic elastomers, and flexible foams. Due to their toughness, 
durability, biocompatibility, and improved biostability, they have been incorporated in a 
wide variety of implantable biomedical devices. Biodegradable polyurethanes prepared 
from biocompatible intermediates, such as polyester polyols and aliphatic and lysine-
derived polyisocyanates, have attracted considerable interest recently for use as tissue 
scaffolds and drug delivery systems.
104, 105
 Their ability to be processed by reactive liquid 
molding renders polyurethanes useful as injectable biomaterials for minimally invasive 
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surgeries, in which the material is injected as a reactive viscous liquid that cures in situ to 
form a viscoelastic solid scaffold. Furthermore, macropores that facilitate cellular 
infiltration can be generated within the scaffold by the process of gas foaming through 
the reaction of isocyanate groups with water
106-108
 or by encapsulation of porogens.
109
 
 
Figure 2.1. Schematic summarizing the synthesis of injectable polyurethane (PUR) foams from 
viscous liquid precursors.  
 
 
The synthesis of injectable PUR scaffolds is shown in Figure 2.1. Component 1 
comprises either an isocyanate or an isocyanate-terminated prepolymer, while 
Component 2 includes all components with active hydrogen groups that react with the 
isocyanate (NCO) groups. The polyol component, which comprises a hydroxyl-
terminated macromer with a polyester, polyether, or polycarbonate backbone, reacts with 
the prepolymer to form a polymer network linked by urethane groups (the gelling 
reaction). The NCO groups also react with water, either added to the formulation or 
present in the wound environment, to yield a di-substituted urea and gaseous carbon 
dioxide, which acts as a blowing agent to form interconnected macropores within the 
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PUR network 
107, 108, 106
 as shown in the SEM image (Figure 2.1). The working time, 
identified by the G’-G” crossover point (rheological profile in Figure 2.1) where the foam 
transitions from a viscous liquid to an elastic solid, can be tuned to targeted values using 
urethane catalysts, such as tertiary amines
110
 or organometallic compounds. Amine-based 
catalysts have low cytotoxicity
111
 and selectively catalyze the water-isocyanate blowing 
reaction,
112
 while the more cytotoxic organometallic catalysts selectively catalyze the 
polyol-isocyanate gelling reaction. In contrast to the temperatures during cure exceeding 
100
o
C observed for aromatic isocyanates, the exotherm for lysine-derived PUR foams is 
<20
o
C (temperature profile in Figure 2.1). Other additives, such as stabilizers and pore 
openers to control miscibility and pore size,
106
 matrix particles to control expansion and 
increase mechanical properties, or biologics to enhance bioactivity,
113
 can also be 
included in component 2.  
While biodegradable PUR foams have been synthesized from aliphatic 
polyisocyanates,
114
 lysine-derived polyisocyanates have shown the greatest promise for 
injectable and settable systems.
107, 115-117, 108, 110, 112, 118
 Reactive PUR scaffolds prepared 
from lysine-derived polyisocyanates, including lysine methyl ester diisocyanate (LDI) 
and lysine triisocyanate (LTI), and tertiary amine catalysts, have been reported to induce 
a minimal inflammatory response on host tissue in both cutaneous and bone defects in 
vivo.
115, 108, 112, 118
 Furthermore, in vitro cytotoxicity testing of the leachates from the 
reactive PUR has shown that the reactive PUR components are non-toxic.
112
 These 
studies highlight the potential of injectable and settable lysine-derived PURs for both soft 
and hard tissue regeneration.  
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Polyurethane scaffolds for bone regeneration 
PUR biocomposites derived from LDI
108, 119
 and LTI
110, 120, 121
 have been 
investigated as injectable bone void fillers and cements. An extracellular matrix 
component, such as demineralized bone matrix (DBM), calcium phosphate particles, or 
allograft bone particles, is blended with the reactive PUR to increase the 
osteoconductivity and mechanical properties of the graft and also to reduce its volumetric 
expansion in situ. Lysine-derived PUR composites are injectable, set within clinically 
relevant working times (e.g., 5-10 min) to form grafts with mechanical strength 
approaching that of host bone, and remodel and heal to form new bone. In an early study, 
a four-armed poly(dioxanone-co-glycolide) prepolymer capped with LDI was mixed with 
calcium phosphate particles in the presence of an diethanolamine catalyst and water to 
form a reactive putty that expanded to form a foam with interconnected pores.
108
 When 
implanted into the pectoralis muscles of rats for up to 42 days, the putty exhibited a 
transient inflammatory response that resolved after 3 days. At longer time points, the 
foams were well integrated with host tissue and showed no evidence of a chronic 
inflammatory reaction.   
In a similar study in bony defects, a settable foam was prepared by reacting an 
LDI-pentaerythritol prepolymer with a poly(lactide-co-glycolide) polyol (functionality of 
4).
119
 The two reactive liquid components were mixed with stannous octoate catalyst, 
water, and β-tricalcium phosphate particles (10 μm) and injected into femoral condyle 
plug defects in sheep, where they cured in ~10 min and expanded for form porous foam. 
Defects showed progressive healing from 6 to 24 weeks, characterized by the formation 
of new cortex, polymer degradation, and appositional bone growth with no signs of acute 
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or chronic inflammation. Cells infiltrated the foam through the processes of migration 
into open pores as well as polymer degradation.  
In an alternative approach, injectable foams prepared from an LTI-PEG 
prepolymer, a poly(ε-caprolactone-co-lactide-co-glycolide) triol, allograft bone particles 
(180 μm), and the low-toxicity tertiary amine catalyst triethylene diamine were evaluated 
in femoral condyle plug defects in rats
110
 and rabbits.
112
 Compared to LDI prepolymers, 
the LTI-PEG prepolymer has reduced viscosity (20,000 cSt versus 80,000 cSt for LDI-
pentaerythritol) and higher reactivity.
112
 Cells infiltrated the scaffold through migration 
into open pores, surface degradation of the PUR to non-cytotoxic breakdown products, 
and osteoclast-mediated resorption of the allograft bone particles, with no signs of 
chronic inflammation.  
While challenges including controlling expansion due to the gas blowing reaction 
and matching the rate of new bone formation to polymer degradation need to be 
addressed, the ability of PUR grafts to cure in situ without adversely affecting host tissue, 
degrade to non-cytotoxic breakdown products, and support infiltration of cells and new 
tissue underscores their potential as scaffolds for bone repair. 
 
Polyurethane scaffolds as drug delivery systems 
Lysine-derived PUR scaffolds have also been investigated as drug delivery 
systems to support both diffusion-controlled release of biologics added as labile 
powders
121-125
 as well as degradation-controlled release of drugs covalently bound to the 
polymer.
117, 126, 127, 116, 128
 An example of diffusion-controlled drug delivery is presented in 
Figure 2.2. SEM (Figure 2.2.A) and confocal (Figure 2.2.B) images of an LTI-polyester 
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foam augmented with FITC-labeled BSA as a labile powder show discrete BSA-FITC 
particles distributed throughout the scaffold.   
 
 
Figure 2.2. Drug delivery from PUR scaffolds. (A) SEM image of an LTI-polyester foam. (B) 
Confocal image of LTI-polyester foam augmented with FITC-labeled BSA as a labile powder. 
Discrete BSA-FITC particles can be observed uniformly distributed throughout the material. 
 
In a recent study, injectable LTI-derived PUR/allograft bone composites 
augmented with recombinant human bone morphogenetic protein-2 (rhBMP-2) as a labile 
powder enhanced new bone formation at 6 weeks in a critical-size rabbit calvarial defect 
model
120
. In other studies, diffusion-controlled release of the antibiotic vancomycin and 
rhBMP-2 controlled infection
123
 and enhanced bone healing
129
 in critical-size defects 
contaminated with 10
5
 Colony Forming Units (CFUs) S. aureus. Release of other 
biologics, such as nanoparticles delivering siRNA,
124
 added to injectable PUR bone grafts 
as a labile powder has also been reported to be diffusion-controlled, with sustained 
release for up to 3 – 8 weeks.  
In an alternative approach, drugs with active hydrogen groups (e.g., primary 
hydroxyl groups and amines), such as ascorbic acid,
130
 naphthalene compounds,
117
 and 
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the anti-tumor drug 7-tert-butyldimethylsilyl-10-hydroxy-camptothecin (DB-67),
128
 were 
dissolved in the reactive PUR prior to injection and subsequently released in biologically 
active form by degradation of the polymer. Recent studies have reported that the release 
kinetics can be controlled by the composition of the drug,
117
 the choice of catalyst,
116
 or 
the addition of ionic ligands,
126
 which offer greater tunability compared to diffusion-
controlled release. Potential advantages of covalently binding drugs to PUR scaffolds 
include the ability to increase drug loading and control release to achieve therapeutically 
relevant doses. For example, clinical evaluation of DB-67 has been limited by the 
inability to deliver it in sufficient quantities to slow tumor growth and disease 
progression. When DB-67 was covalently incorporated into LDI-glycerol PUR scaffolds, 
it was released in vitro at a rate suitable for delivering therapeutic concentrations of the 
drug and inhibited cellular proliferation by 50% for several malignant glioma cell 
lines.
128, 126
 While the degradation-controlled release mechanism has proven successful 
for small molecule synthetic drugs, another study has reported that recombinant human 
proteins dissolved in the aqueous phase prior to foaming are not released from the cured 
foam in a biologically active form.
121
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CHAPTER III 
 
EFFECTS OF LOCAL DELIVERY OF D-AMINO ACIDS FROM BIOFILM-DISPERSIVE 
SCAFFOLDS ON INFECTION IN CONTAMINATED RAT SEGMENTAL DEFECTS 
 
Introduction 
Despite meticulous treatment, infectious complications of open bone fractures 
continue to be a significant factor contributing to patient morbidity and poor healing 
outcomes. The ensuing infection of bone by bacteria (osteomyelitis) is characterized by 
high levels of inflammation and destruction of viable bone tissue. Often the infection 
becomes chronic, resulting in increased rates of surgical revisions, non-union, and 
extremity amputation 
1-3
. Among the pathogenic microorganisms associated with chronic 
osteomyelitis, Staphylococcus aureus is the most frequently isolated organism, 
accounting for >50% of all cases 
4-8
. In addition to the increasing trend of antimicrobial 
resistance among clinical isolates, biofilm formation is a significant contributing factor in 
the development of both device and non-device related chronic orthopaedic infections 
and a major barrier to wound healing 
6, 4
.   
Bacterial biofilms are an association of single or multiple species attached to a 
surface surrounded by an extracellular polymeric matrix (EPM), which constitutes a 
protected mode of growth. Compared to their planktonic counterparts, biofilm-derived 
bacteria have distinctive phenotypes in regards to growth, gene expression, and protein 
production that confer resistance to antimicrobial agents as well as host mechanisms of 
clearance 
5, 9
. Importantly, bacterial biofilms have been associated with a broad range of 
human infections, including chronic non-device-related infections such as osteomyelitis
10, 
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11
. Previous studies have reported that staphylococcal biofilms are present within infected 
bone of patients with chronic osteomyelitis 
6-8
, and that clinical osteomyelitis isolates of S. 
aureus are capable of forming biofilms in vitro 
12-14
. Furthermore, staphylococcal 
biofilms have been implicated as a major cause of osseous non-union 
15
. These studies 
suggest that staphylococcal biofilms play a critical role in both the development of 
chronic osteomyelitis and the sequelae of infectious complications.  
Biofilm development is a highly coordinated and reversible process beginning 
with the attachment and proliferation of cells on a surface and culminating in the 
dispersal of cells from the biofilm into the surrounding environment. The dispersal of 
cells is an essential stage of the biofilm life cycle that contributes to survival of the 
organism and disease transmission. For both Gram-positive and Gram-negative 
microorganisms, biofilm dispersion is mediated by self-produced diffusible factors 
16, 17
. 
Considering the specificity and effectiveness of these molecules for dispersing biofilms, 
the use of biofilm dispersal agents has attracted considerable interest for the treatment of 
biofilm-associated infections 
18, 19
. Recent studies have shown that use of biofilm 
dispersal agents, including bismuth thiols 
20
, recombinant DNAses 
21
, and diffusible 
soluble factors 
22, 23
, can disperse biofilms in vitro and improve healing of biofilm-
associated infections in vivo 
24, 25
. However, toxicity to viable host tissues (as observed 
for bismuth thiols and xylitol), as well as the specificity of these agents for certain 
bacterial species and/or strains, may preclude their use as broad therapeutic strategies. 
Recent studies have shown that the D-isomers of amino acids (D-AAs) can 
prevent and disperse biofilms formed by a diverse range of bacterial species, including S. 
aureus and P. aeruginosa 
26, 27
. In contrast to other biofilm dispersal agents, D-AAs 
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promote the disassembly of biofilms through multiple mechanisms and have minimal 
cellular toxicity 
28
. In this study, we investigated the ability of biofilm-dispersive 
polyurethane (PUR) scaffolds augmented with D-AAs to protect the scaffold from 
contamination from the contiguous wound environment and to reduce microbial burden 
within segmental defects in vivo. A mixture of D-AAs with optimal in vitro anti-biofilm 
activity was evaluated in a rat contaminated segmental defect model to test our 
hypothesis that local delivery of D-AAs would reduce the extent of infection within the 
defect. We also investigated the cytotoxicity of D-AAs on host mammalian cells to 
further evaluate their therapeutic potential. 
 
Experimental 
Materials 
D- and L-isomers of amino acids (free base form), including alanine, isoleucine, 
leucine, methionine, phenylalanine, proline, tryptophan, tyrosine, and valine, were 
purchased from Sigma Aldrich (St. Louis, MO, USA). For use in bacterial and cell 
cultures, D-AA stocks were prepared by dissolving powders in 0.5 M HCl at 
concentrations between 150-200 mM. Stocks were then diluted into cation-adjusted 
Mueller Hinton (MHB-II) broth neutralized to pH 7.4 and stored at -80°C. For 
polyurethane scaffold synthesis, ε-caprolactone and stannous octoate were supplied by 
Sigma-Aldrich, and glycolide and D,L-lactide were purchased from Polysciences. An 
isocyanate-terminated prepolymer (22.7% NCO) comprising polyethylene glycol (PEG) 
end-capped with lysine triisocyanate (LTI) at a 2:1 molar ratio of LTI:PEG was supplied 
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by Medtronic (Memphis, TN, USA). Triethylene diamine was purchased from Evonik 
(TEGOAMIN 33, Hopewell, VA, USA). 
 
Table 3.1. Description of S. Aureus strains investigated in this study 
Strain Strain characteristics Biofilm formation
a
 
UAMS-1 
ATCC strain 49230. Methicillin-susceptible strain of the 
USA200 clonal group and a well-characterized 
osteomyelitis isolate 
Strong 
Xen36 
Bioluminescent strain modified with the luxABCDE 
operon derived from a methicillin-sensitive clinical 
bacteremia isolate of S. Aureus subsp. Wright (ATCC 
49525) 
Weak 
S.Aureus Clinical 
Isolate 1 
Methicillin-resistant strain of the USA300 clonal group; 
wound isolate 
Strong 
S.Aureus Clinical 
Isolate 2 
Methicillin-resistant strain of the USA300 clonal group; 
blood isolate 
Weak 
S.Aureus Clinical 
Isolate 3 
Methicillin-resistant strain of the USA700 clonal group; 
cultured from deep wound 
Strong 
S.Aureus Clinical 
Isolate 4 
Methicillin-resistant strain of the USA200 clonal group; 
cultured from deep wound 
Strong 
a
 Biofilm formation classification is based on previous studies comparing the biofilm forming capacity 
compared to a biofilm positive control, S. epidermidis ATCC 12228; Strong indicates biofilm ≥ S. 
epidermidis and weak biofilm former ≤ than the control as determined by microtiter plate assay. 14 
 
Bacterial strains and growth conditions 
Four clinical isolates of S. aureus from a repository collected from patients 
admitted for treatment not related to research at the San Antonio Military Medical Center 
(SAMMC, Ft. Sam Houston, TX, USA) were used in this study 
14
. Characteristics of the 
clinical isolates used in this study, which were previously confirmed to be positive for 
biofilm formation, are described in Table 3.1. UAMS-1 (ATCC strain 49230) is a 
methicillin-susceptible S. aureus strain of the USA200 clonal group and a well-
characterized osteomyelitis isolate 
29, 30
. Xen36 is a bioluminescent strain modified with 
the luxABCDE operon (Caliper Life Sciences Inc.) derived from a methicillin-sensitive 
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clinical bacteremia isolate of S. aureus subsp. Wright (ATCC 49525). All bacterial 
strains were cultured in tryptic soy broth (TSB) with agitation or on blood agar plates 
overnight at 37°C. 
 
Biofilm formation in 96 well plates and dispersal assays 
Biofilm formation was assessed under static conditions using polystyrene 96-well 
plates (Corning, Inc., Corning, NY, USA) as described previously 
31, 32
. Briefly, overnight 
bacterial cultures were diluted to an OD600 of 0.1 in TSB (~10
7
 CFU/mL), and 20 µL 
were added to individual wells filled with 180 µl of media and incubated at 37°C for 48 h. 
To assess the biofilm dispersal activity of D-AAs, the culture medium from biofilms was 
removed after 48 h and 200 µL fresh medium containing either an individual D-AA or an 
equimolar mixture of D-AAs (1:1:1: D-Met:D-Pro:D-Trp) were added at the indicated 
concentrations. We chose this particular combination because of the individual D-AAs 
broad activity in the in vitro evaluation against clinical isolates. After treatment with D-
AA(s) for 24 h, plates were gently washed with 1X phosphate buffered saline (PBS) to 
remove unattached cells, stained with 0.1% (w/v) crystal violet (Sigma Aldrich, St. Louis, 
MI, USA) for 10 min, rinsed with PBS, and then solubilized with 80% (v/v) ethanol. 
Biofilm biomass was determined by measuring the absorbance of solubilized stain at 570 
nm using a microtiter plate reader. For assays measuring the ability of D-AA to block 
biofilm formation, cells were grown under biofilm conditions as above in the presence of 
media containing D-AAs. Representative images of the plates of CV-stained biofilms 
following treatment with D-AA prior to solubilization were taken using a digital camera. 
All assays were repeated in triplicate with a minimum of four technical replicates. 
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Cell viability assays 
Human dermal fibroblasts and osteoblasts (PromoCell, Heidelberg, Germany) 
were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, Grand 
Island, NY, USA) supplemented with 10% Fetal Bovine Serum (FBS) and 1X 
penicillin/streptomycin at 37°C in 5% CO2. Prior to each assay, cells were seeded at 
100% confluence in black-clear bottom 96-well plates. After 24 h cells were exposed to 
media containing D-AA (1 nM-50 mM) and incubated for 24 h. Following treatment, 
cells were washed, re-suspended in 100 µL of sterile saline, and assessed for viability 
using the CellTiter-Fluor Cell Viability Assay (Promega, Madison, WI, USA) following 
the manufacturer’s instructions. Viability assays were performed in triplicate with a 
minimum of four replicates. Viability was reported as the percentage of viable cells 
relative to untreated controls. 
 
Synthesis of polyurethane (PUR) scaffolds 
Polyester triols with a molecular weight of 900 g mol
-1
 and a backbone 
comprising 60 wt% ε-caprolactone, 30% glycolide, and 10% lactide (T6C3G1L900) were 
synthesized using published techniques 
33, 34
. Appropriate amounts of dried glycerol and 
ε-caprolactone, glycolide, DL-lactide, and stannous octoate (0.1 wt-%) were mixed in a 
100-ml flask and heated under an argon atmosphere with mechanical stirring to 140
o
C for 
24 h. The polyester triol was subsequently washed with hexane and dried. The 
appropriate amounts of each D-AA (as received from the vendor) were pre-mixed.  Next, 
the polyester triol, LTI-PEG prepolymer (excess isocyanate 15%), 2.0 parts per hundred 
parts polyol (pphp) tertiary catalyst, 3.0 pphp water, 4.0 pphp calcium stearate pore 
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opener, and the equimolar mixture of D-AAs (0 – 10 wt% total D-AA, 1:1:1 mixture of 
D-Met:D-Pro:D-Trp) were loaded into a 20 ml cup and mixed for 1 min using a 
Hauschild SpeedMixer DAC 150 FVZ-K vortex mixer (FlackTek). The reactive mixture 
was allowed to cure and foam at room temperature for 24 h. Cylindrical samples for in 
vivo testing (~3mm diameter x 6.5mm height) were cut using a coring tool and then 
sterilized by treating with ethylene oxide (EO). 
 
Characterization of PUR scaffolds  
Scaffold density was determined from mass and volume measurements of cured 
samples, from which the gravimetric porosity was calculated as the volume fraction of 
pores as described previously 
35
. After curing, PUR sections were sputter-coated with 
gold and imaged using a Hitachi 4200 SEM. Pore size was determined from the SEM 
images using MetaMorph 7.1 Image Analysis software (MDS Analytical Technologies). 
Compressive mechanical properties of the scaffolds were measured using a TA 
Instruments Q800 Dynamic Mechanical Analyzer (DMA, New Castle, DE). Samples 
were tested after 24 h or 7 days of incubation in PBS. Stress–strain curves were generated 
by compressing wet cylindrical 6 mm x 6 mm samples at 37C at a rate of 0.1 N/min 
until they reached 60% strain. The compressive modulus was determined from the slope 
of the initial linear region of each stress–strain curve. Since the scaffolds could not be 
compressed to failure due to their elasticity, the compressive stress was reported at 50% 
strain 
36
. 
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Scanning electron microscopy (SEM) analysis of biofilm formation on PUR 
scaffold. 
SEM analysis was performed to examine the effect of augmentation with D-AAs 
on bacterial attachment and biofilm formation on the scaffold in vitro and in vivo. PUR 
scaffolds were fixed with 2% (w/v) glutaraldehyde, 2% (w/v) paraformaldehyde (PFA), 
0.15M sodium cacodylate, 0.15% (w/v) alcian blue for 3 h, rinsed 3X with 0.15M sodium 
cacodylate buffer, and incubated in 1% (v/v) osmium tetroxide in sodium cacodylate for 
1 h. Samples were dehydrated with a stepwise gradient of ethanol and then treated with 
hexamethyldisilizane prior to drying in a desiccator overnight. Samples were sputter-
coated with gold palladium and viewed with a Hitachi 4200 or JEOL-6610 scanning 
electron microscope. 
 
D-AA release kinetics 
PUR scaffolds incorporating 10 wt% of a 1:1:1 mixture of D-Met:D-Pro:D-Trp 
were incubated in PBS for up to 8 weeks. The medium was sampled twice weekly and 
analyzed for D-AAs by HPLC using a system equipped with a Waters 1525 binary pump 
and a 2487 Dual-Absorbance Detector at 200 nm. Samples of released D-AAs were 
eluted through an Atlantis HILIC Silica column (5 µm particle size, 4.6 mm diameter x 
250 mm length) using an isocratic mobile phase flowing at 1mL/min 
37
. The mobile 
phase contained 2.5 mM potassium dihydrogen phosphate with pH = 2.85 (A) and 
Acetonitrile (B) at a ratio of A25:B75. The column oven temperature was maintained at 
30C. Sample concentration was determined in reference to an external standard curve 
using the Waters Breeze system. Standard curves were prepared in the following 
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concentration ranges: (1) 7.8 µg/mL to 1 mg/mL for D-Met and D-Pro and (2) 0.78 
µg/mL to 100 µg/mL for D-Trp.   
 
Table 3.2. Study design investigating the ability of biofilm-dispersive scaffolds to reduce bacterial 
contamination in vitro. Scaffolds were contaminated with 10
7
 CFU/ml S. aureus for 2 h and outcomes were 
assessed after 24 h incubation time in PBS. 
Group Description 
PUR (-) Sterile blank PUR scaffold with no D-AAs 
PUR Contaminated blank PUR scaffold with no D-AAs 
PUR + D-AA-0.1 Contaminated PUR scaffold augmented with 0.1% D-AAs 
PUR + D-AA-1 Contaminated PUR scaffold augmented with 1% D-AAs 
PUR + D-AA-5 Contaminated PUR scaffold augmented with 5% D-AAs 
PUR + D-AA-10 Contaminated PUR scaffold augmented with 10% D-AAs 
 
 
Bacterial adhesion to PUR scaffolds 
Bacterial adherence and biofilm formation on scaffolds with or without D-AAs 
was evaluated as described previously 
38
. The study design is listed in Table 3.2. Sterile 
blank PUR scaffolds with no D-AAs were utilized as a negative control (PUR (-)). Blank 
scaffolds (denoted as PUR) or scaffolds augmented with an equimolar mixture of D-AAs 
(denoted as PUR+D-AA-x, where x = 0.1, 1.0, 5.0, or 10 wt% 1:1:1 mixture of D-Met:D-
Pro:D-Trp) were placed into 24-well polystyrene plates containing sterile PBS for 2 h at 
room temperature, which allowed the scaffolds to become saturated. Samples were then 
transferred into a bacterial suspension of UAMS-1 (10
7
 CFU/mL) in PBS and exposed 
for an additional 2 h at 37°C with agitation in 24-well plates. Following exposure, 
scaffolds were rinsed with PBS to remove non-attached bacteria and incubated overnight 
in PBS at 37°C to allow adequate time for attached bacteria to develop biofilms. 
Following incubation, scaffolds were then placed in 1 mL PBS and sonicated for 10 min 
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using a low-power bath sonicator. Bacterial CFUs per gram of scaffold were determined 
by plating serial dilutions on blood agar plates. Bacterial attachment and biofilm 
formation on scaffolds following incubation was also evaluated by SEM analysis. The 
sample size was 3 with duplicate runs. 
 
Table 3.3. In vivo study design investigating the ability of biofilm-dispersive scaffolds to reduce 
contamination in 6-mm segmental defects in rat femora contaminated with 10
2
 CFU of S.aureus UAMS-1 
or Xen36. Outcomes were assessed at 2 weeks. 
Group Description 
No 
infection 
UAMS-1 Xen36 
PUR (-) Blank PUR scaffold in a sterile defect 10 0 0 
Empty Contaminated defect not grafted with a scaffold 0 10 10 
PUR Blank PUR scaffold in a contaminated defect 0 10 10 
PUR + D-AA-1 
PUR scaffold with 1% D-AAs in a contaminated 
defect 
0 10 0 
PUR + D-AA-5 
PUR scaffold with 5% D-AAs in a contaminated 
defect 
0 10 0 
PUR + D-AA-10 
PUR scaffold with 10% D-AAs in a contaminated 
defect 
0 10 10 
 
Rat femoral 6-mm segmental defect model 
This study was conducted in compliance with the Animal Welfare Act, the 
implementing Animal Welfare Regulations, and the principles of the Guide for the Care 
and Use of Laboratory Animals. A previously characterized contaminated critical size 
defect in rat (Sprague–Dawley; 373 ± 4.15 g) femurs was utilized as the in vivo model of 
infection 
39-41
. The study design is listed in Table 3.3.  Briefly, a 6-mm segmental defect 
was created using a small reciprocating saw blade (MicroAire 1025, MicroAire, 
Charlottesville, VA), stabilized with a polyacetyl plate (length 25 mm, width 4 mm and 
height 4 mm) and fixed to the surface of the femur using threaded K-wires. Blank PUR 
scaffolds implanted in a sterile defect were utilized as a negative control (PUR (-)) and 
for SEM analysis to distinguish between host cellular and bacterial infiltration of the 
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scaffolds. The defects in all other animals were then implanted with 30 mg of type I 
bovine collagen (Stryker Biotech, Hopkinton, MA, USA) wetted with 10
2
 CFU of S. 
aureus strain Xenogen-36 (Xen36 - Caliper Life Science, Hopkinton, MA) or S. aureus 
strain UAMS-1. The Xen36 strain is a weak biofilm producer and was used as a negative 
control. Six hours after contamination, the wounds were opened, debrided, and irrigated 
with saline. PUR or PUR+D-AA-x (1.0, 5.0, or 10 wt% 1:1:1 mixture of D-Met:D-Pro:D-
Trp) scaffolds were then implanted into the wounds. Since cefazolin is recommended for 
primary prevention of infections associated with open fractures 
42
, rats received systemic 
antimicrobial treatment with cefazolin (5 mg/kg) administered subcutaneously for 3-days 
post-surgery. Two weeks following surgery, the rats were euthanized and the femurs 
were weighed, snap-frozen in liquid nitrogen, ground to a fine powder, and re-suspended 
in saline. CFUs (expressed as log10 CFU/g tissue) were determined by plating serial 
dilutions onto blood agar plates and incubated at 37°C for 24 h. Scaffolds from PUR (-), 
PUR and PUR+D-AA-10 groups were evaluated by SEM. 
 
Statistical analysis 
For in vitro comparisons of groups, statistical analyses were performed using a 
One-Way ANOVA with a Bonferroni test to determine statistical differences between 
groups. Non-parametric statistical methods were used to analyze the results from the in 
vivo study. Contingency tables analyzed with a Fisher’s exact test were used to compare 
the number of infected and non-infected samples between groups. The CFU counts of the 
different treatment groups were compared using the Kruskal-Wallis test followed by a 
Dunn’s multiple comparison test to identify differences between groups. Non-parametric 
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analyses were performed using GraphPad InStat Version 3.0 (GraphPad software, San 
Diego California, USA). P<0.05 was considered statistically significant. 
 
Results 
D-amino acids activity in vitro 
To initially evaluate the feasibility of local delivery of D-AAs as a strategy for 
biofilm-dispersive scaffolds, the activity of D-AAs on biofilm dispersal and prevention 
was tested in vitro on a panel of four clinical isolates (described in detail in Table 3.1) of 
S. aureus. Pre-screening of eight individual D-AAs identified four amino acids, D-Met, 
D-Phe, D-Pro, and D-Trp, as highly effective at dispersing biofilms formed by the four 
clinical isolates (Figure 3.1), whereas the other four D-AAs had minimal effects. D-AAs 
dispersed biofilms in a dose-responsive manner and were most effective at concentrations 
≥5mM. Thus, 5mM was chosen as the concentration for future studies. The efficacy of D-
AAs varied between different bacterial strains, although for each strain tested more than 
one of the four D-AAs was effective at dispersing biofilms.  
Consistent with previous studies, the anti-biofilm effect was isomer-specific, as 
no dispersal activity was observed with L-isomers of D-AAs (data not shown). When 
tested against the panel of clinical isolates of methicillin-resistant S. aureus (n=5), D-Phe, 
D-Met, D-Trp, and D-Pro were effective at dispersing established biofilms in vitro as 
determined by the measurement of the biofilm biomass (Figure 3.2A, C). 
In addition to dispersing established biofilms, the four identified D-AAs also 
significantly blocked formation of biofilms by the clinical strains when bacteria were 
cultured in the presence of D-AAs (Figure 3.2B). 
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Figure 3.1. Screening of D-amino acids against clinical strains of S. aureus. Screening of D-Met, 
D-Phe, D-Pro, and D-TRP at concentrations ranging from 0.001 mM to 50 mM against preformed 
biofilms of four representative clinical isolates (described in Table 3.1). Biofilm dispersal was 
assessed by quantitating the remaining biofilm biomass following treatement with D-AAs by 
measuring the absorbance of solubilized CV from the stained biofilms at 570 nm. 
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Figure 3.2. D-amino acids disperse biofilms and prevent biofilm formation in clinical isolates of 
S. aureus. (A) Dispersion of pre-formed biofilms: Biofilm biomass (OD570) following treatment 
of pre-formed biofilms of four representative clinical isolates of S. aureus (described in Table 1) 
with 5 mM of each individual D-AA for 24 h at 37
o
C. (B) Prevention of biofilm formation: 
Biofilm biomass for the same clinical isolates as above following co-incubation of the bacteria 
with 5 mM of D-AA. (C) Representative images of CV-stained biofilms from S. aureus UAMS-1 
(bone isolate) following overnight treatment with individual D-AAs. (D) An equimolar mixture 
ofD AAs is more effective at dispersing biofilms than individual D-AAs. Biofilm biomass 
(OD570) following treatment of pre-formed biofilms of S. aureus UAMS-1 with an equimolar 
mixture (0.1 e5 mM total concentration) of D-Met, D-Pro, and D-Trp for 24 h at 37
o
C. (E) 
Representative images of CV-stained biofilms from S. aureus UAMS-1 following overnight 
treatment with the mixture of D-AAs (0.1 - 5mM). Averages are representative of three 
independent experiments, error bars signify standard deviation. Statistical analysis was performed 
using a One-Way ANOVA followed by a Bonferroni test to identify differences between groups; 
p < 0.05 was considered to be statistically different from the control group. 
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When combined as an equimolar mixture of D-Met, D-Pro, and D-Trp, biofilm-dispersive 
activity was enhanced (Figure 3.2D-E), as suggested by the decrease in biofilm biomass 
observed at D-AA concentrations <5mM (which was not observed for the individual D-
AAs). Importantly, D-AAs had no significant effect on the growth of the bacteria, 
indicating that biofilm dispersal was a specific property and not the result of growth 
inhibition (data not shown). 
 
Cytotoxicity of D-AAs in vitro  
While Figures 3.1 and 3.2 show that D-AAs both block biofilm formation as well 
as disperse established biofilms, the toxicity of D-AAs toward mammalian cells have not 
been extensively investigated. Thus, we evaluated the cytotoxicity of D-AAs in vitro 
using human osteoblasts and dermal fibroblasts that are relevant to bone and wound 
healing, respectively. Osteoblasts and fibroblasts exposed to up to 50 mM of D-Met, D-
Phe, D-Pro showed >70% viability after 24 h. Cytotoxicity was observed in mammalian 
cells exposed to D-Trp at concentrations exceeding 12.5 mM (~60% viability) (Figure 
3.3). Importantly, these studies indicate that the D-AAs have minimal cytotoxic effects 
on mammalian cells at concentrations observed to be effective for preventing and 
disrupting biofilms in vitro.  
 
Scaffold characteristics and in vitro release 
Previous experiments investigating the feasibility of biofilm dispersion by 
exogenous D-AAs have focused on 2D surfaces. As an initial step toward the creation of 
a biofilm-dispersive scaffold, two-component PUR scaffolds prepared by reactive liquid  
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Figure 3.3. D-amino acids have limited cytotoxicity in vitro. Viability of human osteoblasts (A) 
and dermal fibroblasts (B) exposed to media supplemented with D-Met, D-Phe, DPro, and D-Trp 
(1-50 mM) for 24 h at 37
o
C in 5% CO2. Cell viability was determined using the Cell-Titer Flour 
assay by measuring fluorescence 405ex/505em and is represented as a percentage viability 
relative to non-treated controls. Values represent the average of three independent experiments, 
and error bars indicate standard deviation. Statistical analysis was performed using a One-Way 
ANOVA followed by a Bonferroni test to identify differences between groups; p < 0.05 was 
considered to be statistically different from controls (*) 
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Figure 3.4. Characterization of PUR + D-AA scaffolds. (A) SEM images of PUR, PUR + D-AA-
10 (before leaching), and PUR + D-AA-10 (after 24 h leaching) scaffolds. Porosity and pore size 
remain relatively constant with increasing wt% D-AA. (B) Compressive mechanical properties of 
dry and wet (soaked in PBS for 24 h) PUR and PUR + D-AA-10 samples; p < 0.05 was 
considered to be statistically different from controls (*). (C) Cumulative % release of D-Pro, D-
Met, and D-Trp versus time (symbols). The solid lines represent the fit to the Weibull model. 
 
molding were augmented with a mixture of D-AAs (1:1:1 wt% D-Met:D-Pro:D-Trp) as a 
labile powder. Prior to in vivo testing, the PUR+D-AA scaffolds were characterized in 
vitro.  
Scaffolds containing 0 (PUR) or 10 wt% D-AA mixture (PUR+D-AA-10) had 
similar values of density, porosity, and pore size before and after leaching overnight in 
PBS. Representative SEM images of the PUR and PUR+D-AA-10 scaffolds show inter-
connected pores and a mean pore diameter ranging from 370 to 378 µm (Figure 3.4A). 
While the addition of 10% D-AA mix to the PUR scaffolds did not affect the porosity, 
the wet mechanical properties were significantly reduced compared to the empty scaffold 
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(Figure 3.4B). There were no differences in the properties of the scaffolds incubated in 
PBS for 24 hours or 7 days. 
The release kinetics of D-Pro, D-Met, and D-Trp were characterized by an initial 
burst followed by a sustained release for up to 21 days (Figure 3.4C). D-Met released the 
fastest, characterized by a 60% burst on day 1 and nearly 100% release by day 14. The 
release of D-Pro was somewhat slower (45% burst and 85% release by day 28), while D-
Trp released slowly, with only a 25% burst and 44% release after 28 days. The Weibull 
equation has been used to identify the mechanism controlling drug release from 
polymeric materials 
39, 43
: 
       (3.1) 
where Mt corresponds to the mass of drug released in time t, M is the mass of drug 
released at infinite time (which corresponds to the initial loading of drug), and a and b are 
constants. When b<0.75, Fickian diffusion controls drug release, while a more complex 
mechanism involving both diffusion and swelling controls release when b>0.75 
44
. The 
D-AA release data were fit to the Weibull model and the values of the b parameter for D-
Met, D-Pro, and D-Trp were calculated as 0.56, 0.35, and 0.21 respectively, suggesting 
that the release of each D-AA from the scaffolds was diffusion-controlled.  
 
Effects of biofilm-dispersive scaffolds on bacterial contamination in vitro 
The effect of local delivery of D-AAs from biofilm-dispersive scaffolds on 
bacterial contamination was evaluated in vitro prior to in vivo testing. Incorporation of D-
AA into PUR scaffolds at concentrations ≥ 1 wt% D-AA significantly reduced the 
amount of attached bacteria and biofilm formation on the surface compared to the 
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scaffolds without D-AA. PUR scaffolds with 1, 5, and 10 wt% D-AA had a ≥ 4-log 
reduction in the number of bacteria (Figure 3.5A), while PUR scaffolds with 0.1% 
showed a more moderate (~1-log reduction) but significant reduction in bacteria attached 
to the scaffold surface. Consistent with the bacterial counts, SEM images of PUR 
scaffolds augmented with D-AA also demonstrated the dramatic reduction in surface-
attached bacteria within biofilms on scaffolds augmented with the D-AA mixture (Figure 
3.5B). However, as indicated by the bacterial counts, PUR scaffolds without D-AA as 
well PUR scaffolds with 0.1% D-AA had extensive bacterial colonization and the 
presence of biofilms on the surface.  
 
 
Figure 3.5. Augmentation of PUR scaffolds with an equimolar mixture of D-AAs reduces 
bacterial adherence in vitro. (A) log10 CFU/cm
3
 UAMS-1 bacteria adhered to PUR scaffolds 
augmented with D-AAs after 24 h incubation time decrease ~4 orders of magnitude for  >1 wt% 
equimolar D-AA mixture. The PUR negative control (PUR (-)) incubated in sterile medium 
shows no contamination. (B) SEM images of PUR + D-AA scaffolds exhibiting decreased 
biofilm with increasing D-AA concentration. 
 
Effects of biofilm-dispersive scaffolds in vivo  
For the in vivo studies, 6-mm segmental defects in rats were contaminated with 
10
2
 CFUs S. aureus XEN-36, a bioluminescent, septicemic isolate forming weak biofilms, 
or 10
2
 CFUs S. aureus UAMS-1, an osteomyelitis isolate and a strong biofilm producer. 
Treatment of femoral UAMS-1-contaminated defects with PUR+D-AA-5 or PUR+D-
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AA-10 significantly reduced bacterial contamination within the homogenized bone 
(p<0.05) (Figure 3.6A), while lower doses did not reduce contamination compared to the 
empty (untreated) defect control. Similarly, PUR+D-AA-5 and PUR+D-AA-10 reduced 
the number of contaminated samples compared to the PUR scaffold (Figure 3.6B), 
although the difference did not reach statistical significance (p=0.087).  
 
 
Figure 3.6. Augmentation of PUR scaffolds with an equimolar mixture ofD-AAs reduces 
bacterial contamination of segmental defects contaminated with 102 CFU S. aureus UAMS-1 in 
vivo. (A) Bacterial counts (log10 CFU/g) in homogenized bone from segmental defects of rats 
contaminated with 102 CFU of S. aureus UAMS-1 followed by implantation of no scaffold 
(Empty, n ¼ 10), PUR blank scaffold (PUR, n ¼ 10), or PUR scaffold + equimolar D-AA 
mixture (n ¼ 10 per group) for two weeks post-wounding. Bars represent the mean value and 
error bars are the standard error of the mean. Statistical analysis was performed using a Kruskal 
Wallis test followed by a Dunn’s multiple comparisons test to identify differences between 
groups (* significantly different than PUR, p < 0.05) (B) Distribution of contaminated and non-
contaminated bone samples from the segmental defects. Fewer samples were contaminated when 
the PUR scaffold was augmented with D-AA content >5 wt%, although the differences were not 
statistically significant (p ¼ 0.087). Statistical analysis was performed using contingency tables 
analyzed with a Fisher exact test comparing the number of contaminated bone samples for each 
PUR + D-AA treatment group to the PUR blank scaffold. 
 
 
Consistent with these observations, SEM analysis of scaffolds removed from rats 
following infection also showed a dramatic reduction of biofilm attached to the surface of 
the scaffolds (Figure 3.7). Blank PUR scaffolds implanted in contaminated defects 
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exhibited extensive bacterial adhesion and biofilm formation on the majority of the 
surface, whereas PUR+D-AA-10 showed a substantial reduction in the amount of 
attached bacteria. In contrast, PUR+D-AA scaffolds implanted in defects contaminated 
with 10
2
 CFUs Xen-36 strain, an extremely weak biofilm producer, did not significantly 
reduce bacterial contamination or the number of contaminated samples compared to the 
empty defect (data not shown).   
 
 
 
Figure 3.7. Low- and high-magnification SEM images of biofilms on PUR and PUR + D-AA-10 
scaffolds implanted in contaminated femoral segmental defects in rats for 2 weeks show reduced 
bacterial adhesion for the scaffold augmented with 10 wt% of the equimolar mixture of D-AAs. 
PUR scaffolds implanted in sterile defects (PUR (-) negative control) show minimal bacterial 
adhesion 
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 Discussion 
Despite meticulous clinical management including surgical debridement and the 
use of systemic antibiotics, contamination rates of open fractures continue to be a 
significant cause of non-osseous union, potentially leading to extremity amputation.  
Local delivery of antibiotics from bone grafts has been investigated as a strategy to 
reduce bacterial contamination and promote osseous union 
39, 45-52
. However, the efficacy 
of antibiotics against the surface-attached communities of bacteria known as biofilms, 
which are considered a major virulence factor in chronic disease 
6, 4
, is limited due to the 
slow metabolic and growth rates of bacteria within the biofilm 
53
. Furthermore, the 
avascular bone graft may itself serve as a substrate for bacterial colonization and a nidus 
for recurrent infections 
54
. Finally, a small population (i.e., 0.1–10%) of “persister cells” 
survives antimicrobial therapy and rapidly grows after the cessation of antibiotic therapy, 
potentially resulting in recurrent infections 
55
. Recent studies have highlighted the 
potential of bacterial signaling molecules that trigger biofilm dispersal, such as bismuth 
thiols 
56, 20
, quorum-sensing inhibitors and analogs 
57
, and D-AAs 
27, 26
, as therapeutic 
agents for treatment of chronic infections. In this study, we have shown that local 
delivery of D-AAs from PUR scaffolds inhibits biofilm formation by clinical isolates of S. 
aureus both in vitro and in vivo. Dose-response experiments showed that D-AAs 
inhibited biofilm formation and dispersed existing biofilms at concentrations ≥5 mM in 
vitro. A PUR scaffold augmented with ≥5 wt% D-AAs significantly reduced bacterial 
contamination and biofilm formation by the strong biofilm-producing strain S. aureus 
UAMS-1 compared to the control scaffold with no D-AAs in a contaminated segmental 
defect in rats. Interestingly, with careful scanning of the scaffolds with D-AAs, small 
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colonies of bacteria within a biofilm could be found. Conversely, biofilm formation could 
easily be found on the scaffolds without D-AAs that were retrieved from contaminated 
defects. Almost the entire scaffold was covered with biofilm, and the colonies were very 
robust. Furthermore, D-AAs exhibited relatively low cytotoxicity to mammalian cells at 
doses effective at inhibiting biofilm formation. 
 Considering the many human chronic diseases involving biofilms, the use of 
biofilm dispersal agents has gained considerable interest for the treatment of biofilm-
mediated infections. A previous study has reported that D-Phe, D-Pro, and D-Tyr prevent 
biofilm formation and trigger biofilm dispersion in S. aureus WT strain SC01 at 
concentrations as low as 0.5 mM in vitro 
27
. In this study, we have shown that D-Met, D-
Phe, D-Pro, and D-Trp inhibit biofilm formation and disperse established biofilms of 
clinical strains of S. aureus at concentrations ≥5 mM (Figure 3.1), which is ~10 times 
greater than the previously reported dose. The activity of individual D-AAs varied in 
previous studies, with D-Tyr requiring the lowest concentration (3 μM), and D-Met (2 
mM), D-Trp (5 mM) and D-Leu (8.5 mM) requiring higher concentrations for anti-
biofilm activity against Bacillus subtilis strain NCIB 3610 and for S. aureus strain SC01 
26
. Differences between bacterial species as well as strain heterogeneity are likely 
contributing factors to the observed discrepancies between studies. Importantly, from our 
studies we identified concentrations having effective biofilm-dispersive activity active 
against a number of clinical strains. Consistent with a previous study showing that the 
equimolar mixture of D-Phe:D-Pro:D-Tyr lowered the effective dose 
27
, the data in 
Figure 3.2D-E show that an equimolar mixture of D-Met:D-Pro:D-Trp shifted the dose-
response curve toward lower doses compared to the individual D-AAs. Other than for B. 
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subtilis, the mechanisms by which D-AAs disrupt biofilms are not known. However, the 
enhanced anti-biofilm activity of the D-AA mixture is suggestive of multiple mechanisms 
acting on the bacteria, which warrants further investigation.  
 In order to be useful as a clinical therapy, D-AAs must exhibit minimal 
cytotoxicity at concentrations that are effective at dispersing biofilms. As shown in 
Figure 3.3, osteoblasts and fibroblasts treated with D-Phe, D-Pro, or D-Met for 24 h 
exhibited >70% viability at concentrations ≤50 mM, while D-Trp exhibited cytotoxic 
effects (i.e., <70% viability) at concentrations >12.5 mM. While these data suggest that 
individual D-AAs are non-cytotoxic to mammalian cells at concentrations efficacious 
against biofilms, they contrast with a previous study reporting cytotoxicity of D-Phe, D-
Met, and D-Trp toward Chinese Hamster Ovary (CHO) and HeLa cells at concentrations 
≥10 mM 28. The discrepancies in D-AA toxicities between the present study and that 
reported previously may be attributed to differences among cell lines. In another study, 
D-Phe and D-Trp reportedly elicited a chemotactic response in human neutrophils via 
activation of GPR109B 
58
. Additional in vivo studies investigating the biocompatibility of 
D-AAs in sterile defects are needed to further assess their safety, and these studies are 
currently ongoing in our laboratories. 
 As a first step toward the development of a biofilm-dispersive bone graft for 
clinical applications, we evaluated the effects of local delivery of D-AAs from 
biodegradable PUR scaffolds on infection in a contaminated segmental defect model in 
rats. The scaffold investigated in this study has a half-life of 14 weeks in vitro 
36
, and 
degrades to non-cytotoxic breakdown products such as lysine and -hydroxy acids 59. 
PUR scaffolds are effective delivery vehicles for sustained released of biologics, such as 
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antibiotics 
60, 39
 and recombinant human bone morphogenic protein-2 (rhBMP-2) 
61, 44, 40
. 
Furthermore, PUR scaffolds are injectable 
62, 63
 and thus can be delivered using 
minimally invasive surgical techniques. As shown in Figure 3.4, while D-AAs had 
minimal effects on the porosity and pore size, PUR+D-AA scaffolds exhibited 
approximately 2-3-fold decreases in both Young’s modulus and compressive stress at 
50% strain. A previous study reported that PUR scaffolds augmented with 8 wt% 
tobramycin had significantly higher porosity and lower modulus than blank PUR 
scaffolds after 24 h incubation time in PBS, which was attributed to rapid leaching of 
tobramycin and consequent formation of new pores 
60
. Surprisingly, in the present study 
the modulus decreased significantly even after 24 h, at which time only a fraction of the 
D-AAs had released, and did not decrease further for up to 7 days of incubation. These 
observations suggest that the decrease in modulus with addition of D-AAs results from 
defects in the pore walls of the scaffold caused by the presence of the particles rather than 
from the formation of new pores due to leaching of the D-AAs.  
 As shown in Figure 3.4C, PUR+D-AA scaffolds supported diffusion-controlled 
sustained release of the biologically active drug for up to 4 weeks, which is consistent 
with previous studies reporting diffusion-controlled release of active antibiotics 
60, 39
, 
recombinant human growth factors 
64, 44
, and siRNA nanoparticles 
65
. At each time point, 
the order of cumulative release was D-Met>D-Pro>D-Trp, while the order of solubility 
was D-Pro>>D-Met>D-Trp 
66
. At 4 weeks, >85% of D-Pro and D-Met had been released 
and <10% of the scaffold had degraded 
36
, which is consistent with the notion that the D-
AA release was diffusion-controlled at early time points. However, <40% of the D-Trp 
had been released by 4 weeks, suggesting that degradation of the scaffold may control D-
60 
 
Trp release kinetics at later (>4 weeks) time points. Since the free base form of each D-
AA was used in this study, the release kinetics could be increased by using the more 
soluble hydrochloride as reported previously for vancomycin 
39
.  While antibiotic therapy 
for up to 8 weeks is recommended for effective treatment of MRSA osteomyelitis 
67
, the 
optimal release profile for D-AAs is unknown and thus merits further investigation.  
  In a proof-of-concept study, we evaluated the ability of biofilm-dispersive PUR 
scaffolds augmented with D-AAs to prevent biofilm formation and reduce CFUs in a 
contaminated rat segmental defect model. Several recent studies have evaluated the 
effects of local delivery of antibiotics on infection using an acute contamination model, in 
which the bone graft was placed immediately after contamination of the defect with 
bacteria 
68, 69
. However, preclinical models with an established chronic infection 
40, 70
 
represent a more rigorous test for the efficacy of biofilm-dispersive grafts, since they 
ensure that the bacteria are able to adhere to the surface of the wound and form biofilms 
71
. In the present study, rat segmental defects were contaminated with 10
2
 CFU for 6 h 
prior to implantation of the PUR+D-AA scaffolds. Augmentation of the scaffolds with ≥5 
wt% D-AAs significantly reduced bacterial contamination within the segmental defects 
treated with UAMS-1, an osteomyelitis strain. In contrast, the D-AAs had no significant 
effect on defects contaminated with Xen36, which is a weak biofilm producer 
14
. These 
observations are consistent with the notion that D-AAs reduce contamination in the 
defect by preventing the formation of and/or dispersing biofilms, thus limiting the 
application of D-AAs as a treatment for biofilm infections. However, numerous studies 
indicate that the majority of staphylococcal clinical isolates in vitro as well as those found 
in human tissues are strong biofilm producers.   
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  Because D-AAs are not bactericidal, they are anticipated to be most effective as 
an adjuvant therapy to conventional treatment with systemic antibiotics. In this study, rats 
were treated with cefazolin (5 mg/kg) administered subcutaneously for 3-days post 
surgery to simulate the clinical scenario 
42
. Despite the presence of systemic antibiotics, 
one of the untreated rats developed an infection, which increased to four rats when 
treated with blank PUR scaffolds. This suggests that placement of an avascular graft into 
an open fracture potentiates infection. Treatment with PUR+D-AA-5 or PUR+D-AA-10 
scaffolds reduced the number of infected rats to zero, which underscores the potential 
clinical utility of biofilm-dispersive bone grafts as an adjuvant therapy to systemic 
antibiotics. The broad spectrum of D-AAs will allow their use for preventing infection 
without the need of knowing the nature of contaminating bacteria. For chronic infections 
such as MRSA osteomyelitis, treatment with systemic antibiotics is recommended for a 
minimum of 8 weeks 
67
. Importantly, for most patients, the extended duration of systemic 
treatment is associated with a number of risks to the patient’s health, including renal 
toxicity, and is an economic burden to the patient and healthcare system. Our results 
suggest that local delivery of a biofilm dispersion agent alone or co-delivered with 
antimicrobial agents represents a potentially efficacious therapy for treatment of chronic 
infections, which, when combined with the standard systemic antimicrobial treatment 
may reduce the time of treatment and resulting complications and cost for chronic 
orthopedic infections.  
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Conclusions 
The ability of bacteria to establish biofilms substantially hinders the treatment of 
orthopedic infections and is implicated as a significant contributing factor in the sequelae 
associated with open fractures. Biofilm-dispersive scaffolds augmented with D-AAs can 
be used as a novel therapeutic strategy to reduce microbial burden within wounds and 
improve healing outcomes.  
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CHAPTER IV 
 
SURFACE MODIFICATION OF B-TRI-CALCIUM PHOSPHATE IMPROVES THE 
MECHANICAL PERFORMANCE OF SETTABLE CALCIUM 
PHOSPHATE/POLYURETHANE BIOCOMPOSITES FOR BONE TISSUE 
ENGINEERING 
 
Introduction 
Due to their natural presence in bone 
1
, calcium phosphate cements (CPCs) and 
scaffolds have been investigated extensively for the treatment of osseous defects. -
tricalcium phosphate (-TCP) is an osteoconductive 2 and biocompatible ceramic which 
has been reported to bond directly to bone 
3, 4
. However, injectable CPCs derived from -
TCP are susceptible to brittle fracture and graft migration 
5-7
. These conditions limit their 
application in weight-bearing defects, and increase the probability of additional revision 
surgeries for patients. 
 As alternative materials to overcome the mechanical limitations of CPCs, -
TCP/polymer composites have been investigated. A wide range of polymers have been 
used to fabricate composites with calcium phosphates resulting in materials with varying 
porosities and mechanical properties 
8
. In a previous study, we reported that compression-
molded -TCP/polyurethane composites implanted in femoral condyle defects in rats 
supported cellular infiltration and appositional remodeling 
9
. However, few -
TCP/polymer composites are moldable and settable, which precludes their use in 
minimally invasive surgical procedures.  
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Lysine-derived polyurethane (PUR) scaffolds are biocompatible, degrade to non-
cytotoxic compounds 
10-15
, and have tunable working times which make them suitable for 
injectable applications 
16, 17, 14
. The reactive nature of the polyurethane gelling process 
enables interfacial bonding between the polymer and filler phases with functional 
hydroxyl or amine groups at the surface 
13
. Low porosity allograft bone/PUR molded 
composites with high filler loading (>64 vol.%) have also been shown to support cellular 
infiltration and remodel by creeping substitution as cells follow the path provided by the 
interconnected particles 
18
. The limited availability and risks of disease transmission 
associated with allograft bone 
19
 have generated interest in the development of 
composites with similar properties using synthetic matrix particles. 
In the present study, we investigated the effects of -TCP particle loading and 
surface composition on the mechanical and biological properties of -TCP/PUR 
composites. A composite with completely interconnected phases may offer increased 
resistance to crack growth and consequently extend the effective loading range supported 
by the materials 
8
. Thus, we hypothesized that surface modification of the -TCP 
particles with grafted polymeric chains would improve the compatibility of the ceramic 
and polymeric phases by promoting chain entanglements and/or reactivity between the 
phases, resulting in enhanced mechanical properties. Poly(-caprolactone) (PCL - a 
polymer also present in the backbone of the polyurethane) was covalently grafted to 
protonated -TCP particles via ring-opening-polymerization 20, and composite 
mechanical properties were evaluated under dry and wet conditions. Effects of surface 
modification on cellular attachment and differentiation were evaluated in vitro. 
 
70 
 
Experimental 
 Materials 
 Lysine triisocyanate (LTI) was purchased from Kyowa Hakko USA (New York) 
and polyethylene glycol (PEG, MW 200 Da) from Alfa Aesar (Ward Hill, MA). Glycerol, 
-caprolactone, stannous octoate, phosphoric acid, chloroform, the reagents for the 
alkaline phosphatase assay, and the chemicals for intracellular (Sigma kit 387A) and 
extracellular staining of tartrate resistance acid phosphatase (TRAP) were obtained from 
Sigma-Aldrich (St. Louis, MO). Glycolide and D,L-lactide were purchased from 
Polysciences (Warrington, PA). The tertiary amine catalyst (TEGOAMIN33) was 
obtained as a gift from Goldschmidt (Hopewell, VA). -TriCalcium Phosphate particles 
(TCP, grain size distribution 100-300 m) were purchased from Berkeley Advanced 
Biomaterials (Berkeley, CA). MC3T3 osteoprogenitor cells and c57bl wild type mice 
were obtained from Javier Esparza and Dr. James Edwards, respectively, at the 
Vanderbilt Center for Bone Biology (VCBB). Dentin pieces were kindly provided by Dr. 
Julie Sterling also at the VCBB, and were cut into thin chips as controls for osteoclastic 
cell culture. -minimal essential medium (-MEM), fetal bovine serum (FBS), 
Penicillin/Streptomycin solution (P/S), Dulbecco’s phosphate-buffered salt without 
calcium and magnesium (PBS), and the Pierce BCA Protein kit were purchased from 
Fisher Scientific (Pittsburgh, PA). The Live/Dead Viability/Cytotoxicity and CyQUANT 
Cell proliferation Assay kits were purchased from Invitrogen. Osteoclast growth factors 
(recombinant mouse Macrophage Colony Stimulating Factor [MCSF] and Receptor 
Activator of NF-kB Ligand [RANKL]) were purchased from R&D Systems (Minneapolis, 
MN). cD11b Microbeads used in the purification of osteoclast precursors were obtained 
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from Miltenyi Biotec (Auburn, CA). Prior to use, glycerol and PEG were dried at 10 
mmHg overnight at 80C, and -caprolactone was dried over anhydrous magnesium 
sulfate 
21
. All other materials were used as received. 
  
 Surface modification of TCP  
 PCL was covalently grafted to TCP particles following the method proposed by 
Kunze et. al. 
20
. Briefly, the surface of the particles was activated by stirring in 5% 
aqueous phosphoric acid for 1 hr, followed by washing with distilled water and vacuum-
drying at 40ºC overnight. The resulting protonated material (p-TCP) was then reacted 
with -caprolactone at 150C for 4 days. The molar ratio of TCP to -caprolactone was 
1:10. The product (TCP-PCL) was washed with chloroform, filtered, and dried under 
vacuum at 60C for 24 h.  
 
 Characterization of matrix particles 
 The skeletal density, which accounts for both the volume of the solid as well as the 
blind (e.g., inaccessible) pores of the particles, was measured by gas pycnometry using 
nitrogen as the penetrating gas (Micromeritics, Norcross, GA). Particle size distribution 
was measured by static image analysis using a Morphologi G3 (Malvern Instruments). 
Specific surface area was determined using a Micromeritics ASAP 2020 porosimeter 
with nitrogen as the adsorbing gas.  
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 Gel Permeation Chromatography (GPC) 
 Previous studies grafting polystyrene on cellulose surfaces have shown minimal 
differences between the molecular weight of resulting grafted and non-grafted polymers 
22
. Thus, to obtain an approximate molecular weight of the PCL grafted to the surface of 
TCP-PCL, the polymer collected after washing with chloroform (non-grafted PCL) was 
analyzed using a Waters Breeze GPC (Milford, MA). Two MesoPore 300x7.5 mm 
columns (Polymer Laboratories) were used in series with stabilized tetrahydrofuran 
(THF) as the mobile phase at a flow rate of 1 mL min
-1
 at 35°C. 
 
 Thermogravimetric Analysis (TGA) 
 The amount of polymer grafted to the surface of TCP-PCL particles was quantified 
using a TGA Q500 (TA Instruments). As a reference material, non-grafted PCL was 
analyzed by TGA to identify its degradation temperature. TCP-PCL and non-grafted 
PCL samples (~10 mg) were heated from 20ºC to 550ºC at a rate of 20ºC min
-1
 under a 
purge flow of nitrogen. The mass loss taking place at temperatures above the PCL 
degradation temperature was determined to be the polymer content on the particles. 
 
 X-Ray Photoelectron Spectroscopy (XPS)   
 The surface composition of the matrix particles was assessed using a PHI 5000 
VersaProbe X-Ray Photoelectron Spectrometer with a 25 W monochromatic Al K- X-
ray source and a 100 µm spot size. The matrix particles were compressed (12,000lbs) into 
14 mm diameter pellets before analysis. Survey spectra were collected using 187.85 pass 
energy. All measurements were performed using a 45º take-off angle and charge 
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neutralization under ultra-high vacuum. Analysis of the data was performed using the 
software CasaXPS Version 2.3.14 (© 1999-2008 Neal Fairley). 
 
 Contact angle measurements 
In order to track changes in wetting properties of the matrix, contact angles 
between TCP or TCP-PCL particles and unreactive polymer mixture (no catalyst added) 
were measured. Contact angle measurements were completed using sintered TCP pellets 
with further surface modification. Compressed pellets (as prepared as for XPS analysis) 
were sintered at 1100 ºC for 2 hours. The surface modification method described before 
was used to graft PCL to the surface of the pellets. Sessile drops of the polyol-prepolymer 
mixture (without catalyst) were placed on the surface of the pellets and the contact angle 
was measured using a Rame-Hart (Succasunna, NJ) goniometer.  
 
 Prepolymer and polyol synthesis 
 Previously published techniques were applied to prepare the polyol 
23, 21
 and the 
NCO-terminated prepolymer 
13
. A trifunctional polyester polyol (target molecular weight: 
300 g/mol, measured OH number: 429) was prepared from a glycerol starter and a 60% -
caprolactone, 30% glycolide, 10% D,L-lactide backbone using stannous octoate catalyst 
(0.1 wt%). LTI-PEG prepolymer was prepared from LTI and PEG (200 g/mol) with a 
molar ratio of 2:1 (NCO:OH equivalent ratio = 3:1) and NCO number of 22.2%. The OH 
number of the polyol (used to verify the molecular weight) and the NCO number of the 
pre-polymer were measured by titration using a Metrohm 798 MPT Titrino according to 
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ASTM D4274-99 Method C 
24
, and ASTM D2572-97 
25
, respectively. The properties of 
the prepolymer have been reported previously 
14
. 
 
 Matrix/PUR biocomposite synthesis  
The polyol and prepolymer described above were used to synthesize the composites. 
To investigate the effect of PUR composition on the mechanical performance of the 
composites, samples with target index (the ratio of isocyanate and hydroxyl equivalents 
multiplied by 100) of 105 and 140 were prepared. The actual index was calculated from 
the measured OH number for the polyol and %NCO for the prepolymer. The polyol and 
the amine catalyst were mixed in a 10 mL cup at 3300 rpm for 1 min using a Hauschild 
SpeedMixer mixer. The particles (either unmodified or modified) were then added and 
the components hand-mixed for 3 min, followed by addition of the prepolymer and hand-
mixing for another 3 min. The resulting reactive paste was cast into cylindrical molds (6 
mm diameter) and a pressure of 330 kPa was applied for a period exceeding the setting 
time of the material. The green composite was subsequently cured at 37C for 15 hr.  
 
 Scanning electron microscopy (SEM) 
SEM was used to observe the morphology of the composites, in particular near the 
interface between the matrix and polyurethane phases. After curing, disks were cut from 
the cylindrical composites and mounted on conductive carbon tape. Samples were 
sputter-coated with gold and analyzed using a Hitachi S-4200 scanning electron 
microscope. Digital images were obtained using Quartz PCI image management software 
(Hitachi, Pleasanton, CA). 
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 Mechanical testing of the biocomposites 
 Compression testing was performed using an MTS 858 Bionix Servohydraulic Test 
System. Cylindrical specimens (6 mm diameter  12 mm high) were conditioned in PBS 
at room temperature for 24 hr immediately before testing. The dimensions and mass of 
the samples before and after hydration were used to determine dry and wet density as 
well as water uptake patterns of the composites. Next, the specimens were pre-loaded to 
approximately 12 N, followed by continuous compression until failure at a rate of 25 mm 
min
-1
. The load and position were recorded every 0.01 sec. The compressive stress was 
calculated by dividing the load by the initial cross-sectional area of the wet samples and 
reported in MPa. The compressive modulus was calculated as the slope of the initial 
linear section of the stress-strain curve and the compressive strength corresponded to the 
maximum stress tolerated by the material before failure. 
Samples for torsion testing were prepared by potting ~5 mm at each end of 6-mm 
diameter cylinders into Technovit 4000 (Heraeus Kulzer) resulting in a central gauge 
length of about 10 mm. The potting material was prepared by mixing the powder:syrup 
I:syrup II using a ratio of 2:2:1 following the manufacturer’s instructions. After potting, 
the torsion samples were hydrated for 24 hrs in PBS and then tested using an Instron 
DynaMight 8841 machine equipped with a 1.7 Nm torque cell. The potted ends were 
gripped using the Instron clamps in a horizontal setup (such that the residual torque was 
minimal). During testing, the clamps were rotated at an angular speed of 2/s until failure. 
The measured torque and rotation angle were used to determine torsional stress using the 
equation 
26, 27
: 
  = [(dT/d) + 3T]/(2r3)       (4.1) 
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where r is the radius of the cylinder,  = /L is the rotation angle per gauge unit length, 
and T is the measured torque. The derivative dT/d was determined by fitting the T vs.  
data to a 5
th
 order polynomial (between zero up to the maximum torque or ultimate point). 
Torsional strain () was determined as  = r, and the shear modulus calculated from the 
linear region of the stress-strain curve G = / . Toughness was calculated as the 
corresponding area under the stress-strain curve from zero to the maximum stress. 
 
 Osteoblast precursor cell culture and differentiation 
 Samples for cell culture were obtained by cutting thin disks from composite 
cylinders using an IsoMet Low Speed Saw (Buehler). Samples were sterilized with 
ethanol and conditioned with complete media (-MEM with 10%FBS and 1% P/S) in a 
48-well plate overnight. MC3T3 cells were cultured in complete media at 37C in a 
humidified incubator with 5% CO2 enriched atmosphere. 1.5x10
4
 MC3T3 cells were 
seeded on the materials and cultured in the presence of 0.5 ml of complete media. To 
determine the viability of MC3T3 cells seeded on the composites, the media was 
removed after 2 days of culture, the cells were gently rinsed with PBS, and live-dead 
reagent was added to the wells according to manufacturer’s instructions. The surface of 
the materials was imaged and the percentage of cells stained green (live) was determined 
from the total population (which included dead cells stained red). Differentiation of 
MC3T3 cells seeded on the composites was monitored through the expression of active 
alkaline phosphatase (ALP). After 2 days of culture, the medium was changed to 
differentiating media (-MEM with 2.5% FBS, 1% P/S, 100 g/ml ascorbic acid, and 10 
mM -glycerophosphate) and culture continued for up to 7 days, with media change on 
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day 5. At days 2 and 7, cells were washed with PBS, removed from the materials using 
trypsin, centrifuged, re-suspended in 100 l of 0.1% Triton-X, and frozen at -80C. The 
Triton-X solutions were freeze-thawed 3 times to completely lyse the cells. 20 l of the 
lysate were mixed with 100 l of substrate buffer (1.5M alkaline buffer solution pH 10 
[Sigma A9226], 16mM magnesium chloride, 2mg/ml phosphatase substrate [Sigma 
P4744], de-ionized water) and incubated at 37C for 30 min, followed by measuring the 
absorbance of the solution at 405 nm. A standard curve with varying p-nitrophenol 
(product from the reaction of ALP with the substrate) concentrations was used to 
determine ALP activity at each time point. ALP activity was further normalized by total 
protein in the samples, measured using the Pierce BCA kit according to manufacturer’s 
instructions.  
 
 Osteoclast precursor cell culture and differentiation 
 Samples for osteoclastic cell culture were cut, sterilized, and conditioned as detailed 
in the previous section. Osteoclast precursors were obtained from bone marrow cells 
extracted from the tibia and femoral head of 4-7 week old c57bl wild type mice. After 
extraction, CD11b+ osteoclast precursors present in the bone marrow 
28
 were labeled 
with microbeads, and separated from the non-labeled cells using an AutoMacs magnetic 
separator (Vanderbilt University Flow Cytometry Core). cD11b+ cells were seeded onto 
composite and dentin (control) samples at a density of 1.8x10
5
 cells/ml. Complete 
medium was supplemented with 50 ng/mL RANKL and 25 ng/mL MCSF. Cells were 
cultured for up to 21 days with media changes every 2-3 days.  
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 Tartrate Resistant Acid Phosphatase (TRAP) is a histochemical marker of both, 
differentiating and active osteoclasts 
29, 30
. In addition, extracellular release of TRAP by 
osteoclasts has been found to correlate with resorptive activity both in vitro 
31, 32
 and in 
vivo 
33, 29
. Thus, to verify differentiation of the osteoclast precursors seeded on each 
material, cells were fixed and stained for intracellular TRAP activity (Sigma kit 387A). 
Furthermore, media removed from the wells during each change was collected and frozen 
at -80C. Secreted TRAP into the media was quantified using napthol ASBI-phosphate as 
the substrate 
34
. 50 l of diluted media samples (such that the reading was located in the 
range of the total protein calibration curve) were mixed with 150 l of reaction buffer 
(100 mM sodium acetate, 50 mM sodium tartrate, 2.5 mM Napthol ASBI-Phosphate in 
4% 2-methoxyethanol [ethylene glycol monomethyl ether – EGME]) in a 96-well plate, 
followed by incubation at 37C for 35 min. The reaction was stopped with the addition of 
0.6 M NaOH and fluorescence was read at 405 nm (excitation), 520 nm (emission). 
Fluorescence units of secreted TRAP were further normalized to total protein per day and 
are presented relative to dentin controls.   
 
 Statistical analysis 
  Statistical analyses were performed using One-Way ANOVA followed by Tukey-
Kramer tests to identify differences in XPS ratios, contact angles, mechanical properties, 
ALP activity, and secreted TRAP between groups. For all experiments, p<0.05 was 
considered statistically significant. Analyses were run using JMP 9.0. 
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Results 
Characterization of matrix particles 
Surface treatment of -TCP particles led to changes in particle size, density, 
surface area, and composition (Figure 4.1). As shown in Figure 4.1A-B, the particle size 
distribution of TCP shifted towards lower diameters after surface modification. This shift 
took place mainly during the protonation step under continuous mixing in 5% phosphoric 
acid to obtain p-TCP particles. The decrease in particle size was accompanied by a 
decrease in density and a significant increase in surface area.   
 
 
Figure 4.1. Characterization of matrix particles. (A) Matrix particle properties. (B) Frequency 
particle size distributions measured for TCP, p-TCP, and TCP-PCL. (C) Relative atomic 
composition at the surface of TCP, p-TCP, and TCP-PCL measured by XPS. (D)   
Thermogravimetric analysis (TGA) of TCP, TCP-PCL, and PCL. 
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Changes in surface composition were assessed using XPS and TGA. Relative 
atomic surface compositions quantified with XPS are shown in Figure 1C. Significantly 
higher C/Ca and O/Ca ratios were measured in TCP-PCL compared to TCP (p<0.05) 
which validate the presence of PCL on the surface of TCP-PCL. The amount of grafted 
polymer was quantified using TGA (Figure 4.1D). When exposed to the heating ramp up 
to 550ºC, the mass of TCP particles remained constant, while the mass of TCP-PCL 
particles decreased 6.0+0.9% at 500ºC due to degradation of the grafted PCL (as verified 
by the analysis of PCL recovered from the grafting reaction). The grafted PCL was 
further characterized using GPC and was found to have a number average molecular 
weight of 15.2+3.0 kDa and a polydispersity index of 1.34+0.21.   
 
 
Figure 4.2. SEM images of TCP, p-TCP, and TCP-PCL composites. Scale bars correspond to 
300 m. 
 
Composite interfacial interactions 
 Figure 4.2 presents cross-sectional images of composites with 56.7 vol% of 
modified and unmodified matrix particles. As shown by these images, the phase 
continuity of the composite improved as p-TCP and TCP-PCL particles were used as 
ceramic matrix. SEM images also show that porosity of the composites can be attributed 
to voids between the phases and not to pores created in the polymeric phase. Porosity was 
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measured gravimetrically 
14
 and determined to be between 19-27% for the TCP 
composite formulations and 7-16% for the composites with modified matrix (p-TCP or 
TCP-PCL). TCP composites show evidence of TCP particles and voids of varying size 
distributed throughout the material. Although TCP grains with original size (100-300 
m) remain, the images also show many smaller particles. These small particles may 
have been obtained by crushing during the hand-mixing steps. Due to the significant 
decrease in particle size, matrix particles are harder to identify in the p-TCP and TCP-
PCL composites. Though voids were also present in the TCP-PCL composite, higher 
continuity of the phases was evident in the images, suggesting improved interaction 
between the polymeric and ceramic phases.  
Further characterization of this interaction was conducted using contact angle 
measurements. The contact angle () between a solid and a liquid can be used to calculate 
the work of adhesion (WAd) at the interface according to the Young-Dupré relationship 
where  corresponds to the liquid surface tension 35: 
                                   (4.2) 
An interface with strong interactions has high work of adhesion and low contact angle 
(good wetting). Non-reactive polymer was able to wet the TCP pellet surface with a 
contact angle of 29+2. The reduced contact angle on TCP-PCL (26+2) suggests a 
modest improvement in wetting due to PCL grafting, though no significant differences 
were observed between the TCP and TCP-PCL contact angles (n=5, p=0.057). Although 
water contact angles are a more common measure of changes in wettability of a surface, 
in this case, the treatment of the TCP pellets with acid during the protonation step 
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increased the porosity of the samples and water flowed through the TCP-PCL preventing 
the correct measurement of this parameter. 
 
 
Figure 4.3. Wet mechanical properties of composites at different indexes A) modulus, B) 
compressive strength. Statistical analysis compares composites with the same filler but different 
indexes at each filler load; * p<0.05; ** p=0.11 
 
Mechanical properties of composite scaffolds 
Figure 4.3 presents the compressive mechanical properties of composites prepared 
with different matrices and isocyanate indices. While the mechanical properties of TCP 
composites were insensitive to index at both matrix contents evaluated, p-TCP and TCP-
PCL composites exhibited increased mechanical properties when formulated with excess 
isocyanate. At lower matrix loadings (45.8 vol.%), both lower particle size and higher 
index improved the mechanical properties of composites with modified particles. 
However, as the matrix loading approached random close packing (>55 vol.%), 
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mechanical properties were only improved for TCP-PCL composites with 40% excess 
isocyanate. Composites prepared for further mechanical and cell culture analysis were all 
formulated with index 140. 
Water uptake of the composites as a function of matrix loading is presented in Figure 
4.4A. After 24 hrs submerged in PBS, TCP-PCL composites absorbed the least amount of 
water independent of matrix loading (Figure 4A). p-TCP composites exhibited a similar 
behavior except at 61.3 vol.%, while TCP composites absorbed a significantly higher 
amount of water at all matrix loadings. Reduced water uptake is additional evidence of 
improved interfacial interactions between the phases in TCP-PCL composites which 
result in minimal available space inside the material for water to accumulate 
35, 36
. 
 
 
Figure 4.4. Compressive mechanical properties of scaffolds with index 140 as a function of 
matrix composition and loading. (A) Water uptake. (B) Compressive modulus under dry and wet 
conditions. (C) Compressive strength under dry and wet conditions. 
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The behavior of compressive (Figure 4.4B and C) and torsion (Table 4.1) properties 
under dry and wet conditions differed between the TCP treatment groups. Surface 
modification increased the compressive properties with respect to unmodified TCP. This 
can be attributed to a combined effect of reduced particle size and improved interfacial 
interactions. Composites with lower water uptake (TCP-PCL) had more stable modulus 
and strength under aqueous conditions. Increased matrix loading monotonically 
decreased the compressive properties of the composites. Mechanical properties under 
torsion were evaluated for composites with index 140 and 56.7 vol% of TCP or TCP-
PCL. This matrix content was chosen to maximize the amount of matrix without 
compromising the compressive mechanical properties to values below that of trabecular 
bone. As expected, torsion is a more demanding mode of failure, and the measured 
properties for modified and unmodified particles are below the trabecular bone reference.  
 
Table 4.1. Torsion mechanical properties for TCP and TCP-PCL composites 
 TCP TCP-PCL Trabecular 
bone *  Dry Wet Dry Wet 
G (MPa) 1009+191 6.8+0.9 628+244 32.2+6.8 263 - 366 
Max stress (MPa) 7.5+0.94 0.7+0.1 10.7+7.3 1.2+0.2 3.1 - 7.7 
Max. strain (%) 0.9+0.1 10.6+0.5 1.9+0.7 4.9+0.1 4.6+1.3
26
 
Energy to failure (kJ/m
3
) 48.2+3.2 40.8+6.1 155.3+128.2 34+6.3 - 
* Ranges from studies of human, canine, bovine, and ovine samples (references included in the text). 
 
Osteoblastic and osteoclastic cell culture 
Ceramic phases are included in bone tissue engineering composites to provide 
osteoconductivity and bioactivity to the polymer 
7, 37
. Thus, it was important for this work 
to verify that the surface modification of the particles would not affect the attachment and 
differentiation of bone remodeling cells. Osteoblast and osteoclast precursors were 
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seeded on TCP and TCP-PCL composites (56.7 vol.% matrix) in vitro, and their 
differentiation was monitored over time. It was not possible to seed cells on p-TCP 
composites to isolate the effects of changes in particle size, given that the materials 
acidified the media and did not allow cells to attach.  
 
 
Figure 4.5. Osteoblastic cell culture of TCP, and TCP-PCL composites. (A) Live-Dead staining 
of MC3T3 cells seeded on composites after 2 days of culture (>95% viability). (B) The 
biocomposites support the differentiation of MC3T3 cells after 7 days of culture in differentiation 
media. White scale bars represent 200 um, * p<0.05 compared to Day 2. 
 
Both osteoblast and osteoclast precursors attached and differentiated on the surface of 
TCP and TCP-PCL composites. Figure 4.5A shows images of live/dead staining of 
MC3T3 cells after being cultured 2 days. Viability of the cells was >95% for both 
formulations, suggesting minimal toxicity from the scaffolds. Furthermore, increased 
ALP activity in the cultured cells (Figure 4.5B) suggests that the cells differentiated into 
osteoblasts, and no significant differences were identified between the materials.  
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Figure 4.6. Osteoclastic cell culture of TCP, and TCP-PCL composites. (A) Positive TRAP 
staining of bone marrow cells cultured on the biocomposites for 15 days. (B) TRAP secreted into 
the media as a measure of osteoclastic resorption activity. * Significantly different from dentin at 
the same time point (p<0.05). 
 
Similarly, positive staining for intracellular TRAP in osteoclast precursors cultured 
on composites and dentin controls for 15 days (Figure 4.6A) suggests that osteoclast 
differentiation was not hindered by surface modification of the matrix particles. It is 
evident that the positive cells on TCP composites, TCP-PCL composites, and dentin 
samples had different morphology, but this can be attributed to differences in surface 
topographies 
38
. Quantification of secreted TRAP provided additional evidence of 
osteoclast differentiation in vitro. At early time points, osteoclasts cultured on dentin 
substrates had higher resorptive activity than those cultured on TCP and TCP-PCL 
composites. However, by 15 days of culture, osteoclast activity on the composites 
matched the activity on dentin. Combined, these observations suggest that the surface 
modification of TCP particles did not hinder the bioactivity of the ceramic matrix and 
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that the composite formulations developed in this work are candidates to undergo 
remodeling in vivo. 
 
Discussion 
 Development of composite biomaterials for bone tissue engineering, in particular 
for load-bearing applications, has received increased attention in the past decade due to 
the improvements in handling, mechanical properties, and biological performance that 
arise when combining two or more phases 
39, 7
. However, a recent review of the 
mechanical behavior of calcium phosphate/polymer composites reported that few 
formulations have strength and porosity comparable to trabecular bone 
8
. To overcome 
this problem, compression molded composite formulations with polyurethane and 
calcium phosphates (hydroxyapatite and -TCP) 9 or allograft bone particles 13 have been 
developed and tested in vivo. These low porosity composites achieved mechanical 
properties approaching those of cortical bone, and when implanted into femoral defects in 
rats and rabbits the materials supported cellular infiltration and promoted new bone 
deposition. Although these formulations have the potential to be applied as weight-
bearing implants, they still require compaction with high pressures which limits their use 
in operating rooms. In this study, moldable and settable composites incorporating 
modified and unmodified -TCP particles and lysine-derived polyurethanes were 
developed and characterized in vitro. The formulations can be easily prepared in the 
operating room by hand mixing, and delivered to bone defects using a straight-bore 
syringe. The -TCP phase was included to increase osteoconductivity of the composite, 
88 
 
while the reactive polyurethane was anticipated to improve handling properties and 
reduce the brittleness of the calcium phosphate.  
Incorporation of -TCP particles into polymers has been reported to decrease the 
mechanical strength of composites due to incompatibility between phases 
40
. Thus, the 
surface of -TCP particles was modified with covalently grafted PCL chains to improve 
the interactions between the reactive polyurethane and ceramic phases. TGA and XPS 
analysis revealed successful polymer grafting (Figure 4.1C-D) on the surface, with a 
decrease in particle size as an additional effect of the protonation step. Contact angle 
measurements of non-reactive polyurethane on TCP and TCP-PCL pellets suggested a 
slight improvement in the interactions between the phases as evidenced by improved 
wetting of the TCP-PCL pellets. However, contact angle measurements were affected by 
changes in the surface topography and porosity of the pellets, as evidenced by the 
difficulty for measuring water contact angles on TCP-PCL samples. As a result, these 
measurements need to be complemented with additional characterization of the polymer-
ceramic interface. 
Interactions between polymer-coated particles and the polymeric matrix in 
composite materials not only depend on the surface chemistry of the particles but also on 
the arrangement of polymeric chains at the interface 
41
. An important variable influencing 
the conformation of terminally anchored polymer chains is the surface grafting density ( , 
chains/nm
2
) 
42
. Previous work studying the conformation of anchored polymer chains in 
the presence of a cross-linked network identified a critical value of grafting density: 
         (4.3) 
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where b corresponds to the Kuhn length of the polymer and N is the number of repeat 
units in the chain 
43-45
. At low grafting densities ( ) the chains remain close to the 
surface without penetrating the network. On the other hand, if higher grafting densities 
are achieved ( ), the entropic cost of excluding the chains from the network is 
higher than the energy penalty associated to the network swelling due to interdigitation of 
the chains 
44
. As a result, the chains extend away from the surface creating a brush layer 
capable of penetrating the network. The thickness of the resulting brush layer (L) can be 
estimated by assuming equilibrium at the interface such that the chemical potential of the 
polymer network is the same at the interface as in the bulk 
43
. Mean-field theory has been 
used to calculate the free energy at the interface and defined the equilibrium condition in 
terms of  (dimensionless layer thickness) as: 
            (4.4) 
where z (0 under theta-conditions under which the polymer acts as ideal chains) is the 
ratio of excluded volume per chain to the volume occupied by the chain at ideal 
conditions 
43
.  is the dimensionless surface density which takes into account 
three-body interactions of the chains through , where MWRU is the 
molecular weight of the repeating units, v is the specific volume (calculated from density 
values) and NA is Avogradro’s number. After solving for , the layer thickness can be 
calculated as . Layer thickness has been reported to influence the interfacial 
adhesion energy at the interface of a polymeric layer anchored to a surface and an 
elastomeric network 
41
. Deruelle et. al. characterized this relation using the JKR method 
(Johnson, Kendal, Roberts method 
46
) and reported the interfacial adhesion energy 
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approaching a maximum value as the layer thickness approached 15 nm 
41
. Even though 
other variables such as grafting procedure, and molecular weight between crosslinks of 
the elastomer changed the absolute value of the energy, the maximum value was always 
achieved at a similar thickness. The authors associated the enhancement of interfacial 
adhesion to penetration of the chains into the network. 
The relations described above in combination with measured parameters for the 
modified particles, such as PCL surface content and molecular weight, were used to 
characterize the conformation of  PCL chains at the surface of TCP-PCL in the presence 
of the PUR network assuming equilibrium and theta-conditions. These calculations 
provide a boundary condition of the system in which all the grafted chains act as active 
connectors between the ceramic surface and the network. The variables and results of 
these calculations are presented in Table 4.2.  
 
Table 4.2. Interaction parameters between the ceramic and polymer network 
Variable Calculated value 
PCL Kuhn length, b (nm) 0.7 
47
 
Critical surface grafting density, crit (chains nm
-2
) 0.015 
Surface grafting density, TCP-PCL (chains nm
-2
) 0.238 
Dimensionless layer thickness, 0 1.61 
Interfacial layer thickness, L (nm) 13.0 
 
 
The calculated surface grafting density of the modified particles ( ) was 
higher than  suggesting that in presence of the PUR network the PCL grafted on the 
surface of TCP adopted a brush conformation, with a calculated layer thickness of 13 nm, 
close to the thickness with maximum adhesion energy reported by Deruelle et al. 
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Although the real layer thickness between the phases may have different dimensions, 
interpenetration of the chains is also favored by the low elasticity of the network 
41
 before 
the polyurethane completely sets.  
SEM images and mechanical properties of the composites provided additional 
evidence of improved interactions between the modified TCP-PCL particles and the 
polyurethane binder. Compressive properties of formulations with 105 and 140 index 
including TCP, p-TCP, and TCP-PCL particles showed that while TCP composites were 
insensitive to changes in polyurethane index, p-TCP and TCP-PCL both had improved 
mechanical properties when excess isocyanate was present. This suggests that in addition 
to the strengthening mechanism of PCL interpenetration into the PUR network discussed 
previously, reactivity between hydroxyl groups at the surface of p-TCP and TCP-PCL 
with excess isocyanate groups can also improve interfacial interactions. While TCP 
composites exhibited a dramatic decrease (15-97%) of mechanical properties after 24 hrs 
in PBS, TCP-PCL composites had higher stability under water presenting a decrease in 
properties in the range of 35-61%. Reduction of mechanical properties of composites in 
an aqueous environment has been associated to a plasticizing effect of the absorbed water, 
degradation of the polymeric phase, and/or diffusion of water through the 
organic/inorganic interface 
35, 40, 36
. Given that the polyurethane binder in our study had 
the same characteristics between the unstable TCP and more stable TCP-PCL composites, 
it is more likely that increased interfacial interactions in the TCP-PCL composites 
reduced water diffusion and enhanced the performance of the materials. In contrast to our 
results, previous studies incorporating ~10 vol% of modified TCP particles (with grafted 
poly(L-lactide) chains with molecular weight between 390 – 1,050 gmol-1) in a 
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poly(D,L-lactide) matrix have reported improved coupling between phases (imaged with 
SEM) without any improvements in the mechanical properties when compared to 
composites with non-modified TCP particles 
20
. However, for linear polymers, physical 
crosslinks due to chain entanglements result as the molecular weight of the polymer 
approaches the molecular weight for entanglements Me 
48
, which for poly(lactide) is 
~9,000 gmol-1 49. Furthermore, models predicting the mechanical properties of filled 
polymers have shown that tensile strength of composites with significant interfacial 
interactions increases only when the filler volume fraction is above 15% 
50
. In our case, 
the molecular weight of the grafted PCL was similar to the reported Me for PCL (15,000  
gmol-1 51), and the filler loadings evaluated were above 45 vol%. It is important to 
highlight that the effect of filler surface modification was significant up to filler contents 
of 56.7 vol%. It is possible that above this value particle-particle instead of particle-
polymer interactions become more significant due to changes in the packing distribution 
of the filler. 
 As shown in Figure 4.7, TCP-PCL composites developed in this work have higher 
mechanical properties than several calcium phosphate formulations recently reviewed 
8
. 
TCP-PCL composites with high matrix loadings (>55 vol.%) exhibited compressive 
properties in the range of trabecular bone: compressive modulus of 100-500 MPa, and 
compressive strength of 4-12 MPa 
8
. Since the mechanical properties of the composites 
are expected to decrease as initial degradation of the polymer takes place, TCP-PCL  
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Figure 4.7. Compressive strength of calcium phosphates and calcium phosphates/polymer composites 
(modified with permission from 
8
). Blue area: Cortical bone properties, Red area: Trabecular bone 
properties, Yellow area: properties of TCP-PCL composites developed in this study. 
 
composites with initial strength between that of cortical and trabecular bone (<55 vol%) 
can support defects in trabecular bone as degraded polymer is replaced by new bone 
deposition 
8
. However, when composites with 56.7 vol% of TCP or TCP-PCL were tested 
under torsion, their properties were significantly lower than those reported for human 
26, 
52
, bovine 
53, 54
, canine 
55
, and ovine 
56, 57
 trabecular bone (Table 4.1). Due to limited 
reported data of calcium phosphate/polymer composites evaluated under torsion 
58
, 
comparison with other formulations was not possible. However, we have recently 
developed a polymeric biocomposite with surface modified bioactive glass particles 
which has compressive and torsional properties exceeding those of trabecular bone 
(unpublished results). This suggests that the surface modification of a stronger and less 
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brittle ceramic further improves the performance of polyurethane biocomposites under 
both, compression and torsion. 
Low porosity polyurethane composites have been shown to support cellular 
infiltration and remodeling in vivo 
9, 13, 18
. Composite formulations developed in this study 
are expected to remodel in a similar fashion, according to the in vitro characterization 
results which show that surface modification of ceramic surfaces allowed attachment and 
differentiation of osteoblast and osteoclast precursors. Even though compared to dentin 
controls the TCP and TCP-PCL composites had an initial lag in the activation of 
osteoclasts, the lag disappeared after 15 days of culture. Increased surface roughness and 
differences in mechanical properties between the composite phases influence the 
attachment and morphology of cells 
38
. Thus it is possible that osteoclast precursors 
seeded on dentin samples were able to attach faster and start the differentiation process 
before the cells seeded on TCP-PCL materials. This small lag is not expected to pose 
problems for the in vivo remodeling of the composites. A limitation of the in vitro 
methods is that during the cutting of the samples for cell culture TCP-PCL grains are also 
cut through exposing non-modified surfaces which can promote cellular development. In 
vivo studies of hydroxyapatite/PCL composites with high and low levels of embedding of 
the ceramic by the polymer showed enhanced osteoconductive behavior in composites 
with low embedding of the hydroxyapatite (increased exposed surface) 
37
. Thus, further 
in vivo studies should be completed to verify the ability of cells to infiltrate the low 
porosity composites developed in this study.  
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Conclusions 
 TCP-PCL/PUR composites with compressive mechanical properties between 
those of trabecular and cortical bone were developed. Improved interactions between -
TCP particles and the PUR phase were achieved by covalently grafting PCL to the 
surface of the filler. The resulting TCP-PCL composites had higher compressive 
mechanical properties and stability under aqueous conditions than TCP composites (non-
modified). No significant effect of surface modification on cell differentiation or activity 
was identified in vitro. Thus, surface modification of ceramic particles is a suitable 
technique to improve the mechanical performance of settable composites for bone tissue 
engineering. The application of this technique with stronger and less brittle fillers is a 
promising alternative to develop formulations with initial weight-bearing capabilities. 
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CHAPTER V 
 
BALANCING THE RATES OF NEW BONE FORMATION AND POLYMER 
DEGRADATION ENHANCES HEALING OF WEIGHT-BEARING 
ALLOGRAFT/POLYURETHANE COMPOSITES IN RABBIT FEMORAL DEFECTS 
 
Introduction 
Periarticular fractures involve a weight-bearing joint and often have depressed 
portions that require extensive open reduction and internal fixation along with 
subchondral grafting to maintain articular congruence. Maintenance of articular reduction 
and joint congruity are important for both bone healing and articular alignment, since 
lack of articular congruence after fractures increases the likelihood of osteoarthritis 
1. 
While autograft remains the standard of care for bone healing, calcium phosphate (CaP) 
cements (CPCs) have proven to be superior to autograft for maintaining articular 
congruence of tibial plateau fractures 
2
. A recent retrospective study has reported that 
61% of patients treated with buttress plating and autograft experienced loss of reduction 
after one year compared to 23% of patients treated with a hydroxyapatite (HA) bone 
cement 
3. However, HA bone cement does not extensively remodel and is not replaced by 
new bone. Moreover, the brittleness and low shear strength of CPCs adversely impact 
their ability to bear mechanical loads, requiring the use of large, mechanically rigid 
internal fixation devices (such as buttress plating), which has been suggested to increase 
complications 
4. 
Settable, weight-bearing bone grafts ideally exhibit both initial bone-like 
mechanical properties and also remodel with minimal resorption gaps such that the 
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strength of the graft exceeds that of host bone during all stages of healing. Injectable bone 
void fillers (BVFs) include non-setting allograft 
5
 and non-allogenic pastes 
6
, which are 
typically delivered using viscous carriers (e.g., sodium hyaluronate 
7
, glycerol 
8
, or 
dextran 
9
) resulting in weak mechanical properties. Resorbable CPCs 
10-13
, such as -TCP 
(slowly resorbed by osteoclasts) or calcium sulfate (CSH) and brushite (undergo 
dissolution), have also been used to enhance bone healing. Tri-phasic CPCs comprising 
CSH, brushite, and granular -TCP have been shown to heal metaphyseal defects in 
preclinical 
14
 and clinical studies 
15
. However, rapid dissolution of CSH and brushite at 
rates exceeding that of new bone formation can result in loss of mechanical strength 
16
, as 
well as the appearance of a fibrous resorption gap between the ingrowing new bone and 
the resorbing cement 
17, 18
. While the initial compressive strength of CPCs is comparable 
to that of trabecular bone, they undergo brittle fracture at strains less than the yield strain 
of trabecular bone, resulting in failure due to fatigue under physiologically relevant cyclic 
loads where the shear component is significant 
19, 6
. Reinforcement with polymeric, 
bioactive glass, or ceramic fibers has been reported to enhance strength and ductility of 
CPCs, resulting in strengths approaching 50 MPa for poly(lactic-co-glycolic acid) 
(PLGA) fibers 
20
 and 130 MPa for magnesium alloy fibers 
21
. 
 Despite the growing interest in weight-bearing settable bone grafts, there is a 
paucity of studies investigating in vivo remodeling in preclinical models. While several 
studies have reported that weight-bearing grafts heal and form new bone 
22-25
, there is 
limited understanding of the mechanisms by which these grafts remodel in vivo, which is 
essential for designing grafts that ideally maintain bone-like strength during the entire 
healing process 
26
. It has been suggested that the degradation rates of the polymer and 
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ceramic phases must be balanced to optimize healing, which is a challenging problem due 
to the fundamentally different mechanisms by which polymers and ceramics degrade 
26
. 
In this study, we investigated the effects of the rates of new bone formation, matrix 
resorption, and polymer degradation on healing of settable, weight-bearing polyurethane 
(PUR) composites comprising approximately equivalent volume fractions of polymer and 
matrix. Based on our previous study reporting that allograft bone particles (ABP) 
embedded in a degradable lysine-derived PUR network remodel by creeping substitution 
22
, we investigated ABP as the reinforcing particulated matrix phase. We hypothesized 
that matching the rate of new bone formation to that of polymer degradation would 
optimize healing. To test this hypothesis, we augmented the ABP/PUR composites with 
either 105 or 420 μg cm-3 recombinant human bone morphogenetic protein-2 (rhBMP-2), 
which was anticipated to increase the rate of new bone formation. Further, rhBMP-2 has 
been reported to promote zero-order degradation of the PUR network 
27
, resulting in more 
closely balanced rates of bone formation and PUR degradation. The composites were 
injected into cylindrical defects in the femoral condyles of rabbits and evaluated by 
micro-computed tomography (μCT) and histomorphometry at 0, 6, and 12 weeks.  
   
Experimental 
Materials 
LTI-PEG prepolymer (23.6% NCO), poly(-caprolactone-co-D.L-lactide-co-
glycolide) triol [162 mg KOH/g and Mn = 1393 g/mol (measured by gel permeation 
chromatography)], and rabbit allograft mineralized bone particles (ABP, 180 ± 70 m) 
were received as a gift from Medtronic, Inc. (Memphis, TN) 
28
. Triethylenediamine 
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(TEDA) catalyst was received as a gift from Goldschmidt (Hopewell, VA), and 
recombinant human bone morphogenetic protein (rhBMP-2) was purchased from R&D 
systems (Minneapolis, MN). Trehalose dehydrate, heparin sodium salt, acetonitrile, and 
trifluoroacetic acid (TFA) were purchased from Sigma Aldrich (St. Louis, MO). 
 
Preparation of rhBMP-2 
 The rhBMP-2 was supplied as a solution comprising 35% acetonitrile and 0.1% 
TFA. A separate acetonitrile/TFA solution was prepared containing a ratio of 10:1 of 
trehalose dehydrate:heparin sodium. The rhBMP-2 and trehalose mixtures were 
combined such that the ratio of rhBMP-2 to trehalose was 1:125. The resulting mixture 
was distributed in glass vials and frozen at -80
o
C in preparation for freeze-drying, which 
produced a powder.   
 
Synthesis of ABP/PUR Biocomposites 
 The appropriate amounts of polyester triol, ABP, and LTI-PEG prepolymer were 
added to a mixing cup and mixed by hand for 90 s. The index (ratio of NCO:OH 
equivalents x 100) was 130. The resulting paste and the catalyst (5500 ppm TEDA) were 
then added to the rhBMP-2 vial and mixed for 60 s. The filler content (ABP and rhBMP-
2 powder) was maintained at 70 wt% (56.7 vol%) for each biocomposite (BC) treatment 
group (Table 5.1). Two rhBMP-2 doses were investigated: 420 g cm-3 and 105 g cm-3, 
corresponding to 100% and 25% of the dose recommended for the absorbable collagen 
sponge (ACS) for rabbits 
29
. The porosities of the composites (measured 
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gravimetrically
27
) were 5.7 ± 2.0% (0 g rhBMP-2 cm-3), 2.7 ± 0.6% (105 g rhBMP-2 
cm
-3
), and 1.6 ± 0.4% (420 g rhBMP-2 cm-3). 
 
Table 5.1. Treatment groups evaluated in the rabbit femoral condyle plug defect study. 
Treatment Group 
rhBMP-2 
(µg/mL) 
6 weeks 12 weeks 
Empty 0 6 6 
ABP 0 6 6 
Biocomposite (BC) 0 9 10 
BC + BMP-L 105 9 10 
BC + BMP-H 420 9 8 
 
Rheological properties 
 The curing profile of the BC without rhBMP-2 (n=4) was determined using a TA 
Instruments AR2000ex rheometer. The reactive biocomposite was loaded between 25 
mm diameter disposable plates and compressed to a gap of 1.5 mm. Measurements of 
storage (G’) and loss (G”) moduli were performed using an oscillatory time sweep 
method with a frequency of 1 Hz and amplitude of 1% strain. The working time of the 
BC, defined as the time from the start of mixing until cure, was determined as the G’-G” 
cross-over point. The flow characteristics of the BC were analyzed by removing the 
catalyst from the formulation (n=3). Non-setting samples were poured between 40mm 
cross-hatched parallel plates, compressed to a gap of 1.5 mm, and subjected to a dynamic 
frequency sweep (0.1 to 100 rad sec
-1
) at 25C with controlled strain amplitude of 0.02%. 
A Cox-Merz transformation was applied to the dynamic data to obtain the steady state 
viscosity (, Pa*s) as a function of shear rate (, s-1). The data were fit to the Herschel-
Bulkley model, which relates the viscosity and shear rate of solid-filled suspensions with 
high solids content 
30
, to estimate the yield stress (Y, Pa) of the material:  
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  = Y
-1
 + K(n-1)        (5.1) 
where K is the consistency index of the composite (constant) and n is the power-law 
index of the suspending polymer, which in this case is the non-reactive mixture of 
polyester triol and LTI-PEG prepolymer.  
 
Mechanical properties 
 Cylindrical (6-mm diameter) samples of each treatment group were prepared for 
mechanical testing.  The reactive paste was transferred into cylindrical plastic cups and a 
1-lb weight (20.7 psi) was placed on the material for 10 min. Cylinders were cured in a 
vacuum oven at 37
o
C overnight, removed from the plastic cups, and cut using a Buehler 
saw to a length of 12 mm. After 24 hours of hydration in phosphate buffered saline (PBS), 
the samples were tested using an MTS 898 by preloading to 12N followed by 
compression at a rate of 25mm/min until failure. The original cross sectional area of the 
cylinders was used to calculate compressive stress. The ultimate properties reported in 
this article correspond to the point where maximum stress was achieved. To prepare 
samples for torsion testing, ~5 mm at each end of 6-mm diameter cylinders was potted 
into Technovit 4000 (Heraeus Kulzer) resulting in a central gauge length of about 10 mm. 
The potting material was prepared by mixing the powder:syrup I:syrup II using a ratio of 
2:2:1 following the manufacturer’s instructions. After potting, the torsion samples were 
hydrated for 24 hrs in PBS and then tested using an Instron DynaMight 8841 machine 
equipped with a 1.7 Nm torque cell. The potted ends were gripped using the Instron 
clamps in a horizontal setup (such that the residual torque was minimal). During testing, 
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the clamps were rotated at an angular speed of 2/s until failure. The measured torque and 
rotation angle were used to determine torsional stress using the equation 
31, 32
: 
  = [(dT/d) + 3T]/(2r3)       (5.2) 
where r is the radius of the cylinder,  = /L is the rotation angle per gauge unit length, 
and T is the measured torque. The derivative dT/d was determined by fitting the T vs.  
data to a 5
th
 order polynomial (between zero up to the maximum torque or ultimate point). 
Torsional strain () was determined as  = r, and the shear modulus calculated from the 
linear region of the stress-strain curve G = / . Toughness was calculated as the 
corresponding area under the stress-strain curve from zero to the maximum stress. 
 
Animal Study 
 Forty-two New Zealand White (NZW) rabbits weighing between 3.8 and 4.1 kg 
were used in this study.  All surgical and care procedures were carried out under aseptic 
conditions per the approved Institutional Animal Care Use Committee (IACUC) protocol.  
The ABP/PUR putty components were gamma irradiated using a dose of ~25 kGY.  
Glycopyrrolate was administered at 0.01 mg/kg intramuscularly (IM) followed by 
ketamine at 40 mg/kg IM. Bilateral defects of ~6 mm diameter by 11 mm in depth were 
drilled in the lateral metaphysis of the distal femurs of each rabbit. ABP/PUR plugs from 
each treatment group (Table 5.1) were subsequently injected into each defect using a 1 
mL syringe (modified by cutting the needle hub adapter). Treatment groups for each 
composite were dispersed randomly among the rabbits with rhBMP-2 treatment groups 
paired in each rabbit to eliminate systemic effects. The wound was closed approximately 
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3 minutes after injection. The rabbits were euthanized at both 6 and 12 week time points 
using Fatal-plus (2.2 mL/10 kg) intra-venously. 
   
CT Analysis 
 A CT40 (SCANCO Medical) was used to acquire images of the extracted 
femurs post implantation at 6 and 12 weeks. In addition, femurs from NZW rabbits that 
were part of other experimental protocols which did not affect the skeleton (same age, 
sex, and similar weight to the rabbits used in this study) were scanned and analyzed as 
host bone controls. Subsequently, cylindrical defects (6 mm x 11 mm) were created in the 
host bone controls and filled with the BC formulation. The injected material was left to 
cure under PBS for 24 hrs before submerging the bone in formalin for further scanning as 
BC controls (BC, 0w). µCT scans were performed in formalin at 70 kVp energy, 114 µA 
source current, 1000 projections per rotation, 300 ms integration time, and an isotropic 
voxel size of 36 µm. A 0.1 mm thick aluminum foil filter was employed to reduce beam 
hardening. Axial images were reconstructed using manufacturer-provided software. 
Further beam hardening correction was performed during image reconstruction using the 
manufacturer’s 1200 mg HA cm-3 algorithm. Attenuation values were converted to tissue 
mineral density (TMD) through calibration with hydroxyapatite (HA) phantoms with 
densities between 0 and 780 mg HA cm
-3
 (calibration of the instrument was checked 
weekly). Using the cortical borders of the defect for alignment, the reconstructed image 
stack was re-oriented such that the depth of the defect was parallel to the z-axis. A radial 
analysis of the morphometric parameters was conducted from the core of the implant to 
the interphase with host bone. Four concentric annular volumes of interest with thickness 
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of 1 mm and approximate length of 11mm (from the outer cortical surface of the femur) 
were defined for each sample.  The 3 inner regions incorporated the BCs, while the outer 
region provided information about the interphase with host bone. Ossified tissue was 
segmented from soft tissue using a threshold of 480 mgHAcm-3 and Gaussian noise 
filter settings of sigma 0.2 and support 2. The threshold conditions were chosen visually 
and kept constant for the analysis of all the samples. Morphometric parameters within the 
annular volumes were calculated for each region, grouped by treatment and time point, 
and plotted versus the mean radial distance from the core of the defect Rm (Rm=(Ro+Ri)/2, 
where Ro and Ri correspond to the outer and inner radius of each region, respectively). 
Bone volume/total volume (BV/TV), tissue mineral density (TMD, density of the ossified 
tissue), connectivity density (Conn.D.), trabecular number (Tb.N.), trabecular thickness 
(Tb.Th.), and trabecular separation (Tb.Sp.) within the regions of interest were computed 
using SCANCO’s Medical microCT systems software.  
 
Histology and histomorphometry 
 Rabbit femora were placed in a solution of 10% formalin for two weeks followed 
by a series of ethanol dehydrations. After fixation, the femurs were embedded in 
poly(methyl methacrylate) and 200-m sections were cut from the resulting blocks using 
an Exakt band saw. The sections were then ground and polished using an Exakt grinding 
system to less than 100 m and stained with Sanderson’s rapid bone stain counterstained 
with van Gieson. Residual allograft bone particles stained light brown, residual polymer 
stained black, new bone stained pink with dark blue osteocytes within the matrix, red 
blood cells stained torquiose, and other cells stained a lighter blue. The sections were 
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imaged at 10X magnification with an Olympus camera (DP71) using an Olympus BX60 
microscope with and without polarizing the light.  Residual ABPs, new bone formation, 
and remaining polymer were quantified in an area of interest 1.5 mm high  6 mm wide 
located in the center of the defect. To analyze the radial remodeling of the scaffolds in 
time, the rectangular area of interest was further subdivided into 3 concentric annular 
regions (each 1 mm thick): A1, representing the area of the defect in contact with the host 
bone and up to 1 mm away from the edge of the defect; A2, representing the mid-region 
of the defect; and A3, representing the core of the defect. Residual allograft was 
differentiated from new bone by meeting the following three criteria: (i) acellularity, 
(ii)angular in shape, and (iii) ilumination under polarized light. Metamorph (Version 
7.0.1) was utilized to perform histomorphometry using a color thresholding and an image 
layering technique to quantify the number of pixels of each layer and compare it to the 
total pixels in the area of interest. 
 
 Statistical analysis 
 Three-way ANOVA, performed in JMP 9.0, was used to determine whether 
statistical differences existed between treatment groups, area, and time. Comparissons of 
individual sample groups were performed using a Tukey HSD test. For all experiments 
p<0.05 was considered statistically significant. 
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Results  
Rheological properties 
 Figure 5.1A shows a representative plot of the storage and loss moduli of the BC 
without rhBMP-2 during cure. The onset of the curve in Figure 5.1A is delayed due to the 
time (~9 min) required to set the gap and start data collection after mixing. Initially, the 
BC exhibits viscoelastic behavior as evidenced by its permanent deformation in response 
to applied stress, but when the working is reached (G’-G” crossover point at 13.7 ± 3.5 
min), it becomes more elastomeric.  
 
      
Figure 5.1. Rheological properties of the BC measured by rheometry. (A) G’ represents the 
storage modulus and G’’ the loss modulus. The G’-G’’ crossover point is assumed to be the 
working time of the BC. (B) Viscosity versus shear rate plot illustrating calculation of the yield 
stress using the Herschel-Bulkley model.  
 
The yield stress Y of a solid-filled suspension can be defined as the minimum 
stress required for the material to deform 
33
. Among the models developed to calculate Y, 
the Herschel-Bulkley provides the best fit of the data for the non-reactive BC (Figure 
5.1B). The suspending polymer (0% ABP) exhibits Newtonian behavior (dotted line) 
A B 
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over the range of shear rates investigated (0.1 – 10 s-1). Consequently, the power-law 
index n (Equation 5.1) of the suspending polymer is equal to unity, and fitting the  vs.  
data to the resulting expression results in Y = 738 kPa.  Additionally, the viscosity of the 
material at 5 s
-1
 (the recommended shear rate at which the viscosity of an injectable 
material should be reported 
34
) is 179 kPas. The high initial viscosity suggests that the 
material is not flowable; however, up to the working time the BC can be molded to 
conform to the contours of the defect. 
 
       
Figure 5.2. Representative stress-strain curves for the BCs and CaP cement under compression 
and torsion. 
 
Mechanical  properties 
Representative compression and torsion stress-strain curves measured for the BCs 
with and without rhBMP-2 are shown in Figure 5.2 and compared to a tri-phasic CPC 
comprising 75% CSH and 25% brushite/granular β-TCP (ProDense, Wright Medical) 6. 
The Young’s modulus, ultimate stress, ultimate strain, and toughness (area under the 
stress-strain curve) measured under compression and torsion are listed in Table 5.2. 
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Table 5.2. Mechanical properties of the injectable biocomposites (BC) and the calcium phosphate cement 
(CPC) measured under compressive and torsional loads.  Data are reported as the mean ± Standard error of 
the mean (SEM). 
(A) Compression     
Property CPC BC BC+BMP-L BC+BMP-H 
Young’s modulus, MPa 1689  197 503  122 452  103 524  68 
Stress at failure, MPa 19.9  5.1 24.0  4.8 24.7  6.4 28.3  3.2 
Strain at failure, % 1.67  0.03 7.39  0.64 8.41  0.11 8.12  0.28 
Energy-to-failure, kJ m
-3
 168  27 1072  292 1188  180 1395  113 
 
(B) Torsion     
Property CPC BC BC+BMP-L BC+BMP-H 
Young’s modulus, MPa 2051  45 121  18 56.0  9.5 40.0  6.7 
Stress at failure, MPa 2.90  1.38 3.60  1.05 1.80  0.36 1.70  0.20 
Strain at failure, % 0.20  0.08 5.0  1.2 4.0  0.6 5.0  0.6 
Energy-to-failure, kJ m
-3
 4.0  3.0 123  53 55.0  16.3 58.0  7.4 
 
 Under compression, the modulus of the CPC (1689 MPa) was significantly 
higher than that of the BCs (450 – 524 MPa), but the strength of the CPC (19.9 MPa) was 
comparable to that of the BCs (24 – 28 MPa). However, due to the significantly higher 
ultimate strain for the BCs (7.4 – 8.1%) compared to the CPC (1.7%), the toughness was 
approximately an order of magnitude greater for the BCs. Addition of rhBMP-2 did not 
have a significant effect on the mechanical properties of the BCs under compressive 
loading. Under torsional loading, the modulus of the CPC (2051 MPa) was substantially 
greater than that of the BCs (40 – 121 MPa). However, the torsional strength of the CPC 
(2.9 MPa) was comparable to that of the BCs (1.7 – 3.6 MPa). Similar to the results for 
compression, the ultimate strain was dramatically higher for the BCs (4.0 – 5.0%) 
compared to the CPC (0.2%). Consequently, the toughness was more than an order of 
magnitude greater for the BCs. In contrast to the results under compression, the torsional 
properties decreased when rhBMP-2 was added to the formulations.  
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CT Data 
 Representative CT images of the BC and control groups after 6 and 12 weeks 
post-implantation are presented in Figure 5.3. Minimal new bone formation, primarily in 
the region of the femoral cortex, was observed for the empty and ABP-treated groups at 6 
and 12 weeks. These observations suggest that the empty defects did not heal extensively, 
and that in the absence of the settable PUR binder to maintain the structure of the graft, 
the allograft particles had resorbed. All BC treatment groups showed evidence of 
resorption of allograft particles (irregularly shaped bright white particles with sharp 
edges) and remodeling.  
 
 
Figure 5.3. Representative images of the empty defects filled with the allograft bone particles, 
BC, BC+BMP-L, BC+BMP-H at 6 and 12 weeks. Longitudinal sections of the femur and 3D 
reconstructions of the cylindrical defect region of interest. 
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Considering that the BCs remodel by creeping substitution of ABPs initiated at 
the host bone/BC interface, the radial distribution of key morphometric parameters 
35
 was 
measured by CT as shown in Figure 5.4. The defect was divided into four annular 
regions (Figure 5.4A) extending for 11 mm and the morphometric parameters BV/TV, 
TMD, Conn.D., Tb.N., Tb.Th., and Tb.Sp were measured for each region. The measured 
parameters of the samples were compared to those of the BC controls (BC, 0w) and 
healthy host trabecular bone controls (Host bone control).   
 As shown in Figure 5.4B, TMD showed minimal variation as a function of radial 
distance, while the values for all groups were slightly higher at 12 weeks compared to 6 
weeks. At 6 weeks, BV/TV (Figure 5.4C) was relatively constant at ~50 vol% for the BC 
and BC+BMP-H groups, while BV/TV dropped below 40 vol% in the outer regions (e.g., 
near the bone/BC interface) of the BC+BMP-L group. By 12 weeks, BV/TV (Figure 
5.4D) decreased monotonically from the inner core (~50%) to the outer interfacial region 
(30-45%) for all groups. At 12 weeks, the BC group showed the largest radial change in 
BV/TV, ranging from values comparable to the BC control (51+0.4%) at the inner core to 
values comparable to host trabecular bone (30+1%) at the bone-composite interface.  
None of the groups showed resorption gaps where BV/TV dropped below that of host 
trabecular bone. 
 In addition to TMD and BV/TV, several standard morphometric 
parameters 
35
, including mean trabecular thickness (Tb.Th.), mean trabecular separation 
(Tb.Sp.), trabecular number (Tb.N.), and connectivity density (Conn.D.), were plotted as 
a function Rm. Values for each treatment group were compared to measured values for 
BC controls (0 weeks) and host trabecular bone.  
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Figure 5.4. Radial distribution of morphometric parameters measured by CT at 6 and 12 weeks. 
(A) Representative image highlighting subdivision of the defect into four annular shells each 
1mm thick. (B)-(H) Morphometric parameters evaluated are plotted versus the mean radial 
distance from the core (Rm). 
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As shown in Figure 5.4E, F, and H, Conn.D., Tb.N., and Tb.Sp. progressed 
monotonically from values comparable to that of the BC control in the inner core region 
to values comparable to that of the host trabecular bone in the outer annular region. At 
each point in space and time, the differences between each rhBMP-2 dose were modest. 
However, values of Conn.D. and Tb.N. decreased from 6 to 12 weeks at each distance 
and rhBMP-2 dose, while Tb.Sp. increased. Similar to BV/TV, Conn.D., Tb.N., and 
Tb.Sp. did not drop below values measured for host bone in any region for any of the 
groups. Interestingly, Tb.Th. exhibited an opposite trend in which the parameter did not 
converge to the value measured in the host bone as the radial distance increased. Instead, 
Tb. Th. increased monotonically from values close to that of the BC controls (201+4m) 
in the inner core region to 240–340 m in the outer annular region compared to 149+2.6 
m for the host bone.      
 
Histology and histomorphometry 
 Histological sections of the empty defects at 6 weeks (Figure 5.5) show minimal 
new bone formation, which is consistent with the CT data. However, histological 
sections of the BC treatment groups (Figure 5.6) reveal evidence of cellular infiltration 
(CI), allograft (A) resorption, and new bone formation (NB). High magnification views 
show regions of active remodeling, osteoid formation, appositional growth of new bone 
on residual allograft particles, and bridging of allograft particles by new bone, suggesting 
that the biocomposites remodel by creeping substitution 
22, 28, 27
. In contrast, allograft-
treated defects supported minimal ingrowth of new bone, which is consistent with the 
notion that the continuous polymer phase is essential for supporting new bone formation.    
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Figure 5.5. Low (1.25x) and high (20x) magnification images of histological sections of 
untreated (empty – top) and allograft-filled (bottom) defects at 6 weeks. CI: Cellular infiltration, 
A: Allograft particles.  
 
 
Figure 5.6. (A) Low (1.25x) and high (20x) magnification images of histological sections of the 
biocomposite treatment groups at 6 weeks. P: residual polymer, O: Osteoid, NB: New bone 
formation. 
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Figure 5.6 (continued). (B) Low (1.25x) and high (20x) magnification images of histological 
sections of the biocomposite treatment groups at 12 weeks. P: residual polymer, O: Osteoid, NB: 
New bone formation. 
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Histomorphometric analysis of each area of interest (labeled A1, A2, and A3 in 
Figure 5.7A) revealed an increase in new bone formation for all BC treatment groups 
between 6 and 12 weeks (Figure 5.7B-D). Differences over time within a specific area 
were significant only for A1 in the BC+BMP-L and BC+BMP-H groups, and differences 
between areas at each time point were not significant for any groups. Area% new bone 
formation data were fit to the following empirical equation (R
2
 ~ 1 for all fits): 
%B =
at
1+ bt( )
         (5.3) 
where a and b are fitting parameters (Table 5.3). In the outer region (A1), b  0 for all 
groups, suggesting that ingrowth of new bone near the host bone interface is a zero-order 
process. Thus, bone forms at an approximately constant rate rB = d(%B)/dt = mineral 
apposition rate, which has been reported as ~4 μmday-1 for the distal femur of rabbits 36. 
However, b = 0.307 in the inner region of group BC (Figure 5.7B), indicating that the 
rate of new bone formation decreased from 6 to 12 weeks. As anticipated, augmentation 
with rhBMP-2 increased the rate of new bone formation, but differences between the high 
and low dose were not significant.  In the inner region, the parameter b is lower for the 
BC+BMP-L (Figure 5.7C) and BC+BMP-H (Figure 5.7D) groups compared to the BC 
group, suggesting that the rate of new bone formation in the interior of the graft is 
decreasing less in the presence of rhBMP-2.  
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Figure 5.7. Histomorphometric evaluation of remodeling of the biocomposite scaffolds. (A) 
Diagram showing the areas of interest. Area% new bone, Area % remaining allograft particles, 
and Area% remaining polymer for (B,E,H) BC, (C,F,I) BC+BMP-L, and (D,G,J) BC+BMP-H 
 
Table 5.3.  Fitting parameters for bone (B) histomorphometry data, which were fit to area% B = at/(1+bt). 
 A1 A2 A3 
Group a b a b a b 
BC 1.57 0.0059 2.27 0.0560 4.88 0.307 
BC+BMP-L 1.82 -0.0121 5.02 0.149 3.56 0.103 
BC+BMP-H 2.58 0.0304 3.66 0.101 3.00 0.072 
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Histomorphometry data for residual allograft are presented for each area in Figure 
5.7E-G. Area% allograft (A) data for the BC group (Figure 5.7E) were fit to the 
following equation: 
        (5.4) 
where AA,i is the initial area% allograft in the sample at t = 0. Values of the fitting 
parameters a and b for each group are listed in Table 5.4. As anticipated, for the BC 
group the area% allograft decreased with time due to osteoclast-mediated resorption 
27, 22, 
28
, but the differences between 6 and 12 weeks were not significant for any group. The 
half-life varied from 2.3 – 2.9 weeks. In the presence of rhBMP-2, the area% residual 
allograft was significantly less than in the BC group at 6 weeks, suggesting that rhBMP-2 
accelerated allograft resorption at early time points. Interestingly, no significant changes 
in allograft area% were observed in the rhBMP-2 treatment groups from 6 to 12 weeks. 
Due to the transient resorption of allograft at 6 weeks, it was not possible to fit the area% 
allograft data to eq (5.4) in the presence of rhBMP-2.   
 
Table 5.4.  Fitting parameters for allograft (A) histomorphometry data, which were fit to area% A = AA,i - 
at/(1+bt) for the BC group. The parameter AA,i is the initial area% allograft measured by histomorphometry. 
Data for BC+BMP-L and BC+BMP-H groups could not be accurately fit to the exponential or rational 
functions. 
 A1 A2 A3 
Group a b t1/2 (wk) a b t1/2 (wk) a b t1/2 (wk) 
BC 22.8 0.583 2.3 0.318 0.380 2.6 0.023 0.590 2.9 
 
 
Polymer degradation was affected by both time and rhBMP-2 dose (Figure 5.7H-
J). Differences between 6 and 12 weeks were significant within a specific area for all 
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groups, but differences between areas were not significant. Area% polymer (P) data for 
the BC group (Figure 5.7H) were fit to the following equation: 
       (5.5) 
where AP,i is the initial area% polymer in the sample at t = 0. The half-life of the polymer 
ranged from 10.5 – 11.5 weeks, which is substantially longer than that of the allograft but 
slightly shorter than t1/2 = 14 weeks reported in vitro 
37
. Similar to observations from in 
vitro studies, the degradation profile of the poly(ester urethane) is consistent with an 
autocatalytic mechanism 
37
 and does not follow the first-order kinetics associated with 
ester hydrolysis 
38
.  Local delivery of rhBMP-2 (Figure 5.7I-J) changed the shape of the 
area% polymer curve, which was fit to an equation similar to the one used for new bone: 
        (5.6) 
 
Table 5.5.  Fitting parameters for polymer (P) histomorphometry data, which were fit to area% P = AP,i - 
at/(1+bt) for BC+BMP-L and BC+BMP-H groups and to area% P = AP,i – αexp(βt) for the BC group. The 
parameter AP,i is the initial area% polymer measured by histomorphometry. 
 A1 A2 A3 
Group a (α) b (β) 
t1/2 
(wk) 
a (α) b (β) 
t1/2 
(wk) 
a (α) b (β) 
t1/2 
(wk) 
BC 0.408 0.376 10.5 0.318 0.380 11.0 0.023 0.590 11.5 
BC+BMP-L 1.98 -0.0365 6.4 1.69 -0.0425 8.3 1.83 -0.0373 8.2 
BC+BMP-H 3.30 -0.0062 6.3 2.44 -0.0258 7.2 2.24 -0.0292 7.5 
 
As evidenced by the values of b  0 (Table 5.5), the process of PUR degradation 
in the presence of rhBMP-2 is nearly zero-order (i.e., constant rate). Augmentation with 
rhBMP-2 also accelerated PUR degradation, as evidenced by t1/2 = 6.4 – 8.3 weeks for 
BC+BMP-L and t1/2 = 6.3 – 7.5 weeks for BC+BMP-H. Differences in residual polymer 
were significant between the BC group and the BC+BMP-L and –H groups at 6 weeks, 
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but not at 12 weeks. Thus, rhBMP2 both altered the mechanism of PUR degradation and 
also increased the degradation rate.  
 
Discussion  
Weight-bearing bone grafts have generated considerable interest in recent years, 
but the mechanisms by which they remodel, while maintaining their initial bone-like 
strength are poorly understood. In this study, we investigated the effects of the rate of 
new bone formation, the rate of reinforcing matrix (allograft) resorption, and the 
mechanism of polymer degradation on healing of ABP/PUR composites in femoral 
condyle plug defects in rabbits. The initial compressive strength (24–28 MPa) and 
toughness (1070–1400 kJm-3) of the composites were comparable to or exceeding those 
of trabecular bone (6 MPa and 1050 kJmm-3, respectively 39). When injected into femoral 
condyle plug defects in NZW rabbits, new bone formation and healing progressed in both 
space and time for up to 12 weeks. Polymer degradation was autocatalytic and new bone 
formation was approximately zero-order in the absence of rhBMP-2, resulting in 
incomplete healing in the inner core of the graft at later time points.  In contrast, local 
delivery of rhBMP-2 increased the rate of new bone formation, and promoted 
approximately zero-order degradation of the continuous polymer phase, resulting in 
improved healing at later time points. Thus, balancing the rates of new bone formation 
and polymer degradation was observed to improve healing. 
The settable composites exhibited a working time of 13.7 ± 3.5 min, which is 
longer than the value of 4.5 min reported for an injectable, flowable bone void filler (36 
vol% ABP 
27
) and the working times of 6–10 min reported for CPCs 40, 41. A proposed 
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criterion for injectability of CPCs dictates that the material can be administered from a 
syringe by applying a force < 100 N 
6
. Consequently, a syringe with diameter >13-mm 
would be required to inject the BC due to its high yield stress (738 kPa). Similarly, the 
viscosity of the BC at 5 s
-1
 is substantially higher (18×10
3
 Pas) than that of other 
injectable bone grafts, such the flowable ABP void filler (170 Pas 27, 35 vol% ABP) or 
flowable CPCs (5 – 10 Pas, 35 – 39 vol% solids 34). Thus, while the BC has higher initial 
viscosity and yield stress compared to other BVFs due to its high solids content (57 
vol%), it is moldable and settable within a clinically relevant time frame, which enables 
the surgeon to conform the graft to the contours of the bone defect 
42
. 
The initial compressive strength (24.0  4.8 MPa) and modulus (503  122 MPa) 
of the BCs exceed values reported for trabecular bone, which range from 3.7–8.4 MPa 
and 104–300 MPa, respectively 43, 44, 39, 45. Similarly, the ultimate strain of the BCs 
(7.30.6%) exceeds that of trabecular bone in human femora (1.05±0.46%) 46), while the 
toughness (1072292 kJm-3) is comparable to that of trabecular bone (1000 kJm-3 39). 
Under torsional deformation, the strength and modulus of the BCs are 2.9±1.4 MPa and 
121±18 MPa, respectively, which are close to values reported for human 
31, 47
, bovine 
48, 
49
, canine 
43
, and ovine 
50, 51
 trabecular bone ranging from 3.1 to 7.7MPa and 263 to 
366MPa, respectively. However, the ultimate strain of the BC (5.0±1.2%) is comparable 
to a previous study reporting strain at failure of 4.6±1.3% for trabecular bone 
31
. Taken 
together, these observations suggest that the initial mechanical properties of the BCs are 
comparable to those of trabecular bone under compression and slightly weaker under 
torsion. 
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Recent studies have reported that the poor mechanical properties of CPCs under 
the physiologically relevant conditions of cyclic loading with a significant shear 
component 
52
 limit their use to non-load-bearing applications 
19, 6
. The weak shear and 
torsional properties of these materials have been attributed to their inherent brittleness; 
however, there are limited toughness and fatigue data. Therefore, we compared the 
toughness of the BCs to an injectable tri-phasic CPC that supports bone healing in both 
preclinical models 
14
 and patients 
53
. The toughness of the CPC was ~6 times less than 
that of the BC and trabecular bone under compression, while under torsion the toughness 
of the CPC was ~30 times less than that of the BC. The reduced toughness of the CPC is 
attributed in part to its lower ultimate strain compared to the BC and trabecular bone 
under compression (1.7%) and torsion (0.2%). While the area under the stress-strain 
curve is a convenient estimate of toughness, it is not a true material property 
19
, and thus 
the fatigue properties, fracture toughness, and/or other measures of reliability (such as the 
Weibull modulus) must be characterized to assess the potential of the BC to promote 
healing in weight-bearing bone defects. 
While incorporation of calcium phosphate has been reported to increase 
osteoconductivity for some polymers 
54
, a recent review has reported that in most studies 
it does not increase the strength of polymer/ceramic composites 
19
. As an exception to 
this trend, HA/poly(lactic acid) (HA/PLLA) composites incorporating negligible porosity 
and ~20 vol% HA particles exhibited bending strengths up to 280 MPa. However, since 
bridging between the ceramic particles and host bone was dependent upon the 
degradation of PLLA 
55
, the rate of remodeling was slow, as evidenced by the fact that 
4% of the composite implanted in rabbit femora remained after 7 years 
56
. Furthermore, 
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the resorption zone near the host bone interface resulting from phagocytosis of the 
implant by histocytes 
56
 is anticipated to reduce its strength. Compression-molded 
ABP/PUR BCs incorporating 68 vol% ABP exhibited compressive strengths ranging 
from 100 to 170 MPa and supported extensive cellular infiltration at 6 weeks in rabbit 
femoral condyle defects 
22
. However, only modest new bone formation (~2%) was 
observed at 6 weeks. The grafts remodeled by creeping substitution, a process 
characterized by resorption of allograft particles by osteoclasts 
27
 followed by infiltration 
of osteoblasts into the newly formed pore 
27, 22, 28
. Subsequent new bone formation was 
observed on the surfaces of both the polymer and also the residual allograft particles. 
However, as the polymer degraded the grafts filled with fibrous tissue due to the lack of a 
continuous surface for new bone growth. In the present study, the ABP control group 
with no polymer exhibited extensive resorption of allograft particles and minimal new 
bone formation away from the cortex. These observations underscore the need for a 
continuous polymer phase to persist throughout the interior of the BC until the defect has 
almost fully healed. 
To overcome the limitations of previous studies, settable ABP/PUR composites 
were designed to incorporate 43% polymer, which formed a continuous phase.  New 
bone formation in the outer region of all grafts progressed at a nearly constant rate 
(Figure 5.7B-D)). However, rB = d(%B)/dt in the inner regions decreased with time, 
suggesting that mass-transfer limitations associated with infiltration of cells from the host 
bone into the interior of the scaffold slowed bone formation. Recently, a diffusion model 
for bone formation in osteoconductive scaffolds has been proposed 
57
: 
         (5.7) 
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where c denotes BV/TV,  is the Laplacian, and  (mm2day-1) is the scaffold 
osteoconduction coefficient. Incorporation of ABPs, which resorb by osteoclastic 
resorption (fast) rather than dissolution (slow), at loadings sufficiently high to present a 
percolated phase resulted in relatively rapid (t1/2 < 3 weeks) resorption of the reinforcing 
matrix. However, the μCT radial analysis (Figure 5.4) shows that BV/TV progressed 
monotonically toward values approaching those of host bone near the interface, with no 
evidence of extensive resorption gaps. These observations point to the potential 
utilization of  as an independent design parameter that can be controlled by varying 
either the intrinsic resorption rate or loading of the reinforcing matrix. 
Local delivery of rhBMP-2 increased the rate of bone formation and had a 
transient effect on allograft resorption at 6 weeks. These observations are consistent with 
in vitro and preclinical studies reporting that BMP-2 upregulates osteoclast differentiation 
and activity 
58-61
 and drives osteoclast-mediated resorption at high doses 
62
. Similar 
observations have been made for rhBMP-2 released from an absorbable collagen sponge 
(ACS) implanted in femoral condyle plug defects in sheep 
62
. However, transient allograft 
resorption observed in previous studies has generally been associated with doses of 
rhBMP-2 considerably higher than the recommended values. Exogenous rhBMP-2 also 
modified the degradation kinetics of the poly(ester urethane) network 
27, 63
.  While the 
mechanism of polymer degradation in the presence of rhBMP-2 is not well understood, 
rhBMP-2 has been reported to recruit monocytes 
64
 that degrade lysine-derived PUR 
scaffolds by an oxidative mechanism 
65
. Thus, the zero-order polymer degradation 
kinetics observed in the presence of rhBMP-2 may be macrophage-mediated.  
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Figure 5.8. Analysis of histomorphometric data.  The ratio of the rate of new bone formation (rB) 
to that of polymer degradation (rP) was calculated for each group by differentiating the equations 
expressing area% new bone and area% polymer as a function of time. Representative images of 
histological sections with highlighted areas of interest. (A-B) BC, (C-D) BC+BMP-L, and (E-F) 
BC+BMP-H 
 
The histomorphometry data were further analyzed in Figure 5.8 to gain insight 
into the design criteria for weight-bearing bone grafts.  The rate of new bone formation rB 
relative to the rate of polymer degradation (rP = -d(area% P)/dt) is plotted versus the 
parameter fH, which approximates the fractional healing of the defect: 
fH =
area% bone in defect
area% bone in host bone
     (5.8) 
The area% bone in the host bone was measured by histomorphometry to be 
39.3+1.9%. For the BC at early stages of healing, rB/rP >>1 but it decreased dramatically 
with time (Figure 5.8A). A representative histological section (Figure 5.8B) shows poor 
surface connectivity at 12 weeks, characterized by isolated islands of polymer and 
allograft. The consequences of mismatched rates of new bone formation and polymer 
degradation are particularly acute in the inner region, where rB/rP 0 at fH = 32% healing, 
at which time the surface is likely insufficiently interconnected to continue to support 
cellular infiltration and consequent new bone formation. Thus, autocatalytic degradation 
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of the PUR network driven by carboxylic acid groups formed after hydrolysis of ester 
bonds does not match the zero-order kinetics of new bone formation 
66
, resulting in poor 
healing in the inner region.   
In the presence of exogenous rhBMP-2, the rates of new bone formation and 
polymer degradation were more balanced.  Although rB/rP monotonically decreased with 
time in the presence of rhBMP-2 (Figure 5.8C,E), the effect was substantially weaker 
than in the BC group, and in the outer region rB/rP was nearly constant. The relative rate 
rB/rP approached values <0.2 in the inner regions, but by this time (12 weeks) healing had 
progressed to fH>50%.  The representative histological sections from the BC+BMP-L 
(Figure 5.8D) and BC+BMP-H (Figure 5.8F) groups show a more connected surface in 
the inner regions (A2 and A3) for continued bone growth at 12 weeks. Taken together, 
the data in Figure 5.8 suggest that to optimize bone healing, the polymer must persist 
until a sufficient amount of new bone has formed to provide a continuous surface, and 
that the rate of degradation of the continuous polymeric phase should be matched to the 
rate of new bone formation. While a polyester with a longer half-life 
37
 is anticipated to 
delay the onset of rapid polymer degradation until later stages of healing, autocatalytic 
degradation of these materials could result in unpredictable outcomes. In contrast, 
polymers that degrade at a constant rate, for example by enzymatic degradation, are 
anticipated to more closely match the rate of new bone formation 
26
.   
Settable weight-bearing bone grafts could potentially transform the management 
of tibial plateau fractures, screw augmentation, vertebroplasty, and other orthopaedic 
indications, but their success is predicated on the ability to maintain sufficient bone-like 
strength while actively remodeling. Weight-bearing composites generally comprise a 
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resorbable reinforcing matrix (e.g., short fibers 
20, 21
 or particles 
22, 56
) dispersed in a 
continuous phase (e.g., polymers or ceramics). A recent review highlighting the 
challenges associated with the design of weight-bearing composites has suggested that 
the rates of degradation of the reinforcing matrix and the continuous phase should be 
matched to ensure adequate healing 
26
. In this study, we found that early resorption of the 
reinforcing matrix does not affect healing at later time points, but the continuous phase 
must persist until sufficient new bone has formed. Hydrolytically degradable polymers 
undergo autocatalytic degradation, resulting in poor healing in the interior of the graft due 
to transport limitations associated with ingrowth of new bone 
57
. Closely balancing the 
rates of new bone formation and polymer degradation,  accomplished by local delivery of 
rhBMP-2 in this study, allowed healing to progress to later stages (up to fH=70%). A 
limitation of this study is that none of the areas healed >70% over the 12-week time 
course. However, our findings point to the importance of both maintaining a continuous 
surface for bone healing as well as balancing the rates of new bone formation and 
continuous phase degradation as a strategy for maintaining sufficient bone-like strength 
over the lifetime of the graft. Polymers that undergo cell-mediated degradation 
26
 are 
anticipated to promote balanced remodeling at all stages of healing, which should be 
assessed by long-term studies. 
 
Conclusions 
 Moldable, settable ABP/PUR biocomposites exhibited initial mechanical 
properties comparable to those of trabecular bone. When implanted in plug defects in 
rabbit femoral condyles, morphometric analysis of both histological sections and CT 
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reconstructions revealed that new bone formation and healing progressed in both space 
and time from the outer region near the host bone interface to the inner core for up to 12 
weeks. However, the unbalanced rates of autocatalytic polymer degradation and zero-
order new bone formation resulted in incomplete healing in the interior of the composite.  
Augmentation of the composites with rhBMP-2 increased the rate of new bone formation 
and induced approximately zero-order degradation of the polymer. The consequent 
balance of new bone formation and polymer degradation resulted in more extensive 
healing at later time points in all regions of the graft, including the interior. These 
observations underscore the importance of both maintaining a continuous polymer 
surface for new bone growth, as well as matching the rate of new bone formation to that 
of polymer degradation to promote healing of settable weight-bearing bone grafts that 
maintain bone-like strength while actively remodeling.   
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CHAPTER VI 
 
EFFECTS OF PARTICLE SIZE, LOADING, AND MINERAL CONTENT ON THE IN 
VIVO REMODELING OF SETTABLE ALLOGRAFT BONE/POLYURETHANE 
COMPOSITES 
 
Introduction 
Established clinical approaches to treat critical-sized bone defects include the 
implantation of autograft or allograft bone, ceramic scaffolds, or metallic devices 
1
. 
While these materials offer a temporal solution to large bone loss, none of them fulfills 
all the identified requirements for successful bone scaffolds, namely being 
osteoconductive, biocompatible, resorbable, porous, and having mechanical properties 
comparable to those of the surrounding host bone 
2-4
. In addition to providing structure 
for new bone development, ideal bone scaffolds should also act as a reservoir of signaling 
molecules to promote cellular recruitment, differentiation, and/or activation.  
Current efforts in bone tissue engineering focus on developing composite 
scaffolds to replace bone, a natural nanocomposite. Biodegradable polymers are 
biocompatible, and have tailorable mechanical, degradation, and handling properties. 
However, their bioactivity (defined as the ability to induce a specific biological activity 
5
) 
is usually low. Ceramics provide bioactivity and osteoconductivity, although slow 
degradation rates and brittle mechanical properties reduce their effectiveness in 
promoting bone remodeling (particularly for weight-bearing applications). Composite 
bone scaffolds combining different ceramic phases and/or polymers offer improved 
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mechanical stability 
6
 and tissue interaction 
2, 3
, in addition to injectability 
7, 8
, settability, 
and even weight-bearing capabilities 
9, 10
.  
Lysine-derived polyurethane-ceramic composites have been developed as bone 
scaffolds and tested in femoral plug bone defects in rats 
11, 12
, rabbits 
13, 9
, and sheep 
8
. 
The scaffolds generate a minimal and transient inflammatory response, support cellular 
infiltration, and degrade to non-cytotoxic compounds. Low-porosity polyurethane (PUR) 
composites with allograft bone particles (ABP) as the ceramic matrix have been shown to 
remodel by creeping substitution 
13
. In the absence of interconnected pores, osteoclasts 
infiltrate the material through the mineralized particles’ surface, followed by new bone 
deposition. While these materials offer stability, biocompatibility, and support new bone 
formation, further studies detailing the progression of scaffold remodeling in vivo are 
needed to identify target design parameters that improve healing outcomes.  
The polymeric and ceramic phase degradation rate within composite scaffolds has 
been identified as a critical design parameter influencing healing progression. Recently, it 
has been suggested that the two phases should have a similar degradation rate to that of 
new tissue formation 
6
. Furthermore, a detailed analysis of the remodeling of low-
porosity PUR-ABP composites in rabbits highlighted improved healing outcomes by both 
maintaining a continuous phase supporting new bone deposition, and balancing the rates 
of polymer degradation and new bone formation (which was achieved delivering bone 
morphogenetic protein) 
9
. This study continues to improve understanding of the healing 
mechanisms of composites in bone defects. Here, we have investigated the effects that 
ceramic matrix loading, matrix particle size, and mineralization of matrix particles have 
on the remodeling progression of composite PUR-ABP scaffolds. We expected enhanced 
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mechanical properties from the composites with smaller matrix particles, increased 
osteoinductive character provided by the addition of demineralized bone particles (DBM), 
and improved scaffold infiltration and remodeling in composites with higher matrix 
content (approaching a continuous allograft phase). Injectable and moldable formulations 
were implanted into femoral plug defects in rabbits and remodeling progression was 
analyzed at 6 and 12 weeks using micro-computed tomography and histomophometry.  
 
Experimental 
Materials 
Lysine-triisocyanate prepolymer (LTI-PEG, 21.7% NCO), and poly(-
caprolactone-co-D-L-lactide-co-glycolide) triol (187 mg KOH/g) were provided by 
Medtronic, Inc. (Memphis, TN). The backbone of the polyester triol contained 70% -
caprolactone, 20% glycolide, and 10% D-L lactide. Rabbit allograft mineralized bone 
particles and demineralized bone matrix (DBM) were also received from Medtronic, Inc. 
Allograft particles and DBM were frozen and lyophilized before use to minimize water 
content. Triethylenediamine (TEDA) catalyst and dipropylene glycol (DPG) were 
purchased from Aldrich (St Louis, MO) and mixed to obtain a 10% (w/v) solution of 
TEDA in dry DPG. 
 
Synthesis of injectable and moldable composites 
 Table 6.1 summarizes the settable formulations included in this study, which are 
divided into injectable (I, 47 wt% allograft) and moldable (M, 67 wt% allograft) 
composites. All biocomposites were prepared by loading a mixing cup with the 
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appropriate amounts of polyester triol, LTI-PEG, catalyst, and allograft particles followed 
by hand-mixing for 1 min. The index (ratio of isocyanate:hydroxyl equivalents x 100) for 
the injectable and moldable formulations was 115 and 130, respectively. Injectable 
biocomposites contained 3400 ppm of TEDA catalyst, and moldable biocomposites were 
prepared with 5500 ppm TEDA. The effect of allograft particle size on the performance 
of the injectable and moldable biocomposites was measured by using large (L, 105-500 
m) and small (S, <105 m) allograft bone particles. In addition, a portion of the 
allograft component was replaced with DBM for some injectable formulations (D) to 
evaluate its osteoinductive effect. Poor handling properties and lack of cohesiveness 
precluded the use of DBM in the moldable composites. Injectable biocomposites 
contained the maximum amount of allograft that allowed the material to be delivered by 
injection into the defect. The DBM content was chosen as the maximum amount that did 
not affect the cohesion of the composite. Moldable composites were formulated with high 
loading of allograft particles to provide a pathway for cells to infiltrate the composites 
through creeping substitution 
13, 14
.  
 
Table 6.1. Composition and physical properties of injectable and moldable composites 
Treatment 
group 
Category 
Allograft 
(wt%) 
DBM 
(wt%) 
Particle 
size (m) 
Working 
time (min) 
Viscosity at 
5s
-1
 (kPa*s) 
Non-reactive 
yield stress 
(kPa) 
Empty Control N/A N/A N/A N/A N/A N/A 
IDL Injectable 37.4 9.6 105-500 9.3+0.1
a
 30.2+4.5
a
 129+12
a
 
IDS Injectable 37.4 9.6 <105 9.5+0.3
a
 0.073 N/A 
IS Injectable 47 0 <105 8.7+0.1 0.017 N/A 
ML Moldable 67 0 105-500 5.3+0.1 8.1+3.6 34+17 
MS Moldable 67 0 <105 5.9+0.1 28.7+0.01
a
 119+4
a
 
a
 Groups with the same letter are statistically the same (p>0.05) 
Reported error corresponds to the standard error of the mean. 
 
141 
 
Rheological analysis: initial viscosity and working time 
 The curing profile of the biocomposites was determined using a TA Instruments 
AR2000ex rheometer. Reactive biocomposites were loaded between 25 mm diameter 
disposable plates and compressed to a gap of 1.5 mm. Measurements of storage (G’) and 
loss (G”) moduli were performed using an oscillatory time sweep method with a 
frequency of 1 Hz and amplitude of 1% strain. The working time of the formulations, 
defined as the time from the start of mixing until cure, was determined as the G’-G” 
cross-over point. 
The initial flow characteristics of the biocomposites were analyzed by removing 
the catalyst from the formulation (n=3). Non-setting samples were poured between 40 
mm cross-hatched parallel plates, compressed to a gap of 1.5 mm, and subjected to a 
dynamic frequency sweep (0.1 to 100 rad-sec
-1
) at 25C with controlled strain amplitude 
of 0.02%. A Cox-Merz transformation was applied to the dynamic data to obtain the 
steady state viscosity (, Pa-s) as a function of shear rate (, s-1). The data were fit to the 
Herschel-Bulkley model, which relates the viscosity and shear rate of solid-filled 
suspensions with high solids content 
15
, to estimate the yield stress (Y, Pa) of the 
material:  
  = Y
-1
 + K(n-1)        (6.1) 
where K is the consistency index of the composite (constant) and n is the power-law 
index of the suspending polymer. In this case, the suspending polymer corresponds to the 
non-reactive mixture of polyester triol and LTI-PEG prepolymer and has been shown to 
exhibit a Newtonian behavior (n=1) 
9
.  
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In vitro characterization of the biomcomposites 
 Cylindrical samples of each formulation (n ≥ 3) were prepared for 
characterization. To simulate the aqueous environment in the wounds, the formulations 
were loaded into 6 mm-diameter cylindrical plastic cups containing 250 l of water and 
allowed to set at room temperature (cement formulations set under compression with a 1 
lb weight [20.7 psi]). Cylinders were further cured in a vacuum oven at 37
o
C overnight, 
removed from the plastic cups, and cut using a Buehler saw to a length of 12 mm (for 
mechanical testing) and ~2 mm (for scanning electron microscopy [SEM] imaging). Thin 
sections of cured biocomposite samples were sputter coated with gold and imaged using a 
Hitachi S-4200 SEM (Finchampstead, UK). SEM images were analyzed for pore size 
using MetaMorph 7.1 image analysis software. The porosity of the mechanical testing 
samples was calculated from the composite density which was measured gravimetrically 
11
. After 24 hours of hydration in phosphate buffered saline (PBS), mechanical properties 
were measured using an MTS 898 by preloading the samples to 12 N followed by 
compression at a rate of 25 mm/min until failure. The original cross sectional area of the 
cylinders was used to calculate compressive stress. The strength reported corresponds to 
the point where maximum stress was achieved, and compressive modulus was calculated 
as the slope of the linear portion of the stress-strain curve.  
 
Animal Study 
 Twenty-eight New Zealand White (NZW) rabbits were used in this study. All 
surgical and care procedures were carried out at IBEX Preclinical Research, Inc. (Logan, 
UT) under aseptic conditions per the approved IACUC protocol. The biocomposite 
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individual components were gamma-irradiated using a dose of 25 kGY. Bilateral critical-
sized defects of 5 mm diameter by 6-8 mm in depth were drilled in the lateral femoral 
condyles of each rabbit. Metal wires were placed in the distal-most aspect of the defects 
to aid in location. Defects were filled with injectable or moldable formulations (n = 4 
defects per formulation) according to a randomized experimental design (different 
formulations were placed in contralateral defects). Control defects were left untreated 
(Empty). Femoral specimens were harvested after 6 and 12 weeks and placed in 10% 
neutral buffered formalin for fixation.  
   
Micro-computed tomography (CT) analysis 
 A CT80 (SCANCO Medical, Basserdorf, Switzerland) was used to acquire 
images of the extracted femurs post-implantation at 6 and 12 weeks. In addition, femurs 
from NZW rabbits which were part of other experimental protocols that did not affect the 
skeleton (same age, sex, and similar weight to the rabbits used in this study) were 
scanned and analyzed as host bone controls. µCT scans were performed in formalin at 70 
kVp energy, 114 µA source current, 250 projections per rotation, 400 ms integration time, 
and an isotropic voxel size of 36 µm. Axial images were reconstructed using 
manufacturer-provided software. Attenuation values were converted to tissue mineral 
density (TMD) through calibration with hydroxyapatite (HA) phantoms with densities 
between 0 and 780 mg-HA-cm
-3
 (calibration of the instrument was checked weekly).  
Using the cortical borders of the defect for alignment, the reconstructed image stack was 
re-oriented such that the depth of the defect was parallel to the z-axis. A radial analysis of 
morphometric parameters was conducted from the core of the implant to the interface 
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with host bone. Three concentric annular volumes of interest with thickness of 1 mm and 
a cylindrical core with diameter of 1 mm, all with approximate length of 7 mm (from the 
outer cortical surface of the femur) were defined for each sample. The 3 inner regions 
covered the defect volume, while the outer region provided information about the 
interface with host bone. Ossified tissue was differentiated from soft tissue using lower 
and upper thresholds of 140 mg-HA-cm
-3
 and 254 mg-HA-cm
-3
 respectively, as well as 
Gaussian noise filter settings of sigma 0.2 and support 2. Threshold conditions were 
chosen visually and kept constant for the analysis of all the samples. An upper threshold 
was included to avoid the selection of the metal wires as ossified tissue. Morphometric 
parameters within the annular regions were calculated, grouped by treatment and time 
point, and plotted versus the mean radial distance (Rm) from the core of the defect 
(Rm=(Ro+Ri)/2, where Ro and Ri correspond to the outer and inner radius of each region, 
respectively). Bone volume/total volume (BV/TV), trabecular number (Tb.N.), trabecular 
thickness (Tb.Th.), and trabecular separation (Tb.Sp.) within the regions of interest were 
computed using SCANCO’s Medical microCT systems software.  
 
Histology 
 After fixation in formalin, femur specimens were trimmed and embedded in 
methyl methacrylate. Thin sections were cut in a longitudinal plane through the 
approximate center of each defect. Care was taken to ensure that the orientation was as 
similar as possible between specimens. Sections of parallel planes were stained with 
Goldner’s trichrome stain and Hematoxylin and Eosin (H&E) stain to evaluate the in vivo 
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response of the different formulations. H&E sections were evaluated for inflammation 
and the presence of giant cells (GC’s).  
 
Histomorphometry 
For quantitative analysis, Goldner’s trichrome stained sections were imaged at 
10x magnification with an Olympus camera (DP71) using an Olympus BX60 microscope. 
Residual allograft bone particles, newly formed bone, and residual polymer were 
quantified in an area of interest 1 mm high  5 mm wide located in the center of the 
defect. To analyze the radial remodeling of the scaffolds in time, the rectangular area of 
interest was further subdivided into 3 concentric annular regions (each 0.83 mm thick) 
representing (1) the area of the defect in contact with the host bone, (2) the mid-region of 
the defect, and (3) the core of the defect. Mineralized tissue was stained green, and to 
differentiate between the new bone and the residual allograft, the allograft particles were 
identified as meeting the following two criteria: (1) acellular, and (2) angular shape. In 
the stained sections remaining polymer appeared white, newly deposited osteoid stained 
red/fucsia, cellular nuclei stained blue, and red blood cells stained orange/red. For 
histomorphometric analysis, Metamorph (Version 7.0.1) was utilized to color threshold 
each phase, quantify the number of pixels of each material and compare it to the total 
pixels in the area of interest. Similar to the CT data, the content of new bone, allograft 
bone, and residual polymer was plotted as a function of the mean radial distance from the 
core of the defect (Rm). Goldner’s trichrome stain did not reveal DBM particles, so these 
were not included in the histomorphometric analysis. Initial content of allograft bone and 
polymer in each formulation was determined from histological sections of scaffolds 
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prepared in the laboratory and processed as described in the previous section. These 
values were used to calculate rates of allograft resorption and polymer degradation 
throughout remodeling. 
 
Statistical analysis 
A one-way analysis of variance (ANOVA) was performed to compare the 
rheological and mechanical properties, as well as the pore size of different treatment 
groups. Statistical significance was considered for p < 0.05. 
 
Results 
Biocomposite characterization 
 Rheological characterization of the non-reactive and reactive formulations 
provided information about their initial handling properties. Moldable biocomposites had 
the lowest working times, and addition of DBM slightly delayed the setting of injectable 
formulations. Figure 6.1 shows representative curves for moldable and injectable 
biocomposites’ initial viscosity as a function of shear rate. Injectable formulations with 
small particles exhibited Newtonian behavior at shear rates below ~3 s
-1
 (initial plateau), 
followed by power-law behavior at larger shear rates. While these groups showed 
minimal evidence of yield stress (minimal resistance to flow during the rheological 
analysis as well as during injection), the Herschel-Bulkley model 
15
 was used to calculate 
the yield stress for the IDL and moldable groups (Table 6.1). The IDL, ML, and MS 
groups exhibited power law behavior even at low shear rates. The addition of DBM 
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increased the initial viscosity of the formulations (reported at 5 s
-1
 for injectable 
biomaterials 
16
).  
 
 
Figure 6.1. Initial viscosity of PUR/allograft composites. Non-reactive formulations were poured 
between 40mm cross-hatched parallel plates, compressed to a gap of 1.5 mm, and subjected to a 
dynamic frequency sweep (0.1 to 100 rad sec
-1
) at 25C with controlled strain amplitude of 0.02% 
(n=3). Dynamic data was transformed steady state viscosity (, Pa*s) as a function of shear rate 
(g, s
-1
) using a Cox-Merz transformation (geometric figures). Data were fit to the Herschel-
Bulkley model (lines) to determine yield stress in the case of the IDL, MS, and ML formulations. 
 
 As expected, moldable biocomposites had lower porosity than injectables. 
Representative images of the materials (Figure 6.2) show that porosity of moldable 
formulations was associated with voids present between allograft particles, or between 
allograft particles and polyurethane (the size of the voids was not measured due to their 
irregular shapes). Instead, foaming of the polyurethane binder was the main contributor 
of porosity for injectables. Both particle size and DBM influenced the porous structure of 
injectable biocomposites. Comparison of IDL to IDS suggests increased porosity and 
pore size for formulations with large allograft particles. Moldables followed a similar 
trend. While addition of DBM had minimum effect on the total porosity, it promoted the 
generation of some larger pores, resulting in a larger average pore size. 
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Figure 6.2. Scanning electron microscopy images and porosity of ABP-PUR biocomposites. 
Scale bars represent 750 m. Statistical significant differences between groups with different 
letter. 
 
 A summary of the measured compressive properties of the injectable and 
moldable formulations is presented in Figure 6.3. Among the injectable treatment groups, 
compressive modulus remained constant between 20-25 MPa, and strength doubled from 
3.1 MPa to ~6 MPa when small particles were used as fillers. Addition of DBM did not 
affect the mechanical properties of the injectable formulations. In general, moldable 
groups had higher mechanical properties than the injectable formulations. Small particles 
in moldables generated a 30% increase in strength and a 26% decrease in compressive 
modulus when compared to moldables with large particles.  
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Figure 6.3. Compressive strength and modulus of settable ABP-PUR biocomposites. No 
statistical significant difference between groups with the same letter. (a) strength, (b) modulus. 
 
CT analysis 
 Representative CT images of all the treatment groups after 6 and 12 weeks in the 
rabbits are presented in Figure 6.4A. Empty defects did not heal in time, and only showed 
new bone formation towards the femoral cortex. Large particles could be identified in the 
images, particularly at 6 weeks (irregularly shaped radiolucent particles). Visual changes 
between the 6 and 12 week images of the biocomposites suggest ongoing remodeling.   
 Allograft/polyurethane composites remodel by creeping substitution as cells 
infiltrate the scaffold from the host bone-scaffold interface to the core 
13
. Thus, 
morphometric parameters evaluated by CT were plotted as a function of the mean radial 
distance from the core of the defect to monitor the remodeling process in time and space 
(Figure 6.4B). The cylindrical volume of the defect was divided into three concentric 
regions (cylindrical core of 1 mm diameter and two annular regions with thickness of 1 
mm). An additional concentric annular region extending 1 mm from the outer surface of 
the defect was included to evaluate changes in host bone near the interface. Measured  
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Figure 6.4. μCT analysis of mineralized tissue in ABP-PUR biocomposites. (A) Representative 
images at 6 and 12 weeks. (B) Morphometric parameters: BV/TV, Tb.N., Tb.Th., and Tb.Sp., all 
measured as a function of radial distance from the center line of the defect at 6 and 12 weeks and 
compared to host bone values measured separately. 
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values of the morphometric parameters were compared to the host bone control data 
collected from scans of femurs excised from healthy rabbits.  
As a measure of the total content of mineralized tissue (including both residual 
allograft and new bone), BV/TV at 6 weeks showed differences between the injectable 
and moldable formulations. The radial distribution of BV/TV was constant for the 
moldable composites (dashed lines) at values close to 50%, including near the interface, 
suggesting densification of the neighboring host bone in response to grafting with the 
biocomposite. For the injectables (solid lines), BV/TV monotonically increased from 
values close to 10% at the core to ~50% near the host bone interface. For both injectables 
and moldable groups, large matrix particles tended to have higher BV/TV at 6 weeks. 
Ongoing remodeling at 6 weeks was suggested by the mineralized content different from 
the host bone controls (29.7+1.3%). By 12 weeks, BV/TV of all the groups approached 
host bone values although it was radially uniform for the moldable formulations at ~ 30%, 
balanced for the IDL formulation at ~20%, and had a radial increase from the core 
towards the interface of host bone for the remaining injectable formulations (IDS, IS).  
Analysis of trabecular parameters provides additional information about the remodeling 
mechanism of the polyurethane/allograft composites. Tb.N and Tb.Th take into account 
remaining allograft particles and new trabeculae or bone being formed, while Tb.Sp 
measures the space between the trabeculae that can be occupied by polymer, pores, or 
soft tissue. Tb.N (average number of trabeculae per unit length 
17
) is initially a measure 
of the matrix volume fraction. Thus, moldable formulations initially have higher Tb.N 
than injectables. The radial distribution of Tb.N at 6 weeks has opposite trends between 
moldables and injectables, although both approach host bone values. Moldable 
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formulations show a radial decrease in Tb.N from the core to the host interface, which 
suggests either allograft resorption or increased connectivity of the matrix particles at the 
border of the defect. In contrast, Tb.N of injectable formulations increases radially, 
suggesting the creation of new trabeculae near the host bone interface. At 12 weeks, the 
IDS and IS groups had uniform Tb.N with values between 1.5 and 2 mm
-1
, while the ML, 
MS, and IDL groups had a slightly higher Tb.N only at the core (~2.5-3.3 mm
-1
). 
Differences in Tb.Th (mean thickness of trabeculae 
17
) between moldables and injectables 
at 6 weeks can be associated with differences in matrix particle size. Tb.Th increases for 
all the groups from the core to the interface, suggesting new bone deposition as cells 
infiltrate the materials. Between 6 and 12 weeks, Tb.Th for composites with large 
particles showed minimal changes, while Tb.Th increased throughout the defect for 
formulations with small particles. The final trabecular parameter, Tb.Sp (mean distance 
between trabeculae 
17
), at 6 weeks trends with volume fraction of pores and polymer: 
injectable formulations have higher Tb.Sp than moldables, particularly near the core 
where less new bone deposition is expected. The radial increase in Tb.N and Tb.Th for 
the injectable groups results in less space between trabeculae and thus a radial decrease in 
Tb.Sp. Opposite radial trends in Tb.N and Tb.Th of moldable materials result in a 
uniform radial distribution of Tb.Sp at 6 weeks. Radial differences in Tb.Sp resolve after 
12 weeks for all of the groups. Interestingly, similar to the BV/TV results, values of Tb.N 
and Tb.Th higher than the host bone control at 6 weeks in the outer region support the 
idea of initial densification of the surrounding host bone. 
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Figure 6.5. Low-magnification images of histological sections of ABP-PUR biocomposites at 6 
and 12 weeks. Goldner’s trichrome stain, original maginification 1X. 
 
Histology  
 Figure 6.5 shows representative low magnification histological images of all the 
treatment groups at 6 and 12 weeks. Similar to the CT results, the histological sections 
suggest that empty defects did not heal and were largely filled with fatty bone marrow 
surrounded by a shell of bone. Low magnification images of the treated defects suggest 
that large allograft particles promoted more balanced remodeling in time (approaching 
host bone architecture in the defect area at 12 weeks). Histological sections stained for 
H&E revealed that none of the treatment groups generated acute inflammation at 6 or 12 
weeks (data not shown). In general, small numbers of inflammatory cells were present at 
6 weeks and decreased with time. GCs present were associated with remaining allograft 
matrix and contained intracellular material (Figure 6.6-IDS 6 weeks).  
High magnification histological images (Figures 6.6 and 6.7) reveal active 
remodeling of the implanted scaffolds in time. At 6 weeks, bone formation was ongoing 
predominantly at the periphery of treated defects, while the central area remained largely 
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Figure 6.6. High-magnification images of histological sections of defects treated with injectable 
ABP-PUR biocomposites. All of the images show sections stained with Goldner’s trichrome, 
except for IDS at 6 weeks, which is stained with H&E. Original magnification 70X. With 
Goldner’s trichrome stain: white- remaining polymer; light green particles with angled shapes- 
remaining allograft particles; green with cells inside- new mineralized bone with osteocytes; red- 
osteoid; orange- red blood cells; purple- nuclei; BM- bone marrow. Arrows in the IDS-6 weeks 
section point to giant cells. 
 
 
Figure 6.7. High-magnification images of histological sections of empty defects and defects 
treated with moldable ABP-PUR biocomposites. Goldner’s trichrome stain. Original 
magnification reported in each image. With Goldner’s trichrome stain: white- remaining polymer; 
light green particles with angled shapes- remaining allograft particles; green with cells inside- 
new mineralized bone with osteocytes; red- osteoid; orange- red blood cells; purple- nuclei; BM- 
bone marrow. 
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 acellular. New bone was deposited appositionally mostly by intramembranous 
ossification, except at the periphery of the defects where some endochondral ossification 
was present (in particular at 6 weeks). New bone deposited at early time points had 
woven structure for all the treatment groups. This resolved for the ML group at 12 weeks 
with lamellar bone present in the defect (Figure 6.7-ML 12 weeks). After 12 weeks, 
remaining allograft particles were incorporated with new bone and this was more evident 
in scaffolds with large particles. An interesting difference between injectable and 
moldable materials was that at 6 weeks injectable scaffolds showed evidence of new bone 
growing not only on top of allograft particles but also on the surface of the polymer 
(center of Figure 6.6-IDL 6 weeks). Most new bone formation in moldable materials 
initiated at the surface of allograft particles (center of figure 6.7-ML 6 weeks).  
 
Histomorphometry 
Histomorphometric analysis enabled radial quantification of new bone formation, 
allograft resorption, and polymer degradation for each treatment group (Figure 6.8). 
Differences between the groups at different locations and time points were generally not 
statistically significant due to small sample size. As a result, analysis of the 
histomorphometry data focused on trends and rates instead of absolute values of each 
parameter.  
While CT analysis provided information about the mineral phase in the defects, 
histology was used to differentiate new bone from residual allograft, as well as to monitor 
remaining polymer at each time point and location. The total mineralized content 
measured by histomorphometry [NB+A(%) in Figure 6.8] showed similar trends to  
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Figure 6.8. Histomorphometric analysis of new bone formation of ABP-PUR biocomposites at 6 
and 12 weeks. Mineral content (including new bone and allograft), New bone (NB), remaining 
allograft (A), and polymer (P) data are plotted as a function of radial distance from the center line 
of the defect. 
 
BV/TV measured by CT although the values differed. At 6 weeks, all of the treatment 
groups showed increased new bone formation towards the border of the defect and 
minimal new bone formation at the core, matching the histological observations of 
acellular cores. Increased new bone formation near the host bone interface was 
complemented by minimal allograft resorption and increased polymer degradation for 
injectable formulations. Instead, moldable formulations showed increased allograft 
resorption and reduced polymer degradation in the region where new bone was deposited. 
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At 12 weeks, all of the treatment groups achieved a similar amount of new bone 
deposition at the edge of the defect. However, formulations with large particles showed a 
reduced radial gradient in new bone deposition, suggesting a more balanced remodeling 
throughout the defects. After 12 weeks, remaining polymer throughout the defects was 
minimal except at the core of the MS group. 
 
Discussion  
 The golden standard of care for the treatment of bone defects continues to be the 
use of autograft bone. However, unlimited availability and donor site morbidity have 
motivated the search for bone substitute materials that also promote healing. As a 
biocompatible and osteoconductive alternative for autograft bone, surgeons have been 
using allograft bone for more than 20 years 
18, 19
. Our group has developed injectable 
20, 7, 
11
, moldable 
9
, and compression molded 
13
 composites incorporating allograft bone 
particles and biodegradable, lysine-derived polyurethanes. These materials have been 
shown to promote cellular infiltration, allograft resorption, and new bone deposition 
when implanted in vivo. Recently we reported an enhancement in healing progression of 
ABP-PUR composites promoted by balancing the rates of new bone formation and 
polymer degradation 
9
. The aim of the present work was to further improve the 
understanding of the remodeling mechanisms of ABP-PUR biocomposites by evaluating 
the effects of allograft particle size, loading, and mineral composition on the healing of 
femoral plug defects in rabbits. 
 Characterization of the biocomposites in the lab suggested several effects of the 
variables of interest on their handling, structural, and mechanical properties. All the 
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treatment groups in our study contained similar volume fraction of polymer, and were 
classified into 2 general categories: injectable and moldable biocomposites. Injectable 
formulations were porous and had 47 wt% allograft particles. Instead, moldables had low 
porosity and high filler loading (67 wt%) such that the close proximity of the particles 
could provide a pathway for cellular infiltration. As their label suggest, injectable 
biocomposites could be delivered to the bone defect using a syringe. Interestingly, even 
though the IDL and MS groups exhibited the same rheological behavior under non-
reactive conditions, and ML had lower viscosity and yield stress, the moldable 
formulations could not be injected. Most likely, the longer working time of IDL allowed 
the formulation to be loaded into the syringe and injected before the material completely 
transitioned from a viscoelastic to an elastomeric behavior. Addition of DBM increased 
the viscosity of injectable formulations. This observation correlates with studies reporting 
an increase in the resistance of polymers to flow as a consequence of clustering of 
incompatible fillers 
21
. Our results align with reports of mechanical properties of 
particulate-polymer composites depending on particle loading and size 
22, 23
: higher filler 
loading reduced the porosity of the biocomposites and resulted in improved compressive 
modulus; smaller particle size improved the strength of injectable and moldable 
composites. An additional effect of small particles over the structure of the ABP-PUR 
biocomposites was the significant reduction in pore size. While this was an unexpected 
result, it is possible that the increased number of small versus large allograft particles 
generated a more tortuous path for the foaming gas to escape, thus resulting in more and 
smaller pores.  
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Contrary to our expectations, the addition of DBM to injectable formulations 
hindered remodeling of the rabbit femoral plug defects. DBM has been reported to be 
osteoinductive and to stimulate defect healing in dogs 
24, 25
, rabbits 
26
, and humans 
27
. 
However, multiple recent studies have reported variability in the osteoinductive character 
of DBM 
28, 29
, even among lots of the same formulation 
30
. Factors that influence the 
effectiveness of DBM include: the technique to obtain the bone from human donors, 
donor age and gender, differences in preparation and processing methods for bone, and 
sterilization protocols among others 
29
. Our results further support the idea that not all 
DBM is osteoinductive and as a result its use should be highly regulated.  
Previous studies have reported a particle size effect on the remodeling of allograft 
bone particles in vivo. In combination with autogenous bone marrow, allograft particles 
with size in the range of 100-300 m promoted significantly more new bone formation 
than larger particles (1000-2000 m) when placed in the femurs of Rhesus monkeys for 8 
weeks 
31
. Another study in rabbit calvaria reported a greater amount of osteoid tissue and 
little fibrous tissue formation when allograft particles with size <450 m were implanted 
instead of particles with larger size (up to 1000 m) 32. Both these studies also reported 
enhanced resorption and incorporation of allograft when particles smaller than 450 m 
were used. The results of our in vivo study agree with these observations. Independent of 
the porosity, ABP-PUR biocomposites with particles in the size range of 105-500 m 
achieved improved balanced remodeling throughout the defect after 12 weeks, as well as 
deposition of more mature bone. Kluppel et. speculated that the improved osteoinductive 
character of the small particles (within the size range studied) could be the result of the 
higher surface area exposed for resorption and new bone deposition 
32
. While this was 
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our initial expectation when including smaller ABP in the formulations, our results 
contradict this hypothesis. Reduction of particle size below 105 m did not favor 
improved remodeling. However, the particle size range of 100-500 m seems to be ideal 
for new bone deposition. 
Combined analysis of our CT and histomorphometry data suggests interesting 
differences in the remodeling mechanism of injectable and moldable formulations. 
Previously, we and others have demonstrated that bone defects remodel from the 
periphery to the interior of the scaffolds as cells infiltrate the materials 
9, 33
. Thus, the 
remodeling progression of the biocomposites was evaluated by comparing the radial 
distribution of morphometric parameters. The decrease of BV/TV and Tb.N between 6 
and 12 weeks for the moldable groups suggested active allograft resorption throughout 
the scaffold. The radial increase in Tb.Th for this group at 6 weeks suggested new bone 
deposition on the surface of allograft particles, which was verified by histological images. 
Together, these observations suggest that the low-porosity moldable biocomposites 
remodel by creeping substitution: osteoclasts resorb the surface of allograft particles and 
are followed by other cells including osteoblasts which deposit new bone. On the other 
hand, Tb.N and Tb.Th of injectable formulations increased radially at 6 weeks. This 
suggested formation of new trabeculae, and growth of old and new trabeculae from the 
host bone interface towards the interior of the scaffold. Careful inspection of histological 
images revealed that indeed new bone was deposited on the surface of the PUR phase, 
and we believe that this corresponds to the new trabeculae detected by CT. As a result, 
our data suggests that injectable composites remodel as cells infiltrate the pores and 
deposit new bone on the pore walls as well as on the surface of allograft particles.  
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Interconnected porosity has long been considered a fundamental requirement for 
the success of bone scaffolds 
34, 4
. However, as discussed above, our results show that 
composites with high and low porosity remodel in femoral plug defects, although they 
achieve this through different mechanisms. From these observations we propose that a 
more important parameter for the successful remodeling of bone scaffolds is the 
persistence of a continuous phase. Visual inspection of the histological images obtained 
in this work suggests higher continuity in the groups that achieved better remodeling 
outcomes (ML, IDL). A method to quantify the continuity or the connectivity of an image 
is through the calculation of the Euler number defined as: 
          (6.2) 
where C corresponds to the number of connected objects, and H to the number of holes
35
. 
As such, E=1 represents an image without holes, E>>1 an image with low connectivity, 
and E<<1 a highly connected image with holes. For the remodeling studies, the 
connected objects in the defect can be selected as allograft particles, new bone, and 
remaining polymer. As a result, connectivity will depend on several parameters such as 
filler particle size and loading, scaffold porosity, polymer stability, and filler resorbability. 
We hypothesize that a scaffold with increased connectivity (E<<1) will provide a 
pathway for cells to infiltrate the scaffold resulting in improved remodeling. Preliminary 
Euler number calculations for a single sample of each treatment group (at 6 weeks) are 
promising: IDS, IS, and MS had the highest Euler values (2001, 361, and 71 respectively), 
while IDL and ML (the formulations that achieved more balanced healing) had the lowest 
Euler values representing higher connectivity (-214 and -81 respectively). A recent 
publication studying the effect of particle size on the osteointegration of silicate-
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substituted calcium phosphates (Si-CaP) reported enhanced performance of particles with 
size in the range of 250-500 m 36. Similar to our study, the authors found that smaller 
particles (90-125 m) promoted a less favorable healing outcome. However, the 
formulation tested was a combination of high loading of particles with slower resorption 
rates than allograft, and fast polymer degradation (no evidence of polymer after 4 weeks 
in femoral plug defects in sheep). In contrast to the best candidate formulations from this 
work (IDL and ML), the Si-CaP will result in high Euler numbers as remodeling 
progresses, and as shown by the authors, this state can also promote remodeling of the 
defect. Further work is needed to verify these propositions, and this is discussed in the 
future work section of this dissertation.  
 
Conclusions 
 Moldable and injectable ABP-PUR biocomposites supported cellular infiltration, 
and remodeling when implanted in rabbit femoral plug defects, although through 
different remodeling mechanisms. Moldable biocomposites remodeled by creeping 
substitution with new bone being deposited on the surface of allograft particles; cells 
infiltrated injectable formulations through the pores and deposited new bone on the 
surface of the polymer and allograft particles. Evaluation of the effect of filler mineral 
composition on the remodeling of injectable formulations, suggested improved 
performance of mineralized allograft particles without the addition of DBM. 
Formulations incorporating 105-500 m sized allograft particles promoted deposition of 
more mature bone throughout the defects in a radially balanced progression. The results 
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presented point to connectivity and distance between filler particles as possible influential 
parameters in the remodeling progression of composite bone scaffolds. 
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CHAPTER VII 
 
EFFECT OF SUBSTRATE COMPOSITION ON THE IN VITRO DIFFERENTIATION OF 
OSTEOCLAST PRECURSORS AND RESORPTIVE ACTIVITY OF OSTEOCLASTS  
 
Introduction 
Developing scaffolds that deliver living cells and/or biologically active molecules 
to promote the repair and regeneration of injured bone has been the focus of bone tissue 
engineering. To this end, organic/inorganic composite formulations that combine the 
mechanical and biological advantages of polymers and ceramics have been produced 
1, 2
. 
Polymeric phases include saturated aliphatic polyesters 
3-6
, polypropylene fumarates 
7-10
, 
and polyurethanes 
11-13
, among others. Examples of synthetic ceramic phases are 
bioactive glasses 
14
, and calcium phosphates 
1
, while non-synthetic ceramics include 
autograft and allograft bone 
15
.  
The natural process of bone remodeling is a combination of bone resorption by 
osteoclasts, followed by new bone deposition by osteoblasts. In order to mimic this 
phenomenon in bone defects, effective third generation composite biomaterials (those 
that stimulate specific cellular responses at the cellular level) must combine resorbability 
and bioactivity 
16
. Much attention has been devoted to the bioactivity requirement of 
biocomposites, and several formulations have been shown to promote cellular infiltration 
and new bone deposition in vivo 
17-19, 15, 20, 21
. On the other hand, composite degradation 
has been mostly associated with hydrolytic degradation of polymers and the dissolution 
of calcium phosphates at rates dependent on their solubility.  In order for biocomposites 
to be effectively integrated into the remodeling cycle, it has been suggested that they 
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must undergo active resorption at a similar rate of new bone formation 
22
. Consequently, 
detailed understanding of osteoclasts’ effect on different materials is critical information 
for the design of bone-regenerating biocomposites.  
In vitro models can be used to characterize the response of different materials to 
the action of osteoclasts. Although these models do not take into account all the 
interactions present in vivo, they allow the isolation of specific parameters of interest and 
serve as a screening tool to identify materials for future animal testing. Previous in vitro 
studies of osteoclasts on ceramics have reported the presence of differentiated cells on 
bioactive glasses 
23-25
, calcium phosphates 
26-29
, and dentin (used as an approximation to 
bone) 
30, 31
. Several of these studies also include evidence of resorbed areas on the surface 
of the different matrices. While this confirms that osteoclasts can attach and modify 
ceramics, few studies have focused on osteoclastic resorption rates. Furthermore, studies 
measuring in vitro resorptive rates of selected calcium phosphates and dentin have been 
completed with methods that i) are coupled with the differentiation of precursor cells, ii) 
only include one time point, and/or iii) have based the rate calculations on 2D 
measurements 
32, 33
.  
This study’s purpose was to determine the effects of different materials on the 
differentiation of osteoclast precursors and the resorptive activity of differentiated 
osteoclasts. In order to decouple the processes of precursor differentiation and 
osteoclastic resorption, two culture protocols were implemented.  
The first protocol was used to study the differentiation progression of osteoclast 
precursors. CD11b+ mononuclear monocyte/macrophages (which differentiate into 
functional osteoclasts 
34, 35
) were isolated from murine bone marrow cells and cultured on 
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the different matrices. Tartrate Resistant Acid Phosphatase (TRAP) is a histochemical 
marker of differentiating and active osteoclasts 
36, 37
. Additionally, extracellular release of 
TRAP by osteoclasts has been found to correlate with resorptive activity both in vitro 
38, 
39
 and in vivo 
36, 40
. Thus, intracellular and extracellular TRAP levels were monitored in 
time to verify the differentiation progression of the seeded precursors on different 
matrices.  The expression of osteoclastic genes in time was monitored using quantitative 
real time PCR to identify different stages of osteoclastic differentiation. Given that TRAP 
is expressed both by osteoclast precursors and differentiated cells 
41
, it served as an early 
marker of differentiation. The vacuolar ATPase subunit d2 (ATP6V0d2) has been 
reported to regulate cell fusion during osteoclast differentiation, and to be an essential 
component of the proton pump that mediates osteoclastic acidification of the resorption 
pit 
42
. Thus, ATP6V0d2 (labeled as ATP) was hypothesized to represent a mid- and late-
stage differentiation marker. Cathepsin-K (CTSK) is a lysosomal protease used by 
osteoclasts to degrade the organic component of bone 
37
. Therefore, expression of CTSK 
was expected to increase as osteoclasts became active resorbers.  
A second protocol was used to quantify the resorptive activity of osteoclasts 
independently from the differentiation process. Bone marrow osteoclast precursors were 
first differentiated on tissue culture plastic and then cultured on different matrices. 
Scanning electron microscopy and confocal imaging techniques were used to characterize 
osteoclast attachment and morphology. Quantification of resorbed volume of dentin at 
different time points enabled the calculation of its volumetric resorption rate.  
An additional objective of this work was to study the effects of bone 
morphogenetic protein 2 (BMP-2) on the differentiation of osteoclast precursors and the 
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resorptive activity of osteoclasts in the presence of mineralized matrices. Our lab has 
previously reported that delivery of recombinant human BMP-2 in rabbit femoral plug 
defects stimulated new bone formation, allograft resorption and promoted changes in the 
degradation mechanism of the polymer 
43, 44
. The latter two observations, in combination 
with in vitro and pre-clinical studies reporting enhanced osteoclast differentiation and 
activity in the presence of BMP-2 
45-48
 suggested that BMP-2 could be directly 
influencing osteoclasts at different stages. The two culture protocols described above 
were used to characterize the behavior of precursor and differentiated osteoclasts seeded 
on mineralized matrices in the presence of BMP-2. 
 
Experimental 
Materials 
Dentin (ivory) was kindly provided by Dr. Julie Sterling (Vanderbilt Center for 
Bone Biology [VCBB]), and used as a mineralized surface control. Melt-derived 45S5 
bioactive glass rods (diameter 10 mm) were purchased from Mo-Sci Health Care (Rolla, 
MO). -tricalcium phosphate pellets (48-well compatible) were obtained from 3D Biotek 
(Hillsborough,NJ).-minimal essential medium (-MEM), fetal bovine serum (FBS), 
Penicillin/Streptomycin solution (P/S), Dulbecco’s phosphate-buffered salt without 
calcium and magnesium (PBS), and the Pierce BCA Protein kit were purchased from 
Fisher Scientific (Pittsburgh, PA). Osteoclast growth factors (recombinant mouse 
macrophage colony stimulating factor (MCSF) and receptor activator of NF-kB Ligand 
(RANKL), transforming growth factor beta (TGF-), and interleukin-1 alpha (IL-1)), 
were purchased from R&D Systems (Minneapolis, MN). CD11b MicroBeads used in the 
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purification of osteoclast precursors were obtained from Miltenyi Biotec (Auburn, CA). 
Chemicals for intracellular (Sigma kit 387A) and extracellular staining of tartrate 
resistance acid phosphatase (TRAP), as well as the glutaraldehyde (25% in water) and 
osmium tetroxide (4% in water) solutions for electron microscopy, and Triton X-100 
were obtained from Sigma-Aldrich (St. Louis, MO). Recombinant human bone 
morphogenetic protein-2 (BMP-2) was received from Dr. Josh Wenke (Institute of 
Surgical Research, San Antonio, TX). The BMP-2 was provided in a solution with 1:100 
BMP-2:sucrose in weight, 2.5% w/v glycine, 0.5% w/v sucrose, 0.1% v/v Tween80, and 
0.5 mM glutamic acid (R&D Systems). This solution was aliquoted into small quantities 
for cell culture and stored at -80⁰C. Rhodamine phalloidin was purchased from Life 
Technologies (Carlsbad, CA) to stain actin filaments of differentiated osteoclasts. 
 
Preparation of matrices for cell culture 
Dentin pieces were cut into square chips (~1 mm thick, and cross-sectional area 
compatible with a 24-well plate) and bioactive rods were cut into disks (~2 mm thick) 
using an IsoMet Low Speed Saw (Buehler). The surface of bioactive glass disks was 
polished using wet silicon carbide paper. The resulting material (BG) had a surface 
roughness lower than 1m (measured with a Veeco Dektak 150 Stylus Surface 
profilometer [Plainview, NY]). After polishing, BG disks were cleaned to ensure 
homogeneous surface activity 
49
. Disks were sonicated for 5 min in a solution of acetone 
and deionized (DI) water (5:95 volume ratio), followed by washing with DI water under 
sonication for an additional 5 min. After repeating three washings the clean bioactive 
glass (CBG) was either sterilized for cell culture or further modified in the presence of 
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simulated body fluid (SBF, prepared according to published techniques 
50
). CBG disks 
were submerged in 15 ml of SBF in a conical plastic tube making sure that the polished 
surface of the disk was exposed to the solution. The tube was incubated at 37⁰C for 3 
days. Modified disks (SBG) were removed from the solution and gently rinsed with DI 
water. Polyurethane disks were prepared by mixing polyester polyol (900Da MW), LTI-
PEG prepolymer (formulation index: 130), and 7800 parts per million (ppm) 
triethylenediamine catalyst as a 10% solution in dipropylene glycol. All the reagents were 
loaded into a 5 ml cup and mixed at low speed using a Hauschild SpeedMixer. The 
resulting viscous polymer mixture was loaded into plastic cups (diameter of 14 mm) up to 
a height of ~5 mm and allowed to cure overnight. The polyurethane disks (PUR) 
removed from the plastic cups had a flat (in contact with the base of the cup) and a 
concave surface. Surface characterization and cell seeding was completed on the flat 
surface. Mineralized matrices and polyurethane disks were sterilized with ethanol and 
conditioned with complete media (-MEM with 10% FBS and 1% P/S) in an incubator at 
37⁰C in 5% CO2 overnight. During the entire process, care was taken to ensure that the 
working surface of the materials was facing up.  
 
Differentiation of osteoclast precursors on different materials 
The differentiation of osteoclast precursors cultured on different materials was 
assessed using CD11b+ mouse bone marrow cells. In each experimental run additional 
material samples were incubated with complete media (no cells) as controls. 
Primary bone marrow cells were extracted from the tibiae and femurs of 4-8 week 
old c57bl mice. Mice were sacrificed by cervical dislocation following ethical guidelines. 
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Femurs and tibiae were dissected, followed by complete removal of the surrounding soft 
tissue. The bone ends (away from the knee) were cut and the bones were submerged in 
PBS and centrifuged to collect the bone marrow. Centrifuged cells were re-suspended in 
complete media. Osteoclast precursors were labeled with CD11b microbeads and 
separated from the bone marrow population using an AutoMacs magnetic separator 
(Miltenyi Biotec) according to manufacturer’s instructions. CD11b+ cells were seeded 
onto materials and tissue culture plastic at a density of 1.8x10
5
 cells/ml (per well of a 24-
well plate – density equivalent to 9x104 cells/cm2). To seed the cells, conditioning media 
was removed from all the wells and the samples were air dried inside the sterile hood. A 
concentrated drop of complete media (~15 l) containing the cells was located on top of 
the materials and cells were allowed to sediment for ~20 min. 1 ml of complete medium 
supplemented with RANKL (50 ng/ml) and MCSF (25 ng/ml) was carefully added to 
each well and cells were cultured for up to 28 days. Media was replenished every 3-4 
days. Previous studies have reported the synergetic effect of BMP-2 with suboptimal 
levels of RANKL (<<60 ng/ml) on the in vitro differentiation of osteoclast precursors 
46
. 
Thus, to study the effect of BMP-2 over the differentiation progression of CD11b+ cells 
seeded on different mineralized surfaces, complete media was supplemented with MCSF 
(25 ng/ml), RANKL (30 ng/ml), and BMP-2 (30 ng/ml). 
 
Intracellular and extracellular TRAP staining 
 To verify differentiation of the osteoclast precursors seeded on each material, cells 
were fixed and stained for intracellular TRAP activity (Sigma kit 387A). Furthermore, 
media removed from the wells during each change was collected and frozen at -80C. 
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Secreted TRAP into the media was quantified using napthol ASBI-phosphate as the 
substrate 
51
. 50 l of media were mixed with 150 l of reaction buffer (100 mM sodium 
acetate, 50 mM sodium tartrate, 2.5 mM Napthol ASBI-Phosphate in 4% 2-
methoxyethanol [ethylene glycol monomethyl ether – EGME]) in a 96-well plate, 
followed by incubation at 37C for 35 minutes. The reaction was stopped with the 
addition of 0.6 M NaOH solution and fluorescence was read at 405 nm (excitation), 520 
nm (emission). Fluorescence from control wells (no cells) was subtracted from 
fluorescence values of the corresponding materials with cells. Fluorescence units of 
secreted TRAP were further normalized to total protein in the sample.   
 
Quantitative real-time PCR (qPCR) of osteoclast gene markers 
Total RNA was isolated from cultured primary cells using the QIAShredder and 
RNeasy kits from Qiagen. RNA from minimum 4 samples per treatment group was 
pooled together to obtain enough genetic material for an accurate concentration 
measurement. cDNA synthesis was performed with the iScript cDNA synthesis kit 
(BioRad). Quantitative real time PCR of 9-25 ng cDNA/well was performed using the IQ 
Real Time SybrGreen PCR Supermix (Biorad) and 500 nM of primer mix (250 nM 
forward, 250 nM reverse). qPCR was completed in a CFX96 system (BioRad) using a 2 
step amplification protocol (with annealing temperature of 62⁰C) followed by a melt 
curve analysis. Gene expression was normalized to GAPDH. Primer sequences used are 
summarized in Table 7.1. Primer optimization was completed by the Molecular Cell 
Biology Resource (MCBR) Core at Vanderbilt University.  
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Table 7.1. Primer sequences for osteoclastic genes 
Gene 
Approved 
nomenclature 
Primer sequence TA (⁰C) 
Accession 
number 
TRAP Acp5 
Forward: CAAGAGGTTCCAGGAGAC 
Reverse:  
TTTCCAGCCAGCACATAC 
55-62 NM_007388 
     
CTSK Ctsk 
Forward: ATAACAGCAAGGTGGATG 
Reverse:  
CACTTCTTCACTGGTCAT 
62 NM_007802 
     
ATP Atp6v0d2 
Forward: GAAGCTGTCAACATTGCAGA 
Reverse: TCACCGTGATCCTTGCAGAAT 
60 NM_175406.3 
     
GAPDH Gapdh 
Forward: GAGAAACCTGCCAAGTATG 
Reverse:  
GGAGTTGCTGTTGAAGTC 
55-63 NM_008084 
TA – Annealing temperature 
 
Culture to study the resorptive activity of differentiated osteoclasts  
Fully differentiated osteoclasts are capable of polarizing their cell body and 
forming a tight junction between the basal membrane and the bone surface to delimit a 
sealed resorption compartment 
41
. Thus, resorptive activity of osteoclasts can only be 
quantified after the precursors have achieved differentiation. In order to de-couple the 
effects of matrix chemistry over the differentiation of osteoclastic precursors and the 
resorptive activity of osteoclasts, osteoclasts precursors were completely differentiated on 
tissue culture plastic and then cultured on different matrices to evaluate their resorptive 
activity. Osteoclasts were obtained by inducing differentiation of non-adherent MCSF-
dependent bone marrow cells according to published methods 
52
. Stromal cells were 
removed from the bone marrow cell population by culturing the cell suspension in a T150 
flask at a density of 3x10
5
 cells/ml for 24 hrs with complete media supplemented with 5 
ng/ml of MCSF. Media (containing the non-adherent cells) was collected and centrifuged. 
7.2x10
6
 non-adherent cells/dish were seeded in 90-mm-diameter cell culture dishes and 
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cultured with 25 ml of complete media containing MCSF (50 ng/ml), RANKL (30 ng/ml), 
and TGF- (0.1 ng/ml). 15 ml of culture medium were replaced every 2-3 days. Cultures 
were incubated for 5-7 days monitoring the formation of multinucleated cells. When 
osteoclast formation was maximal, the media was removed from the dishes and the cells 
were washed 3 times with PBS. While active osteoclasts formed on plastic are resistant to 
EDTA removal, initial EDTA treatment reduces substrate adhesion and facilitates the 
removal of functional multinucleated cells with a cell scraper 
52
. Thus, 6 ml of 0.02% 
EDTA (Sigma Aldrich) were added to each dish and the cells were incubated for 20 min 
at room temperature. EDTA was then removed and replaced with 6 ml of PBS. Cells 
were carefully scraped from the plastic using a cell scraper, suspended in PBS and 
counted. 1.8x10
5
 cells/ml (per well of a 24-well plate – density equivalent to 9x104 
cells/cm
2
) were seeded onto materials and tissue culture plastic. To seed the cells, 
conditioning media was removed from the wells, and 1 ml of complete media containing 
the cells was added drop-wise to each well. The cells were allowed to sediment onto the 
materials for 25 min while being incubated at 37⁰C and 5% CO2. Next, the samples were 
transferred to new plates (or media was removed in case of the tissue culture plastic 
samples), and 1 ml of complete media supplemented with MCSF (50 ng/ml), RANKL 
(30 ng/ml), IL-110 ng/ml)and in some cases BMP-2 (30 ng/ml) was carefully added 
to the wellsCells were cultured at 37⁰C and 5% CO2 for up to 48 hrs.  
 
Morphology characterization of differentiated osteoclasts on different materials 
Scanning electron (SEM) and confocal microscopy were used to characterize the 
morphology of seeded osteoclasts on different matrices. Samples for SEM were washed 
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with PBS and fixed in a 5% glutaraldehyde solution in DI water for 2 hrs. Samples were 
then rinsed with DI water and submerged in 1% osmium tetroxide for 15 min as a 
secondary fixation step. Next, the samples were washed 3 times with DI water, and 
sequentially dehydrated using increasing concentrations of ethanol. Fixed samples were 
dried, sputter-coated with gold and imaged using a Hitachi S-4200 SEM (Finchampstead, 
UK). Confocal microscopy was used to verify the presence of actin rings, characteristic 
of active osteoclasts, on differentiated cells seeded on dentin. After cell culture, samples 
were washed twice with PBS, fixed with 10% formalin for 10 min at room temperature, 
and washed again with PBS. Cells were then permeabilized with 0.1% Triton X-100 in 
PBS for 5 min, followed by washing with PBS. Cells were incubated with 5 l of 
reconstituted methanolic rhodamine phalloidin stock solution per 200 l of PBS (1% 
bovine serum album was added to avoid non-specific binding) for 45 min at 37⁰C 
protected from light. Samples were washed with PBS, air dried, and cells were imaged 
using a Zeiss LSM 510 META inverted microscope using a HeNe1 laser at 543 and 633 
nm wavelengths, and 20x magnification. 
 
Quantification of volumetric resorption rates 
After 24 or 48 hrs culturing on dentin, active osteoclasts were carefully removed 
from the surface using a cell scraper and the samples were air dried overnight. 3D images 
of the surface of dentin were obtained using a Zeta instruments Zeta-20 True Color 3D 
Optical Profiler (San Jose, CA). Images were collected using a Z-range of 42-48 m and 
200 steps resulting in a Z-step size of 0.211-0.239 m. 20x magnification (field of view: 
474x356 m2) was used to image at least 3 different areas per sample (total samples: 2). 
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Roughness of the dentin surface with and without cell treatment was measured using the 
Zeta 3D imaging software. Zeta Feature Detection Software was used to detect resorption 
pits on the surface. A reference surface was established on the non-resorbed areas of 
dentin. Deviations from this baseline with depth >1m were selected by the software as 
features of interest (resorption pit), and volume of each feature was reported. The total 
resorbed volume per image was normalized to the cross sectional area analyzed.  
 
Results 
Differentiation of CD11b+ osteoclast precursors mineralized matrices and tissue 
culture plastic 
Figure 7.1 shows images of CD11b+ osteoclast precursors fed with differentiating 
growth factors and cultured on tissue culture plastic and TCP surfaces. After 28 days, 
differentiated precursors fused and stained positive for intracellular TRAP (cells cultured 
on dentin and BG were also TRAP+). Cells with a wide range of size and number of 
nuclei were identified on tissue culture plastic (Figure 7.1A-B). While cells seeded on 
mineralized matrices also stained positive for intracellular TRAP, the size of the cells was 
significantly smaller (Figure 7.1C). Culture of osteoclast precursors with only MCSF 
generated no positive staining for TRAP which confirmed the lack of committed 
osteoclasts in the initial cell population (Figure 7.1D).  
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Figure 7.1. Intracellular TRAP staining of osteoclast precursors cultured for 28 days on 
A,B,D) on tissue culture plastic, and C) TCP. Cell culture media consisted of complete 
media supplemented with MCSF (25ng/ml) and RANKL (50ng/ml) for A-C, or MCSF 
(25ng/ml)  for D. 
 
Differentiation progression of osteoclast precursors seeded on tissue culture 
plastic (well), dentin, and BG was monitored in time by measuring their gene expression 
and secretion of TRAP into the media (Figure 7.2). Expression of all the genes was 
higher for cells cultured on wells. Cells differentiated on dentin and BG had similar 
TRAP, and CTSK gene expression, while ATP expression was more similar between 
cells seeded on wells and dentin. However, the measured trends did not match the 
expected profile of gene expression in time, and this was true for all the materials.  
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Figure 7.2. Longitudinal characterization of the differentiation of osteoclast precursors 
cultured on tissue culture plastic (well), dentin, and BG. A) Gene expression, B) 
Quantification of secreted TRAP 
 
In contrast to gene expression, after 7 days of culture, cells differentiated on wells 
secreted the least amount of TRAP into the media. Since secreted TRAP is associated 
with resorptive activity of the osteoclasts, these results indicate that differentiation 
markers are not good predictors of resorptive activity. Furthermore, as improved 
differentiation was promoted on tissue culture plastic while secreted TRAP (associated 
with resorptive activity) was higher on cells cultured on mineralized matrices, 
osteoclastic differentiation and resorption might be modulated by different factors. 
Gene expression and secreted TRAP in time were also evaluated for cells cultured 
on mineralized matrices in the absence or presence of BMP-2 (Figure 7.3). The obtained 
results have high variability between runs, hence additional work is required to optimize 
the experimental methods. However, when comparing treatment effects in each run, it  
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Figure 7.3. Longitudinal characterization of the differentiation of osteoclast precursors cultured 
on dentin, CBG, SBG and TCP with and without addition of exogenous BMP-2. A) Gene 
expression quantified in run 1, B) Gene expression quantified in run 2, C) Quantification secreted 
TRAP in run 1 and 2. 
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can be concluded that the addition of BMP-2 (even at non-optimal concentrations of 
RANKL) did not modify the differentiation progression or resorptive activity of 
osteoclast precursors. 
 
 
 
Figure 7.4. Differentiation of non-adherent bone marrow osteoclast precursors. Day 0-8: 
Representative images of the cells during the differentiation process. White arrowheads point to 
an example of multinucleated cells in each image. Scale bars represent 100 um. Graph: 
summarizes the number and average size of multinucleated cells during the differentiation 
process. These variables were monitored to decide when to stop the experiment to collect 
differentiated osteoclasts. * Significantly different (p<0.05) from the value quantified the day 
before. 
 
 
Differentiation of non-adherent osteoclast precursors on tissue culture plastic  
Bone marrow osteoclast precursors were successfully differentiated into 
multinucleated osteoclasts. Figure 7.4 shows representative images of the cells at 
different time points during the differentiation process. The number of multinucleated 
cells increased in time until it achieved a maximum value between days 5 and 7. Due to 
the variation of this parameter between experimental runs, the total number of 
multinucleated cells per field of view and the average size of cells per field of view were 
183 
 
evaluated as variables to identify the time point at which the differentiation process 
should be stopped and osteoclasts collected. As shown in Figure 7.4, there was a peak in 
the number of multinucleated cells (day 7 in that particular run) followed by a significant 
decrease. This behavior was replicated in each run. On the other hand, average cell size 
per field of view only showed a significant change compared to the previous day when 
the number of multinucleated cells had already significantly decreased. According to 
these results, differentiation of bone marrow precursors should be stopped the day in 
which a significant increase in number of multinucleated cells is observed.   
 
 
Figure 7.5. Confocal images of osteoclasts seeded on dentin 
 
Morphology of differentiated osteoclasts seeded on different materials 
Differentiated osteoclasts were lifted into suspension and seeded onto various 
surfaces according to the seeding procedure described in the experimental section. The 
cells obtained exhibited characteristics of active osteoclasts: formation of actin rings 
when seeded on dentin (Figure 7.5), and positive TRAP staining after being cultured on  
tissue culture plastic (well), dentin, and PUR, for 24 and 48 hrs (Figure 7.6). Previously, 
the Chambers research group reported minimal changes in osteoclast-like multinuclear 
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cells during the first 6 incubation hours on bone slices 
52
, indicating  the cells were 
already competent for bone resorption when they were sedimented onto bone. In our 
studies however, the number and size of large multinucleated cells on wells and dentin 
significantly increased between 24 and 48 hrs of culture (Figure 7.6E). Thus the 
resorptive activity of the cells was evaluated during longer periods of time (up to 48 hrs 
compared to 6 hrs by the Chambers group) to ensure full activity of the seeded cells.  
 
 
Figure 7.6. Intracellular TRAP stain of osteoclasts seeded on different matrices. Inset graph 
presents size of the +TRAP cells as a function of material. Scale bars represent 200m. 
 
An interesting observation from the images in Figure 7.6 is that even though the 
cells seeded on the different materials were obtained from the same differentiation batch, 
they adopted different morphologies when exposed to different materials. As expected, 
all the cells were TRAP+ differentiated osteoclasts. Cells cultured on tissue culture 
plastic expanded and fused at a higher rate compared to cells cultured on dentin and PUR. 
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Furthermore, after 48 hrs in culture, large (>350 m) multinucleated cells completely 
covered the well surface.  
In the case of dentin, at 24 hrs the differentiated cells were smaller than those on 
the wells. By 48 hrs, the cells increased in size due to fusion of smaller cells (Figure 
7.6D). Compared to dentin and wells, a significantly lower number of osteoclasts 
attached to the surface of PUR. The cells that attached expanded and by 48 hrs their 
average size was similar to that of cells on dentin, although no large multinucleated cells 
were present. It has been reported that large osteoclasts are more active resorbers than 
small osteoclasts 
53
. Thus, these results suggest that even cells with the same extent of 
differentiation might have different resorptive performance on matrices of different 
nature.  
 
Figure 7.7. Morphology of osteoclasts cultured on different materials observed by SEM. 
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SEM images of osteoclasts cultured on different matrices for 24 hrs confirm 
differences in cell size and provide evidence of resorptive activity on each matrix (Figure 
7.7). On dentin, cells had a more extended morphology and larger cells (up to 25 m) 
were identified in comparison to PUR, CBG, SBG, and TCP. Images show polarized 
cells with ruffled membranes towards the surface of dentin which suggest active 
resorption. On PUR, cells were smaller (~9 m) and rounder. Some cells were fusing, 
and underneath them changes on the surface of the material were evident. Osteoclasts 
cultured on CBG and SBG had similar size to cells cultured on PUR, although a 
significantly higher number of cells attached to the bioactive glass surfaces. Cells 
cultured on CBG and SBG had protrusions extending towards the surface of the materials 
(similar to cells on dentin) suggesting stronger attachment to the surface than the cells on 
PUR. At the top of the SEM image of Figure 7.7 corresponding to CBG a large cell (~30 
m) was removed during the processing. The CBG surface that was underneath the cell 
shows evidence of etching towards the center of the cell and of extended protrusions 
towards the border where the cell formed the sealing zone of the resorption pit. Images of 
SBG with osteoclasts show the characteristic hydroxyapatite nodules surrounded by 
osteoclasts. No differences between the morphology of osteoclasts cultured on CBG and 
SBG were identified, although active resorption areas were not easily identified on the 
SBG materials. Osteoclasts cultured on TCP adopted a small (~7m) and round 
configuration on the materials. Extended protrusions towards the surface were not present 
on most of the cells. Higher magnification images revealed areas in close proximity to 
osteoclasts with exposed “micro-needled” crystals. Other groups have reported similar 
results in which these areas are generated by acid etching of the TCP surface 
30
.  
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 Volumetric resorption rate of dentin 
 The surface topography of dentin was characterized before and after 24 and 48 hr 
of osteoclast culture. Cells were removed from the surface and line roughness 
measurements were completed. Roughness (Ra) of dentin was initially <1m, and this 
parameter significantly increased after osteoclast culture (Figure 7.8A). 3-dimensional 
images of the surface suggest that this increase in roughness was associated with the 
creation of resorption pits by osteoclasts (Figure 7.8B). Figure 7.8C summarizes the 
characteristics of the resorption pits at different time points. Total resorbed volume 
normalized to cross-sectional area constantly increased between 0 and 48 hr. Initially 
(first 24 hr), this increase was generated by the creation of resorption pits with relatively 
constant cross-sectional area. In the second 24 hr period, the cells continued to resorb the 
surface by expanding the area of a fraction of the pits (thus increasing the variability of 
the pit area), as well as by increasing the excavations’ depths. The dependence of 
resorbed volume on time in these first 48 hr of culture can be approximated by a linear 
function as shown in Figure 7.8D. According to this, the volumetric resorption rate of 
dentin by murine osteoclasts in vitro corresponds to 0.032 m3m-2hr-1, or 0.768 
m3m-2day-1.  
 
 Effect of BMP-2 on the volumetric resorption of dentin 
 In order to evaluate if BMP-2 influenced the resorptive activity of osteoclasts, 
differentiated cells were seeded onto dentin slices and 30 ng/ml of BMP-2 were added to 
the culture media. After 48 hr of culture, the resorbed volume and area % were measured 
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and no significant differences were identified between the groups treated with and 
without BMP-2, as shown in Figure 7.9.  
 
 
Figure 7.8. Resorption for 2 days with BMP2. (A) Roughness of the surface before and after cell 
culture, (B) 3D view of dentin surface after resorption, (C) Characteristics of the resorption pits 
generated by osteoclasts on dentin, (D) Quantification of dentin’s volumetric resorption rate. 
 
 
 
Figure 7.9. Effect of BMP-2 on the volumetric resorption of dentin. 
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Discussion  
Osteoclasts have been reported to differentiate and generate resorption pits when 
cultured on different mineralized matrices, and our results further support these 
observations. While analysis at only one time point suggests that all the materials support 
osteoclast precursor attachment and differentiation, it does not provide information about 
when this happens. Thus, to monitor the differentiation process in time, osteoclastic gene 
expression was quantified after 7, 14, 21, and 28 days of culture. Three genes were 
identified as possible markers of state changes of differentiating osteoclasts 
41, 37, 42
: 
TRAP (early marker), ATP (mid and late marker), and CTSK (late marker). According to 
studies of  osteoclast precursors obtained from human peripheral blood mononuclear cells 
(PBMC), the cells only began resorbing dentin after 3 weeks of culture 
33
. This suggests 
that resorptive capabilities develop after the cells differentiate on top of the materials. We 
expected to capture this change in behavior by monitoring gene expression. However, as 
shown in Figures 2 and 3, gene expression did not follow the expected profiles. No 
consistent changes could be identified in the gene expression profiles of cells cultured on 
different materials in time. One possible explanation for this is that the profiled genes 
start being expressed earlier than day 7 in culture. Indeed, detailed analysis of the 
transcriptional program of mouse osteoclasts has suggested that pre-osteoclasts express 
almost all genes necessary for differentiation 
54
. Another possibility for not detecting 
changes of gene expression in time is that the protocol needs to be further optimized. 
Suggestions to improve the characterization of the differentiation process in time are 
presented in the future work section of this dissertation.  
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 Osteoclastic differentiation and function are regulated by different humoral agents 
52
. Maintaining these agents constant in cell culture, our goal was to characterize the 
resorptive activity of osteoclasts when exposed to matrices of different nature. Thus, the 
differentiation protocol of murine non-adherent bone marrow cells into osteoclasts on 
tissue culture plastic was fully characterized. During differentiation, a significant increase 
in the number of multinucleated osteoclasts signals that the cells should be collected for 
further activity studies. Following the described protocol, functional TRAP+ osteoclasts 
that generate characteristic actin rings when seeded on dentin were obtained (Figures 7.4-
7.5).  
 Microscopy analysis of differentiated osteoclasts cultured on wells, dentin, PUR, 
CBG, SBG, and TCP surfaces revealed morphological variances that could be related to 
differences in their resorptive activity (Figures 7.5-7.6). Although the seeding procedure 
for all the materials was the same, a lower number of cells attached to the PUR disks. The 
cells that did attach remained small and round without a polarized cell body characteristic 
of actively resorbing osteoclasts (Figure 7.6-PUR). A similar cell body was evident for 
the osteoclasts seeded on TCP, although higher number attached to this surface (Figure 
7.6-TCP). However, areas with evidence of changes on the substrate surface were present 
in close proximity of cells seeded on these materials (PUR and TCP). The changes on the 
surface correspond to that reported as resorption of TCP by other authors 
27, 28
, and were 
shallow and localized. In contrast, osteoclasts cultured on dentin and bioactive glass 
surfaces (CBG and SBG) had a polarized structure with extensive protrusions towards the 
substrate away from the apical region (Figure 7.6- Dentin, CBG, SBG). The extended 
protrusions of cells cultured on dentin, CBG, and SBG suggest tighter attachment to these 
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substrates than to PUR and TCP, and correlate with observations of other groups 
reporting different modes of resorption for cells with various sizes 
55
 or on materials with 
different chemistries 
32
. Against a widely accepted consensus in the field about 
osteoclasts recognizing bone as a substrate for resorption due to the bone mineral content, 
it has recently been reported that “bone is not essential for osteoclast activation”, and that 
resorptive activity is induced by v3 ligands (vitronectin) which have high affinity for 
bone 
56
. Since cell culture in this work was completed using 10% FBS in the media, it is 
possible that vitronectin present in the serum adhered to the substrates and influenced the 
cellular behavior. As suggested in the future work section, it would be worthwhile to 
quantify the affinity of vitronectin to the surface of the mineralized matrices and PURs 
analyzed in this work to verify if this is the controlling factor that promotes different 
resorption rates of materials in vivo.  
 Measurement of the resorbed volume in time enabled the determination of the in 
vitro volumetric resorption rate of dentin as 0.768 m3m-2day-1. This value is much 
higher than that reported for calcium phosphate ceramics as 0.01 m3m-2day-1 32. The 
difference between these resorption rates is in line with in vivo observations of calcium 
phosphates remaining in the body even after years of implantation 
57
. However, the 
analysis of calcium phosphates was conducted using human cells (which have lower 
metabolic activity than mice cells), as well as a protocol that includes the period of 
osteoclast differentiation in the calculation. Thus, it is important to use the same in vitro 
protocol described in this work to characterize and compare the resorptive rates of 
synthetic matrices. A challenge associated with the measurement of resorption rates of 
the synthetic matrices is that these contain pits even before cell culture. We have tested 
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polishing the materials before culture, but due to the porosity of the materials, polishing 
exposes pits on the final surface. To overcome this, the pit volume of each sample should 
be quantified before and after cell culture, and the resulting difference used to calculate 
the corresponding resorption rates.  
 Addition of BMP-2 to the culture media did not significantly change osteoclastic 
differentiation or resorptive activity on mineralized matrices. These results contrast to 
previous reports of BMP-2 stimulating the direct differentiation of osteoclasts in vitro. 
However, this stimulation took place under very specific culture conditions: on tissue 
culture plastic and suboptimal doses of RANKL 
46
. It is possible that the addition of a 
matrix to the protocol modified the behavior of the cells, and even masked the effect of 
BMP-2. Evidence of the impact that the substrate has on the behavior of the cells is 
present in Figure 7.5 which shows significant differences in the size of differentiated 
osteoclasts cultured on several substrates. An additional observation to keep in mind for 
future experiments is that for the experimental runs measuring resorptive activity in the 
presence of BMP-2, the cell seeding procedure used was the one described for the 
differentiation studies. As a result, the seeded cells were concentrated on a section of the 
materials instead of being homogeneously distributed among the whole area. 
Consequently, the normalized resorbed volume is lower than that measured for the 
resorption rate calculations. While the normalized resorbed volumes should not be 
directly compared between these experiments, comparisons between groups in the same 
experiment are valid. For future experiments however, the preferred seeding procedure is 
the one described for the activity studies since it generates a homogeneous distribution of 
the cells on the materials. The preferred seeding procedure removes bias from the results 
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since it allows the experimenter to image random areas of the sample instead of having to 
locate the specific area where the cells were initially seeded. 
 
Conclusions 
In vitro cell culture methods enabled the characterization of the differentiation 
and resorptive activity of osteoclast precursors cultured on different substrates. Pre-
osteoclasts attached and differentiated on mineralized surfaces. BMP-2 did not have a 
direct effect on osteoclastic differentiation or activity. When differentiated osteoclasts 
where cultured on dentin, CBG, SBG, TCP, and PUR, they exhibited different 
morphology. It is expected that differences in morphology will be associated to different 
resorption rates, and this remains to be studied in future work. The results from this work 
suggest that differentiation of osteoclast precurors is not sufficient for effective resorption. 
While this has been reported in the past and associated with lack of expression of specific 
genes in the cells 
37
, we have shown that even equally differentiated cells behave 
differently depending on the substrate for culture. The in vitro cell culture protocol to 
study the resorptive activity of murine bone marrow cells on different matrices 
introduced in this work was used to determine the volumetric resorptive rate of dentin. 
The application of this method for the quantitation and direct comparison between 
volumetric resorptive rates of synthetic matrices provides a useful screening tool in the 
design of effective biocomposite bone scaffolds. 
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CHAPTER VIII 
 
CONCLUSIONS 
 
The research presented in this dissertation describes the development and 
characterization of biodegradable lysine-derived polyurethane (PUR) formulations that 
actively participate in the bone healing process. Findings and conclusions presented in 
the previous chapters have provided insight into structure-property-performance relations 
of PUR foams and composites.  
To our knowledge, Chapter III demonstrates the first biofilm-dispersive scaffold 
capable of reducing bacterial burden within infected wounds.
1
 In vitro studies on biofilms 
of clinical isolates of Staphylococcus Aureus identified D-Methionine (D-Met), D-
Phenylalanine (D-Phe), D-Proline (D-Pro), and D-Tryptophan (D-Trp) as D-Amino 
Acids (D-AA) highly effective at dispersing and preventing biofilm formation. 
Incorporation of a free-base D-Met:D-Pro:D-Trp mixture (1:1:1 mass ratio) into a porous 
PUR formulation had minimal effects over scaffold porosity and pore size. It did however 
reduce the compressive mechanical properties of the materials due to the solid particles 
creating defects on the pore walls. The D-AA mixture was released by diffusion 
controlled mechanisms for up to 4 weeks, with minimal scaffold degradation. When 
implanted into segmental rat defects contaminated with an osteomyelitis bacterial strain 
(UAMS-1), PUR foams augmented with ≥5% D-AA mixture significantly reduced 
bacterial burden. These results highlight the capability of porous PUR scaffolds to act as 
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delivery vehicles that modify the wound environment and improve the conditions for 
future bone remodeling. 
PUR composites incorporating -tricalcium phosphate (TCP) particles exhibited 
mechanical properties between those of cortical and trabecular bone. Improved interfacial 
interactions between the ceramic and PUR phases were promoted by the covalent grafting 
of polycaprolactone (PCL) to the surface of TCP particles. As a result, composites 
incorporating surface modified particles had reduced water absorption and improved 
stability under aqueous conditions as confirmed by the measured mechanical properties. 
When tested in vitro, no differences were observed between the differentiation of 
osteoblasts and osteoclasts seeded on the composites with modified and unmodified 
particles. These results suggest that surface modification of ceramic fillers is a suitable 
technique to improve the mechanical performance of settable bone composites. However, 
in the case of the TCP particles, a side effect of surface modification was a significant 
decrease in particle size. In vitro studies have shown that small particles of 
hydroxyapatite (<20 m) generate a strong and cytotoxic inflammatory response.2 To 
avoid this response in vivo, surface modification of less brittle and stronger ceramic 
fillers should be considered. An example is the use of surface modified bioactive glass 
particles, which in turn provide initial weight-bearing capabilities to the PUR scaffolds 
(ongoing work in the lab).  
Settable ABP-PUR biocomposites exhibited initial mechanical properties 
comparable to those of trabecular bone. Independent of allograft particle size, loading, 
mineral content, porosity, or BMP-2 dose, all the studied formulations promoted new 
bone deposition and progressive healing in time from the host bone interface towards the 
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core of the defects. However, the extent to which healing was achieved varied according 
to the parameters listed above.   
BMP-2 addition to ABP-PUR biocomposites not only increased the rate of new 
bone formation, but also altered the polymer degradation mechanism to approximate a 
zero-order process.
3
 The resulting similar rates of both new bone formation and polymer 
degradation resulted in more extensive healing at later time points throughout the graft. 
These observations underscore the importance of balancing new bone formation and 
polymer degradation rates so as to promote healing of settable weight-bearing bone 
composite grafts that maintain bone-like strength while actively remodeling.  
Care should be taken with the incorporation of demineralized bone matrix (DBM) 
in to bone grafts. Contrary to our initial expectations, when DBM was included in ABP-
PUR composites, healing progression slowed. We associate this with reported variability 
of the osteoinductive character of DBM.
4-6
 This property is affected by several factors 
such as donor age and gender, processing, and sterilization protocols.
5
 However, there are 
currently no target properties or standards to describe the osteoinductive capacity of 
DBM. Consequently, caution should be exercised by surgeons when incorporating DBM 
as part of a treatment, and by scientists when they aim to pose conclusions in studies  
utilizing DBM.  
In contrast, particle size had a strong effect on the porosity and pore size of ABP-
PUR biocomposites.  Both these parameters were reduced upon incorporation of allograft 
particles with size <105 m. Furthermore, particle size proved to have an effect on the 
healing progression of plug defects. After 12 weeks, particles in the size range of 100-500 
m promoted more balanced radial remodeling throughout the defects than particles <105 
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m. Particles in the effective size range also stimulated the deposition of higher quality 
bone. 
Combined analysis of CT and histomorphometry data suggests interesting 
differences in the remodeling mechanism of injectable and moldable ABP-PUR 
formulations. Moldable composites (<20% porosity, 67 wt% filler) remodeled by 
creeping substitution: osteoclasts resorbed the surface of allograft particles and generated 
new pores for cellular inflitration. As part of the infiltrating cells, osteoblasts followed 
and deposited new bone on the surface of the remaining allograft particles. In comparison, 
injectable composites (37-47% porous, 47 wt% filler) remodeled as cells infiltrated 
through the pores and deposited new bone on both the pore walls and the surface of 
allograft particles. These observations suggest a fully interconnected osteoconductive 
surface is required for bone graft healing. Although porosity might promote faster initial 
bone deposition, it also reduces the bone grafts’ mechanical properties. Such reductions 
pose significant limitations for weight-bearing applications in which a slower remodeling 
progression can favor the appropriate incorporation of the bone graft.  
In addition to the in vivo characterization of the various ABP-PUR formulations, 
an in vitro cell culture protocol that independently studied the differentiation and 
resorptive activity of murine bone marrow cells in the presence of different matrices was 
introduced. Pre-osteoclasts attached and differentiated on mineralized matrices. However, 
differentiated osteoclasts cultured on dentin, bioactive glass, TCP, and PUR disks 
exhibited different morphology. These differences are expected to be associated with 
different resorption rates, and this remains to be studied with the implementation of the 
developed protocol. Given that osteoclasts were simulateously differentiated and then 
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seeded on the different materials, our observations suggest that osteoclastogenesis 
(differentiation) might not be sufficient for effective resorption of matrices. The in vitro 
cell culture protocol to study osteoclastic resorptive activity on different matrices was 
implemented to determine volumetric resorptive rate of dentin (0.768 m3m-2day-1). 
Future application of this method to quantify and compare volumetric resorptive rates of 
synthetic matrices will provide a useful screening tool to design effective biocomposite 
bone scaffolds.  
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CHAPTER IX 
 
SUGGESTIONS FOR FUTURE WORK 
 
In addition to identifying and describing useful structure-property-performance 
relations of PUR foams and composite formulations, the results presented in this work 
have generated several new and interesting questions. The following are suggestions for 
future work that address these new research avenues and continue advancing the PUR 
technology as a viable therapeutic treatment for bone defects.  
 
Biofilm-dispersive PUR scaffold 
 The promising results obtained with the diffusion controlled release of D-AAs 
from PUR scaffolds in contaminated wounds open exciting avenues of research in the 
area of dual-purpose bone grafts. While augmentation with ≥5 wt% D-AA mixture 
reduced bacterial colonization of scaffolds implanted for 2 weeks in rats, it is not clear if 
this could further be improved using a different release profile. Effective treatment of 
MRSA osteomyelitis includes antibiotic treatment for up to 8 weeks.
1
 However, the 
optimal release profile of D-AA remains unknown and merits further investigation. 
Several strategies could be explored to modify the release profile of the D-AA: a) deliver 
the D-AAs as hydrochloride salts to accelerate release due to increased solubility,
2
 
b)encapsulate D-AAs in PLGA microspheres to slow down release, 
3
 and c) decrease the 
PUR scaffolds’s porosity to slow D-AA diffusion. Given the non-bactericidal character of 
D-AAs, their effectiveness is enhanced when used as an adjuvant therapy with antibiotics 
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(unpublished results from our collaborators at the Institute of Surgical Research in San 
Antonio, TX). Consequently, dual delivery of antibiotics and D-AA could be explored 
with PUR as the delivery vehicle. This would localize the action of both molecules in the 
wound. Furethermore, optimization of the antibiotic and D-AA release profile should still 
be completed. A final suggestion is to replace D-Tryptophan for D-Phenylalanine due to 
the lower in vitro cytotoxicity of the latter.  
 
Remodeling mechanisms of PUR biocomposites 
Chapter V presented the strong dependence of wound healing extent on the 
relative rates of new bone formation and polymer degradation. In this study, these rates 
were modulated by the addition of rhBMP-2. However, different strategies can be 
implemented to modify these rates: a) incorporation of mineralized fillers that promote 
different rates of new bone deposition and resorption (for example, bioactive glass 
particles), b) development of enzyme-degradable polymers (including for example 
cathepsin k sensitive peptides in the backbone 
4
) which are anticipated to more closely 
match the constant rate of new bone formation.
5
 
Chapters V and VI both suggest that maintaining a continuous surface in the 
scaffold during bone healing is important to achieve improved remodeling. This 
observation has been mostly based on histological observations. In order to provide 
quantifiable evidence, it is suggested to study the relationship between the extent of 
healing and the samples’ connectivity. Thus, histological sections analyzed by 
histomorphometry can be further processed to calculate their Euler number (eq. 6.2).
6
 We 
speculate that formulations with consistently low Euler numbers (<1, high connectivity) 
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during remodeling will achieve improved healing at earlier time points compared to those 
with Euler numbers approaching or higher than unity.  
Preliminary work characterizing the new bone formation and polymer degradation rates, 
as well as the Euler number distribution by areas in the samples studied in Chapter VI, 
shows promising results. Figures 9.1 and 9.2 plot the histomorphometry values for new 
bone, and remaining allograft and polymer in the injectable and moldable formulations 
respectively. Similar to the analysis conducted in Chapter V, data for new bone, allograft, 
and polymer content were fit to equations 5.3, 5.4, and 5.6 respectively (connecting lines 
in Figures 9.1 and 9.2). However, given that no new bone formation is present in the 
acellular cores of injectable materials at 6 weeks, we speculate that new bone formation 
in this area would be best modeled by an expression that includes a time lag. Currently, 
new bone formation is suggested to rapidly increase between 6 and 12 weeks. However, 
we believed the observed profile is an artifact of the fit since the materials are not 
delivering any growth factor that could promote this response. Figure 9.3 presents the 
relative rates of new bone formation and polymer degradation as a function of healing 
extent. In addition, the preliminary Euler number (E) for one sample of each formulation 
is presented with each graph. These plots show that indeed, samples with lower Euler 
number achieved a more balanced remodeling throughout the defect (close to balanced 
rates of new bone formation and polymer degradation, and all the areas achieved >50% 
healing). Instead, samples with higher Euler numbers exhibited variations in each area’s 
healing extent. To fully characterize the effect of connectivity on healing extent, it is 
recommended to quantify the Euler number by areas and compare it to the measured rates 
in time. It is important to note that this preliminary data set includes estimated, as  
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Figure 9.1. Histomorphometric evaluation of remodeling in the injectable scaffolds described in 
Chapter VI, as a function of time and location. 
 
 
Figure 9.2. Histomorphometric evaluation of remodeling in the moldable scaffolds described in 
Chapter VI, as a function of time and location. 
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Figure 9.3. Relative rates of new bone formation and polymer degradation for the injectable and 
moldable formulations described in Chapter VI, as a function of fraction healed and location. E 
corresponds to the Euler number calculated from a single section for each group at 6 weeks. 
 
opposed to measured, initial values of allograft and polymer (t=0). Thus, in order to 
ensure proper modeling of the remodeling progression it is necessary to quantify by 
histomorphometry the initial area % of allograft and polymer in each formulation using 
samples that were not implanted into the animals (ongoing work in the lab).  
 
Osteoclastic resorption of mineralized matrices 
The protocol developed in Chapter VII offers the possibility to independently 
monitor differentiation of osteoclast precursors and resorptive activity of osteoclasts in 
vitro. Keeping in mind the results from Chapters V and VI which demonstrate high 
connectivity of the scaffolds as a remodeling requirement, comparing different materials’ 
volumetric resorptive rates in vitro will identify the best candidate materials to 
incorporate in formulations with balanced new bone formation and scaffold degradation 
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rates. To start, the protocol should be implemented to quantify and compare the 
volumetric resorptive rates of different mineralized matrices used in our lab (TCP, 
bioactive glass). While studies have reported osteoclastic effects on the surface of these 
materials,
8-14
 our preliminary studies have shown that these changes are very shallow and 
seem to be of significantly smaller volumes than the changes on dentin’s surface. This 
also correlates to the observed morphological differences of the cells seeded on each of 
these materials. Thus, it is speculated that the volumetric resorption rate of the synthetic 
mineralized matrices will be significantly lower than that measured for dentin, and it will 
most likely be larger for bioactive glass than for TCP. Rate quantification for these 
synthetic matrices poses challenges not present with the dentin samples. In contrast to 
dentin, TCP and bioactive glass disks contain pits on the surface even before cells are 
cultured on them. To overcome this, the pit volume of each sample should be quantified 
before and after cell culture and the resulting difference used to calculate the 
corresponding resorption rates. The samples should be very well labeled to avoid 
confusion when subtracting initial pitted volumes. Given the location variability of the 
initial pits, the subtraction of average initial volume should be avoided to reduce error.  
Now that the protocol to quantify volumetric resorption rates is in place, it can be 
used to answer questions related to PUR biocomposite formulation for improved healing. 
For example, it has recently been reported that the way osteoclasts recognize bone for 
resorption is due to its high affinity to vitronectin (an v3 ligand).
15
 Thus, it would be 
interesting to quantify the affinity of vitronectin to the different matrices of interest. A 
possible way to do this would be by submerging samples of the same size into a set 
protein solution volume. At several time points, the samples could be removed from the 
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solution and incubated in a solution with a set vitronectin antibody set concentration, 
followed by incubation with a secondary horseradish peroxidase (HRP)-conjugated 
antibody. Further incubation with a solution containing ABTS (an HRP substrate) and 
quantification of the optical density at 405 mm would allow determining the total amount 
of vitronectin adsorbed on the material’s surface. A follow up question to answer will be: 
does the forced adsorption (by drying a known amount of protein on the surface of the 
materials) of vitronectin improve the volumetric resorption rates of the matrices? Do 
improvements depend on matrix composition? The answers to these questions will aid in 
the selection of matrices to further incorporate in PUR biocomposites for in vivo testing.  
The polymers used so far in the PUR biocomposite formulation have mostly 
undergone hydrolytic degradation in vivo. Results from this work and other research 
projects in our lab have shown that a better option would be for the polymers to undergo 
cellular degradation. Thus, the protocol developed in Chapter VII can also be 
implemented to study the effect that rigidity, as well as oxidative and proteolytic 
degradation might have on the volumetric resorptive rates of different polymeric 
formulations.  
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APPENDIX A 
 
EXPERIMENTAL PROTOCOLS
 Guelcher Lab     
Grafting of polycaprolactone to the surface of -TCP particles  
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Method based on the protocol reported in: 
C. Kunze, T. Freier, E. Helwig, B. Sandner, D. Reif, A. Wutzler, and H. J. Radusch, 'Surface 
Modification of Tricalcium Phosphate for Improvement of the Interfacial Compatibility with 
Biodegradable Polymers', Biomaterials, 24 (2003), 967-74. 
 
Materials 
 -caprolactone (Sigma-Aldrich) 
 Phosphoric acid (5% in distilled water prepared from concentrated acid bought from 
Sigma-Aldrich) 
 Chloroform (Sigma-Aldrich) 
 -TriCalcium Phosphate particles (TCP - Berkeley, CA) 
 Beaker 
 Magnetic stirrer 
 Three-necked flask and setup for continuous stirring 
 Argon 
 Ceramic funnel 
 Filter paper 
Protonation of TCP particles 
1. In a beaker with a magnetic stirrer, add TCP particles and phosphoric acid (5% in 
distilled water) with a mass ratio of 1:2 
 
2. Set up the mixing speed such that the TCP particles are well mixed with the acid 
 
3. Mix for 1 hour 
 
4. Stop mixing, allow the protonated TCP particles (p-TCP) to sediment, and remove the 
acid solution 
 
5. Wash with distilled water at least three times 
 
6. Filter and dry under vacuum at 40ºC overnight 
Grafting reaction 
1. Load the three-necked flask with p-TCP particles and -caprolactone using a mass ratio 
of 1:4 (molar ratio of 1:10) 
 
2. Setup and start the continuous stirring and flow of argon 
 
3. Heat the reaction flask to 150ºC and allow the reaction to proceed for 4 days 
 
4. To stop the reaction, cool down the reaction flask below 60ºC and continue stirring 
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5. Add chloroform to the reaction flask to solubilize the polymerized polycaprolactone 
(PCL) 
 
6. Transfer the content of the reaction flask (PCL and surface modified particles: TCP-PCL) 
into 50ml centrifuge tubes 
a. TIP: Transfer about 5-10 ml of the reaction content, and 40-45ml of chloroform 
to each centrifuge tube 
 
7. Centrifuge for 5 min at 2500 rpm 
 
8. Remove extra chloroform (save this material for further analysis of molecular weight of 
the grafted PCL – see note below), add fresh solvent, and mix well 
a. NOTE: The molecular weight of the grafted PCL can be measured by GPC. To 
do this, collect the chloroform used to wash the reaction flask. Using a rotavapor, 
evaporate the chloroform and collect the remaining polymer for further 
chromatography analysis 
 
9. Repeat steps 7-8 until the chloroform appears clear after centrifugation.  
 
10. Consolidate all the TCP-PCL powder in one centrifuge tube 
 
11. Dry under vacuum at 40ºC overnight 
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The Euler number is a measure of the connectivity of an image and is calculated by: 
E = C – H 
Where ‘C’ corresponds to the number of connected objects, and ‘H’ to the number of holes in the 
image (Pratt, 2001). As such, E=1 represents an image without holes, E>>1 an image with low 
connectivity, and E<<1 a highly connected image with holes. 
 
Materials 
 Stained histology sections 
 GIMP software 
 ImageJ software 
 MATLAB software 
 
Procedure 
1. Image the region of interest of the histology section 
 
2. Using GIMP, manually color over the areas corresponding to new bone, allograft, and 
remaining polymer 
 
3. When all the objects have been colored, use GIMP threshold to select the colored areas 
a. Colors  threshold 
b. Use this tool to only select the manually colored areas 
c. Export as a TIFF file 
 
4. Convert the TIFF file generated in step 3 into a binary image using ImageJ 
a. Open the file using ImageJ 
b. Select Process  Binary  Make binary 
c. At this point, the colored areas should be white. If this is not the case, invert 
image using: Edit  Invert 
d. Save and replace the TIFF file 
 
5. Use MATLAB to calculate the Euler number of the image 
a. Open MATLAB and import the image 
b. Use the function: bweuler()  
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Materials 
 Bioglass rods (Mo-Sci Health Care) 
 IsoMet Low Speed Saw (Buehler)  
 Silicon carbide paper or sandpaper (800, 1000, 1200 grade) 
 Deionized Water 
 X-Acto Knife 
 
Procedure 
1. Preparation: Clean saw blade with DI water. 
 
2. Add water to the basin below the saw blade. Secure the bioglass rod and cut one disk at a 
speed of 6.5. Discard this disk. 
 
3. Cut pieces of the same thickness. Use the micrometer on the saw to measure the thickness 
of each disk. After each cut, remove the disk from the water basin, dry the disk using a 
kimwipe, and continue to cut the next disk. 
 
4. After all pieces are cut, polish one side of the disk using the three different sandpapers. 
Make sure to add DI water to the sandpaper before polishing 
o Polishing times for each roughness: 
 800: 10 seconds 
 1000: 10 seconds 
 1200: 60 seconds 
 
5. Dry the disk after polishing. Make a mark on the non-polished side of each disk using an 
x-acto knife 
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Materials 
 Samples to sterilize (usually as disks) 
 Sonicator 
 Beaker 
 DI water 
 Sterile DI water (filtered for cell culture) 
 70% ethanol 
 -MEM (Fisher scientific) 
 Fetal bovine serum (FBS – Fisher scientific) 
 Penicillin/Streptomycin solution (Fisher scientific) 
 
Procedure 
1. Load the samples to sterilize into a beaker. If sterilizing several groups, prepare one 
beaker per group 
 
2. Sonicate samples in deionized distilled water to remove any loose particles: 3 times, 7.5 
min each time 
 
3. Submerge in 70% ethanol for 5 min, 2 times 
 
4. Wash with sterile deionized distilled water for 5 min, 2 times 
 
5. Transfer samples to tissue culture plastic plates 
 
6. Condition the sample in incomplete culture medium (MEM) for 5 min, 2 times 
a. NOTE: Make sure that the sample is completely covered by the media – for 
example, if using a 24-well plate, add 1 ml of media 
 
7. Incubate the sample in complete medium (MEM containing 10% FBS and 1% 
Pen/Strep) overnight in cell culture incubator at 37C  
a. NOTE: Make sure that the sample is completely covered by the media – for 
example, if using a 24-well plate, add 1 ml of media 
 
8. After the incubation, remove the media and proceed to seed cells according to the 
specific experiment 
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Original method received from: Javier Esparza (Vanderbilt Center for Bone Biology)  
 
Materials 
 1.5 ml centrifuge tubes 
 0.65ml centrifuge tubes 
 PBS 
 70% ethanol 
 Complete media: MEM + 10% Fetal bovine serum + 1% antibiotics (Pen-Strep) 
 Dissection instruments: forceps and scissors (Fine Science Tools) 
 Pipettes (200 l and 1 ml) and sterile pipette tips 
 6-well plate 
 Ice box with ice 
 c57bl male mice 4-8 weeks old 
 
Preparations the day before 
1. Using 18G needle, punch 2-3 holes at bottom of the 0.65 ml centrifuge tubes. 
 
2. Introduce a 0.65 ml tube into a 1.5 ml tube. Two of these sets will be needed per mouse. 
 
3. Autoclave the tube sets, as well as the forceps and scissors. 
 
Procedure (work under the hood to maintain sterility) 
1. Sedate mice using either isofluorane (sedated for minutes), or ketamine (~30 min 
sedated) 
a. Isofluorane machine settings: 2.5 Iso, 2.5 Oxygen 
b. Ketamine: intramuscular injections completed by personnel from the bone center 
 
2. Sacrifice mice by cervical dislocation and excise femur and tibia keeping the whole 
bones 
a. TIP: keep the fur wet during all the process (using PBS)  
b. If removing bones from several mice, submerge the whole bones in PBS in a 6-
well plate and remove the bones from all the mice. Then continue with the 
process below.  
 
3. Remove soft tissue from bone 
 
4. Dunk femur and tibia in 70% ethanol for 10sec. 
 
5. Hold femur and tibia with forceps by the knee and using the scissors cut femur and tibia 
ends to expose bone marrow 
 
6. Place bones, with the exposed ends towards the bottom, into the 0.65 ml tube inside the 
1.5 ml tube 
 
7. Add 500 l PBS into the 0.65 ml tube to keep marrow from drying up 
a. Place samples on ice until centrifugation 
 
8. Spin tubes at 12,000 rpm for 2 min 
 Guelcher Lab     
Extraction of murine bone marrow cells 
 
220 
9. Discard 0.65 ml tube. Bone marrow cells should be at the bottom of the 1.5ml tube, in 
500 l PBS 
 
10. Remove PBS; add 500 l complete media to wash cells 
 
11. Spin tube at 12,000 rpm for 2 min 
 
12. Remove media and resuspend cells in (1-5 ml) complete media  
 
13. Count cells: 
a. Transfer 50 l of cell suspension into 450 l of fresh complete media and mix 
well (1:10 dilution) 
b. Use the cell counter to count diluted cells 
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Method based on: instructions from Dr. James Edwards (Vanderbilt Center for Bone Biology), 
and adapted for the AutoMACS sorter in the Flow Cytometry Core at Vanderbilt. 
 
Materials 
 CD11b MicroBeads (human and mouse – Miltenyi Biotec, Cat. No. 130-049-601) 
 Separation buffer (also called Running buffer – Miltenyi Biotec, Cat. No. 130-091-221) 
 Rinsing solution (Miltenyi Biotec, Cat. No. 130-091-222) 
 MACS separator (in the flow cytometry core – reserve time following the link: 
http://www.mc.vanderbilt.edu/root/vumc.php?site=flowcytometry) 
 PBS (Fisher scientific) 
 Complete media: MEM + 10% Fetal bovine serum, 1% antibiotics (Pen-Strep) 
 Ice box with ice 
 15 ml centrifuge tubes 
 
Cell labeling (starting solution: cells in complete media) 
1. Determine cell number 
 
2. Centrifuge cells – 5 min / 1700 rpm 
 
3. Remove media and wash with PBS 
 
4. Centrifuge and obtain pellet – 5 min / 1700 rpm 
 
5. Remove PBS 
 
6. Re-suspend pellet in 90 l of MACS Separation Buffer (or Running buffer) per 107 total 
cells 
 
7. Add 10 l of CD11b MicroBeads per 107 total cells and mix well by pipetting 
 
8. Incubate for 15 min at 4-8ºC (on ice) 
 
9. Wash cells with 1-2 ml of separation buffer per 107 total cells and centrifuge to obtain 
pellet – 10 min, 1200 rpm 
 
10. Remove supernatant 
 
11. Re-suspend up to 108 in 500 l of separation buffer and proceed to magnetic separation 
 
Magnetic separation using the AutoMACS Separator 
1. Check the dates on the columns. The columns last ~2weeks. If they need to be 
changedlook for a flow cytometry core administrator. 
 
2. Run a CLEANING procedure. The run will end by priming the equipment with running 
buffer. 
 
3. Place the magnetically labeled cells in the autoMACS separator, and choose the 
separation program: Positive selection – “POSSEL” 
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4. Collect positive cell fraction in a 15 ml centrifuge tube (outlet port pos1). This is the 
purified CD11b+ cell fraction. 
 
5. When done, run a CLEANING procedure 
 
6. Run the SLEEP program and wait until it is sleeping to remove the bottles 
 
7. Turn off the equipment (button on the lower right) 
 
8. Centrifuge, remove buffer 
 
9. Add 1-5 complete media and count cells 
 
10. Prepare a solution with appropriate cell density for seeding according to each experiment 
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Materials 
 PBS (Fisher scientific) 
 5% glutaraldehyde solution in DI water 
 DI water 
 1% Osmium tetroxide solution in DI water (concentrated Osmium tetroxide bought from 
Sigma-Aldrich) – TOXIC REAGENT 
 100%, 95%, 75%, 50%, 25% ethanol in DI water 
 SEM stubs 
 Double sided carbon tape 
 Scanning electron microscope (VINSE) 
 
Cell fixation 
1. Wash with PBS  
 
2. Fix in 5% glutaraldehyde solution for ~2 hrs at room temperature, or overnight at 4⁰C 
a. NOTE: Make sure the sample is completely covered with the solution 
 
3. Rinse with DI water x3 times at room temperature 
 
4. UNDER THE HOOD: Fix in 1% Osmium tetroxide for 15 min at room temperature 
 
5. Wash with DI water x3 times at room temperature 
 
6. Sequentially dehydrate sample in increasing concentrations of ethanol 
a. 25% ethanol – 1 hour 
b. 50% ethanol – 1 hour 
c. 75% ethanol – 30-45 min 
d. 95% ethanol – 1 hour 
e. 100% ethanol – 1 hour 
f. 100% ethanol – 1 hour  
g. 100% ethanol – 1 hour 
 
7. Dry samples either at the critical point in the EM core (preferable) or under vacuum 
overnight 
 
Stub preparation for SEM imaging 
1. Cover the surface of the SEM stub with double sided carbon tape 
 
2. Locate the sample on top of the carbon tape (making sure the side with the cells is on top) 
 
3. If imaging disks, cut a thin and long strip of carbon tape and put it on top of the sample 
making sure it connects the surface of the disk and the metallic SEM stub (this will help 
reduce charging) 
 
4. Leave the SEM stubs with samples under vacuum until further processing 
 
5. Sputter-coat with gold (at VINSE) 
 
6. Image 
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This protocol can be used to stain cells on tissue culture plastic or on disks of different materials.  
 
Materials 
 PBS (Fisher scientific) 
 10% formalin 
 0.1% Triton X-100 in PBS 
 Rhodamine phalloidin (Life Technologies) 
 Bovine Serum Albumin (BSA - optional) 
 Mattek plates (for confocal imaging – Cat. # P50G-0-30-F) 
 Confocal microscope (Cell Imaging Shared Resource) 
 
Procedure 
1. Wash cells 2 times with PBS 
 
2. Fix cells in 10% formalin for 10 min at room temperature 
a. Make sure the cells are completely covered with the fixative  
 
3. Wash cells 2 times with PBS 
 
4. Permeabilize cells 0.1% Triton X-100 for 5 min 
 
5. Wash cells 2 times with PBS 
 
6. Incubate cells for 45 min at 37⁰C in 5 l of the reconstituted methanolic stock solution of 
rhodamine phalloidin per 200 l of PBS (prepare enough to completely cover the cells) 
a. Add 1% BSA to avoid non-specific binding 
 
7. Wash with PBS 
 
8. Air dry samples protected from light 
 
9. Image using confocal microscope. Use Mattek plates (with glass center) to support the 
samples during imaging 
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This protocol is designed to monitor in time the differentiation process of osteoclast precursors 
seeded on matrices with different chemistries. Amounts are based on 24-well plates and disk 
samples with diameter of 10-12 mm. 
 
Materials 
 Matrices with different chemistries (ex. dentin, TCP, bioglass) 
 Reconstituted MCSF (R&D Systems) 
 Reconstituted RANKL (R&D Sytems) 
 BMP-2 (R&D Systems) 
 Complete media (-MEM + 10% Fetal bovine serum + 1% Pen/Strep) 
 Forceps 
 24-well plate 
 
Procedure 
1. Sterilize and condition matrix samples (according to protocol) 
a. Prepare 3 plates with replicates of the materials. Each plate will be stopped at a 
different time point for gene expression analysis  
 
2. Extract bone marrow cells (according to protocol) 
 
3. Select CD11b+ cells from bone marrow population (according to protocol) 
 
4. Remove conditioning media from the sample wells 
 
5. Slowly and drop-wise add 1 ml of complete media containing 1.8x105 CD11b+ cells to 
each well 
 
6. Allow the cells to sediment for 25 min in the incubator at 37⁰C 
 
7. Carefully, transfer the samples to a new well plate 
 
8. Using the walls of the wells carefully add 1 ml of complete media augmented with 
growth factors: 
a. Optimal concentrations: MCSF 25 ng/ml; RANKL 50 ng/ml 
b. Concentrations to study the effect of BMP-2: MCSF 25 ng/ml; RANKL 30ng/ml; 
BMP-2 30 ng/ml 
 
9. Incubate the samples at 37⁰C for up to 14 days changing the media every 3-4 days.  
a. To change the media of the plate that will be cultured for the longest time: collect 
media from each well and freeze for future analysis of TRAP activity on culture 
supernatant (according to protocol) and replace with fresh complete media 
containing growth factors 
b. To change the media of the other plates: aspirate the media and replace with 
fresh complete media containing growth factors 
 
10. At 3 different time points (for ex. Days 4,7,14 or 1,4,7): stop one of the plates and collect 
mRNA for gene expression (according to protocol) 
 
11. After all plates are stopped analyze the TRAP activity on the collected media (protocol) 
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Materials 
 RNAse Zap wipes 
 Forceps 
 24-well plate to transfer samples  
 1.5 ml RNase free vials  
 KIMWIPES (these are RNAse free) 
 RNAse free tips 
 Pipettes 
 Centrifuge for 2 ml tubes 
 70% ethanol 
 QIAShredder Kit (QIAGEN) 
 RNeasy mini Kit (QIAGEN) 
 Sterile Water- RNase free  
 RNase-Free DNase set – (QIAGEN Cat #79254) 
 
NOTE: Change gloves frequently during the process 
 
Procedure 
1. Prepare DNAse digestion mixture (1 column per group of pooled samples) 
a. Add 10 l DNAase to 70 l RDD buffer per column (include an extra column in 
your calculations to have enough material). Mix by GENTLE inversion.  
Reagents sensitive to mechanical force. Keep on ice. 
 
2. COMPLETELY remove media from wells w/ pipette and wash with PBS or water 
 
3. Move samples to empty well  
a. NOTE: To achieve enough mRNA you will need to pool samples together. To do 
this, either a) combine more than one sample into a clean well and continue with 
the steps below, or b) follow step 4 and transfer the RLT buffer to the next well 
with a sample; repeat this until the cells from all the wells of interest have been 
pooled together into the 700 l of RLT buffer 
 
4. Disrupt cells by adding 700 l RLT Buffer/well (pipette around to mix). All the samples 
should be covered in buffer. Incubate at room temperature for about 5 min. 
 
5. Transfer lysate into a QIAshredder spin column (PURPLE) in 2 ml collection tube 
(transfer maximum 700 l to each column at a time). 
 
6. Centrifuge at 2 min full speed (13200 rpm) and collect the homogenized lysate. 
 
7. Repeat for remaining lysate 
 
8. To the homogenized lysate, add volume equal to the total amount RLT buffer of 70% 
ethanol. Mix by pipetting, do not centrifuge.  
 
9. Add 700 l of lysate with ethanol to pink column in 2 ml collection tube (RNeasy kit) 
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10. Cetrifuge at ≥10,000 rpm for 15 s.  DISCARD FLOW THROUGH 
 
11. Repeat with the remaining lysate from the purple shredder columns (each time adding up 
to 700 l per column) 
 
12. Add 350 l of wash RW1 to columns and centrifuge for 15 sec at 10,000 rpm. DISCARD 
FLOW THROUGH 
 
13. Add 80 l of DNA digestion mix to each column 
 
14. Incubate at room temp for 15 min 
 
15. Add 350 l RW1 again and centrifuge for 15s at 10,000 rpm. Change collection tubes.  
 
16. *****Make sure ethanol has been added to RPE buffer***** Add 500 l Buffer RPE to 
the spin column. Centrifuge for 15s at 10,000 rpm. DISCARD FLOW THROUGH 
 
17. Wash again with 500 l RPE. Centrifuge for 2 min at full speed.  
 
18. Centrifuge 1 min at max speed. 
 
19. Transfer column to collection tube with top (1.5 ml)  
 
20. Add 40 l RNase free H20 to column. SOAK 10 min at room temperature 
 
21. Centrifuge 10,000 rpm 1 min 
a. RNA will be collected in 40 l water in tube.  
 
22. Remove pink column, close the centrifuge tube and put it on ice.  
 
23. Quantify the concentration of mRNA in each sample using the: 
a. Biophotometer and cuvettes (Eppendorf – in the room with the autoclave), or 
b. NanoDrop (in Dr. Jamey Young’s lab) 
 
24. Preferably: prepare cDNA immediately. If not possible, store mRNA at -80⁰C 
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Materials 
 RNAse Zap wipes 
 200 l RNase free vials  
 KIMWIPES (these are RNAse free) 
 RNAse free tips 
 Pipettes 
 IQ Real Time SybrGreen PCR Supermix (Biorad) – Cat # 1708880 
 Microseal ‘B’ adhesive tape for PCR plates – Cat #MSB1001 
 PCR Plates – Cat #MLL9601 
 Centrifuge for PCR plate 
 Thermocycler 
 Biorad PCR machine 
 iScript cDNA Kit – Cat # 170-8890 
 Sterile Water- RNase free  
 IQ Real Time SybrGreen PCR Supermix (Biorad) – Cat # 1708880 
 Specific primers 
 
cDNA synthesis 
Each tube for cDNA synthesis will contain a total of 20 l mixture distributed as: 
a) 4l reaction mix 
b) 1 l reverse transcriptase 
c) X l mRNA  
d) Y l nuclease free water 
Where X+Y = 15 l, and a,b,d are part of the iScript kit 
 
1. From mRNA concentration measurements, determine the amount of mRNA to reverse-
transcribe into cDNA per treatment group 
a. NOTE: the maximum amount possible will be that in 15 l of mRNA solution 
 
2. Prepare enough mixture of reaction mix and reverse transcriptase for the total amount of 
cDNA tubes + 1 extra (for ex. If you have 3 treatment groups, pre-mix 16 l of reaction 
mix with 4 l of reverse transcriptase) 
 
3. Transfer into each cDNA tube 
a. 5 l of reaction mix and reverse transcriptase pre-mix (prepared in step 2) 
b. X l of mRNA (determined in step 1) 
c. Y l nuclease free water (such that X+Y=15 l) 
 
4. Centrifuge 3,000 rpm for 3 minutes 
 
5. Load into thermal cycler. Select iScript protocol (details below): 
a. 5 minutes at 25C 
b. 30 minutes at 42C 
c. 5 minutes at 85C 
d. Hold at 4C 
 
6. Store the cDNA at -20C 
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Real time qPCR 
This information is to run the real time qPCR in 20 l using a flat surface 96-well PCR plate in a 
CFX machine at the Molecular Biology Core at Vanderbilt. Reserve machine ahead of time using 
the Core ordering website. 
 
1. Prepare primer mix (2l of primer mix are needed per well) 
a. For a final concentration of 500 nM of primer mix in the reaction well: Mix 95 l 
water with 2.5 l forward primer and 2.5 l of reverse primer 
 
2. Determine the cDNA template concentration per well 
 
3. Dilute stored cDNA to desired concentration. Keep in mind that only 8 l of cDNA 
solution will be transferred to each reaction well 
 
4. Pre-mix supermix and primer mix enough for all the reaction wells and 1-2 extra ones 
a. 10 l supermix/well 
b. 2 l of primer mix/well (prepared in step 1) 
 
5. While keeping the PCR plate on ice, load into each well: 
a. 12 l of the premix prepared in step 4 
b. 8 l of cDNA solution prepared in step 3 
c. NOTE: when transferring these amounts avoid making bubbles in the solutions 
and change tip for each well 
 
6. Place sticker seal on top of plate making sure it is well sealed 
 
7. Centrifuge at 3,000 rpm for 3 min 
 
8. While on ice, take the plate to the core 
 
9. On the reserved machine: 
a. Select the lab’s profile  User: Guelcher Password: SG3-4977 
b. Go to protocol 
c. Select existing (unless you have a different protocol to use) 
d. Use CFX_2StepAmp+Melt Protocol (found under PCR protocols in sample files 
folder) 
e. Press: “Edit selected” 
f. Enter temperature information according to your experiment, and save the 
protocol 
g. Under USER PREFERENCES, make sure that your email is included so that 
results are sent to you at the end of the run 
h. Open machine by pressing OPEN LID (under start run menu) 
i. Place plate firmly on metal grid 
j. Close lid using the software by pressing CLOSE LID (under start run menu) 
k. Click START RUN 
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This method is for staining cells on tissue culture plastic or seeded on disks of materials 
 
Materials 
 Sigma kit 387A (contains citrate solution, fast Garnet GBC base solution, sodium nitrite 
solution, naphthol AS-BI phosphate solution, acetate solution, tartrate solution, and 
hematoxylin solution) 
 Acetone 
 Formaldehyde, 37% 
 DI water 
 
Procedure 
The amounts below can be modified according to the number of samples as long as the 
proportions remain constant. 
 
1. Pre-warm sufficient DI water for day’s use to 37⁰C. Check temperature before use 
 
2. Prepare fixative solution in a glass vial: 
a. 25 ml citrate solution + 65 ml acetone + 8 ml of formaldehyde 37% 
b. Cap tightly and allow to equilibrate at room temperature 
 
3. In a glass vial prepare diazotized fast Garnet GBC solution: 
a. 0.5 ml fast Garnet GBC solution + 0.5 ml sodium nitrite solution 
b. Mix by gentle inversion for 30s and let stand 2 min 
 
4. In a clean glass vial prepare staining solution by mixing well the following: 
a. 45 ml DI water at 37⁰C 
b. 1 ml diazotized fast Garnet GBC solution (from step 3) 
c. 0.5 ml Naphthol AS-BI phosphate solution 
d. 2 ml acetate solution 
e. 1 ml tartrate solution 
 
5. Warm solution to 37⁰C in water bath or incubator 
 
6. Remove media from wells and wash with DI water 
 
7. Add fixative solution to wells (making sure all the cells are covered) and let stand for 30s.  
 
8. Wash with DI water and do not allow cells to dry 
 
9. Add warm staining solution (from step 5) to each well, making sure all the cells are 
covered 
 
10. Incubate for 20 min at 37⁰C protected from light 
 
11. Remove the solution and wash thoroughly with DI water 
 
12. Air dry and evaluate microscopically 
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Secretion of tartrate resistant acid phosphatase (TRAP) 5b into the supernatant has been found to 
correlate with bone resorptive activity.   
 
Biochemical measurement of TRAP activity in culture supernatant is typically conducted using 
either para-nitrophenylphosphate (pNPP) or naphthol-AS-BI phosphate (N-ASBI-P) as a 
substrate. Compared with nPP, N-AS-BI-P is a more specific substrate for TRAP 5b activity 
(Janckila et al., 2001).  As opposed to nPP, N-ASBI-P is selectively hydrolyzed by the 5b isoform 
(Janckila et al., 2001). Vaughan et al. (1971) compared the fluorescent properties of various 
naphthol derivatives and concluded that AS-BI phosphate was the most effective substrate for 
both acid and alkaline phosphatase. Phosphatase hydrolyzes N-AS-BI-P to yield fluorescent N-
AS-BI.  
 
After quantifying the amount of TRAP in the media, total protein in the sample is used to 
normalize the results. Total protein is quantified using the BCA kit. 
 
Materials 
 Napthol AS-BI phosphate - -20⁰C freezer (in the HPLC lab – Sigma Cat. # N2125) 
 Sodium Acetate 
 Sodium Tartrate 
 EGME (2-Methoxyethanol) (Refrigerator in the mixer lab) 
 0.6 M NaOH (prepare as needed) 
 DI water 
 96-well plates (preferably with clear bottom, but all black also work) 
 BCA Protein kit (Fisher Scientific) 
 
Procedure 
1. Thaw frozen media and vortex to mix 
 
2. Prepare buffer 
a. Total = 150 µl * (# samples) 
i. Ex. = 0.150* 164= 24.6 ml. Make 27 ml 
 
b. To have a total of 2.5mM Napthol AS-BI Phosphate in 4% EGME in 27 ml of 
buffer: 
i. (27x10-3 L)*(2.5x10-3 mol/L)*(452.19 g/mol) = 0.031 g Napthol ASBI-P 
ii. Dissolve in 1 ml EGME (add it and vortex it. If it doesn’t dissolve you 
can put it in the 37⁰C incubator for a few minutes and vortex again) 
 
c. To have a total of 100 mM sodium acetate in 27 ml of buffer: 
i. (27x10-3 L )*(100x10-3 mol/L)*(82.03 g/mol) = 0.221 g 
ii. Add 0.221 g Na Acetate to 13 ml DI water  
iii. ml DI water = (Total buffer ml – ml EGME)/2 
 
d. To have a total of 50 mM sodium tartrate in 27 ml of buffer 
i. (27x10-3 L)*(50x10-3 mol/L)*(230.08 g/mol) = 0.311 g 
ii. Add 0.311g Na Tartrate to 13 mL DI water 
iii. ml DI water = (Total buffer ml – ml EGME)/2 
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e. Measure pH of buffer.  Aim for pH of 6.1-6.3  
 
3. Add 150 µl buffer to each well (using a 96 well-plate) 
 
4. Add 50 µl of sample to each well  
 
5. Allow to react for 35 min at 37⁰C protected from light (Be sure all samples carry out 
reaction for the same amount of time) 
 
6. Stop with addition of 50 µl 0.6 M NaOH per well 
 
7. Check pH of one well. Need basic conditions 
 
8. Measure fluorescence of the plate 
a. Go to the Molecular Biology core in Light Hall 
b. Set the fluorescence plate reader: 
i. Shake duration: 10s 
ii. Read From Top 
iii. Measure Fluorescence: 405 Excitation, 520 Emission 
c. Run the reading and save data 
 
Total protein measurement 
1. Prepare the BCA protein buffer (each sample well will need 200 µl of buffer) 
a. Solution A  ml = (Total ml) 
b. Solution B  ml = (Total ml)*0.02 
 
2. Prepare the protein standards with the standard concentrations suggested by the BCA 
total protein assay kit: 
             J         200l  200 l of vial H dilution 12.5 g/ml 
     K       200l  200 l of vial J dilution           6.25 g/ml 
 
3. Add to each sample well:  
a. 5 L sample media (or incomplete media for blank) 
b. 15 L PBS (take into account this dilution when reporting total protein in each 
well) 
c. 200 L buffer 
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4. To generate the calibration curve add:  
a. 20 l of each standard  
b. 200 l of the buffer  
 
5. Incubate at room temperature protected from light for 30 min 
 
6. Measure the absorbance at 562 nm (using the plate reader in the cell culture room) 
 
7. Use the calibration curve to determine the total protein concentration in each well. If the 
absorbance reading of the samples is higher than the higher standard, repeat the 
experiment using an even more diluted sample. 
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Differentiation of osteoclast precursors based on published methods from: Karen Fuller, 
Barrie Kirstein, and Timothy J. Chambers, 'Murine Osteoclast Formation and Function: 
Differential Regulation by Humoral Agents', Endocrinology, 147 (2006), 1979-85. 
 
In this method, osteoclast precursors are first differentiated into active osteoclasts, and then 
seeded on different matrices. After culturing the active osteoclasts on the matrices, they are 
removed, and the resorbed volume is quantified in time. 
 
Materials 
 Sterilized and conditioned matrices for analysis (according to protocol) 
 Complete media: -MEM + 10% Fetal bovine serum + 1% Pen/Strep (all from Fisher 
Scientific) 
 PBS (Fisher Scientific) 
 Reconstituted MCSF, RANKL, TGF-, IL-1 (R&D Systems) 
 24-well plate (this can change depending on the size of the samples) 
 T150 cell culture flasks (Fisher Scientific) 
 90-mm diameter cell culture dishes 
 0.02% EDTA solution (Sigma Aldrich) 
 Cell scraper (Fisher scientific) 
 Zeta-20 True Color 3D Optical Profiler (Zeta Instruments; located in the National 
Research Resource for Imaging Mass Spectrometry – 9th floor in MRB III) 
 Forceps 
 
 
Differentiation of non-adherent bone marrow cells 
1. Extract murine bone marrow cells from c57bl male mice 4-8 weeks old (according to 
protocol) 
 
2. Remove the stromal cells from the bone marrow cell population: 
a. Seed the bone marrow cells in a T150 cell culture flask at a density of 3x105 
cells/ml 
b. Feed with ~30 ml of complete media supplemented with 5 ng/ml MCSF 
c. Incubate for 24 hrs at 37⁰C and 5% CO2 
d. Aspirate the media and centrifuge (3000 rpm for 3 min) 
e. Re-suspend in complete media and count 
 
3. Seed and differentiate the non-adherent cells 
a. Seed 7.2x106 cells/dish in 90-mm diameter cell culture dishes 
b. Feed with 25 ml of complete media augmented with 50 ng/ml MCSF, 30 ng/ml 
RANKL, and 0.1 ng/ml TGF- 
c. Every 2-3 change 15 ml of the media per flask 
d. Incubate for 5-7 days at 37⁰C and 5% CO2. 
i. NOTE: In order to know when to stop the culture, monitor the number of 
multinucleated cells each day (for ex. count the number of 
multinucleated cells in several regions each day). Stop the culture the day 
that the number of multinucleated cells significantly increases compared 
to the previous day. 
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4. Collect differentiated osteoclasts 
a. Remove media from cell culture dishes 
b. Wash 3 times with PBS 
c. Add 6 ml of 0.02% EDTA solution to each dish 
d. Incubate the cells for 20 min at room temperature 
e. Gently tap the dishes, and remove the EDTA solution.  
f. Add 6 ml of PBS to each dish 
g. Carefully scrape the cells using a cell scraper such that the cells are suspended in 
PBS 
h. Combine all the cells, pipette up and down, and count the cells 
 
Culture of osteoclasts on matrices 
1. Remove conditioning media from the sample wells 
 
2. Slowly and drop-wise add 1 ml of complete media containing 1.8x105 osteoclasts to each 
well (equivalent seeding density to 9x10
4
 cells/cm
2
) 
 
3. Allow the cells to sediment for 25 min in the incubator at 37⁰C 
 
4. Carefully, transfer the samples to a new well plate 
 
5. Using the walls of the wells carefully add 1 ml of complete media augmented with 
50ng/ml MCSF, 30 ng/ml RANKL, 10 ng/ml IL-1 
a. Depending on the experiment, other growth factors can also be included in the 
media 
 
6. Culture the samples for up to 48 hrs at 37⁰C and 5%CO2 
a. NOTE: Initially prepare enough samples to stop several wells at different time 
points. For example, stop some samples after 6, 24, 48 hrs of resorption. This 
will provide data in time to determine the volumetric resorption rate 
 
Quantification of volumetric resorption rates 
1. Stop several samples after different times of culture (for ex. 6, 24, 48 hrs) 
a. Remove media from sample wells 
b. Wash with PBS 
c. Carefully remove attached cells using a cell scraper 
d. Air dry samples overnight 
 
2. Image the surface of the matrices (using the Zeta profiler) 
NOTE: For matrices with high roughness of the surface, this step should also be 
completed before cell culture. The pit volume before culture can be subtracted 
from the pit volume after culture to obtain the real resorbed volume. 
 
a. Open Zeta 3D software (icon on the desktop of the microscope computer) 
b. Enter Username: a, and Password: a 
c. Click OK to initialize Z and XY stages 
d. Make sure the objective with lowest magnification is being used 
e. Place the sample on the sample holder 
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f. On the ‘Live Image” menu click: DOWN and follow instructions to lower the 
microscope head. This will lower the objectives to a set position, but you will 
still need to move them closer to the sample. To do this, position the mouse 
cursor on the ‘Mouse Wheel’ (found on the ‘Scan Dialog’ window). Use the 
scroll wheel to move the microscope head up and down. You can also use the 
buttons: PGUP and PGDN to move faster. 
 
 
 
 
g. Find the height of the microscope in which most of the image appears focused on 
the screen 
i. NOTE: Here you can change magnification to the one you want to use 
for your analysis 
 
h. From the focused position, move up and down to mark your lower and higher 
limits for the scan (set bottom, set top). These limits will determine the height of 
the scan. 
i. NOTE: When analyzing several samples try to keep this height and the 
magnification constant between samples such that the resolution of the 
analysis is the same 
 
i. Click Scan 
 
j. Save the image 
 
k. Repeat until you have imaged several regions of the samples 
 
3. Quantify the resorbed volume 
a. Using the Zeta 3D software, open the image to analyze 
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b. Go to ‘Analysis’ menu  click on ‘Z 3D view’  uncheck ‘True color’ 
i. NOTE: This will provide a color map of height 
 
 
c. Check the image to see if it needs to be leveled. If so, go to ‘View type’, select ‘Z 
Analysis’, right click on the image, set a reference surface, and level the 
reference surface 
 
d. In the ‘Scan Dialog’ window (found on the ‘Live Video’- towards the right on 
the screenshot in the previous page) make sure that the Diamond recipe is loaded.  
i. If the Diamond recipe is not loaded, click ‘Load’ and locate the 
corresponding file: Program files  Zeta Instruments  zmm  
Diamond.rcp 
 
e. Towards the bottom of the ‘Scan Dialog’ window click on ‘Edit recipe’ 
 
f. Under the ‘Analysis’ tab select the threshold selection method as Z (depth) and 
provide the threshold for detection (in m) 
i. NOTE: To select pits input a negative value for the threshold for 
detection (ex. -1, would select all pits deeper than 1 m). Positive values 
select structures above the surface. 
ii. NOTE: The software will automatically select any features that have a 
depth equal or larger to the threshold value.  
 
g. Go back to the ‘Z view 2D’ image and the ‘Z view 3D’ to visually check the 
selected pits. Make changes to the threshold if necessary. 
 
h. Save the data of the thresholded volumes by right clicking on the data table 
(lower left quadrant of the ‘Z view 2D’ window) and following the link to save 
the file 
